Art. -Nr.: HY-10221

Vorinostat

(Synonyms: SAHA; Suberoylanilide hydroxamic acid)

166 Cited Publications

Kundenbewertung

Based on 166 publication(s) in Google Scholar

Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.96%
CAS. Nr.: 149647-78-9
Formel: C₁₄H₂₀N₂O₃
Molecular Weight:264.32

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Vorinostat Chemical Structure

CAS. Nr.: 149647-78-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (166)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis^[1]^[4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification^[7].

IC₅₀ & Target^[1]^[3]^[4]

HDAC1

10 nM (ID₅₀)

HDAC3

20 nM (ID₅₀)

HDAC2

HDAC7

HDAC11

Autophagy

Mitophagy

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle Filovirus Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	4.76 μM Compound: Vorinostat	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
4T1	IC₅₀	4.317 μM Compound: SAHA	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
4T1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
4T1	IC₅₀	12.12 μM Compound: SAHA	Antiproliferative activity against mouse 4T1 cells assessed as cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse 4T1 cells assessed as cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
518A2	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human 518A2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human 518A2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
518A2	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human 518A2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human 518A2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
786-0	GI₅₀	3.2 μM Compound: SAHA, Zolinza	Growth inhibition of human 786-0 cells after 72 hrs by MTS assay Growth inhibition of human 786-0 cells after 72 hrs by MTS assay	[PMID: 22435669]
A20	IC₅₀	0.112 μM Compound: SAHA	In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells	[PMID: 11960489]
A20	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse A20 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse A20 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
A2780	IC₅₀	2600 nM Compound: 1, vorinostat	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A2780	CC₅₀	2600 nM Compound: 1	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A2780	IC₅₀	1.62 μM Compound: SAHA	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 20451378]
A2780	GI₅₀	3150 nM Compound: SAHA, vorinostat	Antiproliferative activity against human A2780 cells after 72 hrs by WST-1 assay Antiproliferative activity against human A2780 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
A2780	IC₅₀	1.62 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
A2780	IC₅₀	0.44 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.53 μM Compound: SAHA, vorinostat	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	2.42 μM Compound: SAHA, vorinostat	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	3.12 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	1.9 μM Compound: SAHA	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 23906422]
A2780	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 26443078]
A2780	EC₅₀	377.48 nM Compound: SAHA	Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	EC₅₀	399.25 nM Compound: SAHA	Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	IC₅₀	870 nM Compound: SAHA	Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
A2780	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 29150335]
A2780	IC₅₀	0.64 μM Compound: Vorinostat	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay	[PMID: 31431326]
A2780	IC₅₀	1.16 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
A2780	IC₅₀	0.96 μM Compound: Vorinostat	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay	[PMID: 31762274]
A2780	IC₅₀	2.42 μM Compound: Vorinostat	Cytotoxicity against human A2780 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	[PMID: 31762274]
A2780	IC₅₀	0.91 μM Compound: 1	Inhibition of HDAC in human A2780 cells Inhibition of HDAC in human A2780 cells	[PMID: 31787463]
A2780	IC₅₀	2.04 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
A2780	IC₅₀	2.42 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33360560]
A2780	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human A2780 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human A2780 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
A2780	IC₅₀	0.43 μM Compound: 3; SAHA	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
A2780	IC₅₀	8.82 μM Compound: SAHA	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
A2780	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A2780	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
A2780	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A2780 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A2780	IC₅₀	380 nM Compound: Vorinostat	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 37875056]
A2780S	IC₅₀	5541 nM Compound: SAHA	Antiproliferative activity against human A2780S cells after 72 hrs by MTT assay Antiproliferative activity against human A2780S cells after 72 hrs by MTT assay	[PMID: 31177073]
A-375	IC₅₀	4.1 μM Compound: SAHA	Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
A-375	IC₅₀	2.68 μM Compound: SAHA	Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
A-375	IC₅₀	2.827 μM Compound: SAHA	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
A-375	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human A-375 cells Antiproliferative activity against human A-375 cells	[PMID: 37875056]
A-431	IC₅₀	4.2 μM Compound: 2	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 17691763]
A-431	IC₅₀	4.2 μM Compound: 2a	Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay	[PMID: 21080629]
A-431	IC₅₀	5.13 μM Compound: Zolinza, SAHA	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22698782]
A-431	GI₅₀	4.48 μM Compound: SAHA, Vorinostat	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 23601706]
A-431	IC₅₀	2.29 μM Compound: 8	Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
A-431	IC₅₀	3.5 μM Compound: SAHA	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay Antiproliferative activity against human A431 cells after 72 hrs by SRB assay	[PMID: 29150335]
A-431	IC₅₀	1.47 μM Compound: Vorinostat	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
A-431	IC₅₀	0.63 μM Compound: SAHA	Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
A-431	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
A-431	IC₅₀	3.81 μM Compound: SAHA	Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
A498	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human A498 cells after 72 hrs by MTS assay Growth inhibition of human A498 cells after 72 hrs by MTS assay	[PMID: 22435669]
A498	GI₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
A498	IC₅₀	25.08 μM Compound: SAHA	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 34111829]
A549	IC₅₀	1.8 μM Compound: 2	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17691763]
A549	IC₅₀	12.6 μM Compound: SAHA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 18247554]
A549	IC₅₀	1800 nM Compound: 1, vorinostat	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A549	IC₅₀	1800 nM Compound: 1, SAHA	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
A549	IC₅₀	2.2 μM Compound: 6, SAHA	Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
A549	IC₅₀	1800 nM Compound: 1, SAHA	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19410459]
A549	CC₅₀	1800 nM Compound: 1	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A549	IC₅₀	0.6 mM Compound: Vorinostat	Antiproliferative activity against human A549 cells after 2 days by MTT assay Antiproliferative activity against human A549 cells after 2 days by MTT assay	[PMID: 19608304]
A549	GI₅₀	>200 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 19822426]
A549	IC₅₀	0.76 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs Antiproliferative activity against human A549 cells after 48 hrs	[PMID: 20576572]
A549	IC₅₀	0.868 μM Compound: SAHA	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20855208]
A549	IC₅₀	1.8 μM Compound: 2a	Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay	[PMID: 21080629]
A549	GI₅₀	5700 nM Compound: SAHA, vorinostat	Antiproliferative activity against human A549 cells after 72 hrs by WST-1 assay Antiproliferative activity against human A549 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
A549	IC₅₀	0.74 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21476600]
A549	GI₅₀	0.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 21712146]
A549	IC₅₀	0.69 μM Compound: SAHA, Zolinza	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21733698]
A549	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human A549/ATCC cells after 72 hrs by MTS assay Growth inhibition of human A549/ATCC cells after 72 hrs by MTS assay	[PMID: 22435669]
A549	GI₅₀	3.1 μM Compound: SAHA, Zolinza	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 22435669]
A549	GI₅₀	1.85 μM Compound: 1, SAHA	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 22439863]
A549	IC₅₀	27.8 μM Compound: Zolinza, SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22698782]
A549	IC₅₀	3.8 μM Compound: 1, SAHA	Inhibition of human A549 cell proliferation after 48 hrs by MTT assay Inhibition of human A549 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
A549	IC₅₀	4.5 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23570542]
A549	GI₅₀	1.78 μM Compound: SAHA, Vorinostat	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 23601706]
A549	IC₅₀	1.079 μM Compound: SAHA	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23644210]
A549	IC₅₀	17.9 μM Compound: SAHA, vorinostat	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
A549	IC₅₀	80.3 μM Compound: SAHA, vorinostat	Cytotoxicity against SAHA-resistant human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against SAHA-resistant human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23707260]
A549	IC₅₀	1.08 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
A549	EC₅₀	8.3 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23820574]
A549	IC₅₀	2.27 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human A549 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
A549	IC₅₀	3.7 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs Antiproliferative activity against human A549 cells after 48 hrs	[PMID: 24262004]
A549	IC₅₀	3.9 μM Compound: SA, SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24694055]
A549	IC₅₀	1.54 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24766560]
A549	GI₅₀	5.27 μM Compound: vorinostat, SAHA	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
A549	EC₅₀	1.03 μM Compound: SAHA	Inhibition of HDAC6 in human A549 cells assessed as tubulin acetylation after 17 to 18 hrs by cytoblot assay Inhibition of HDAC6 in human A549 cells assessed as tubulin acetylation after 17 to 18 hrs by cytoblot assay	[PMID: 25238284]
A549	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25462271]
A549	EC₅₀	1 μM Compound: SAHA	Inhibition of HDAC6 in human A549 cells assessed as induction of tubulin acetylation after 17 to 18 hrs by ELISA Inhibition of HDAC6 in human A549 cells assessed as induction of tubulin acetylation after 17 to 18 hrs by ELISA	[PMID: 25734520]
A549	IC₅₀	1.65 μM Compound: SAHA, Zolinza	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
A549	IC₅₀	1.65 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
A549	IC₅₀	5.32 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
A549	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26443078]
A549	IC₅₀	1.079 μM Compound: vorinostat	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
A549	GI₅₀	3.13 μM Compound: 1, SAHA	Growth inhibition of human A549 cells after 96 hrs by MTT assay Growth inhibition of human A549 cells after 96 hrs by MTT assay	[PMID: 26814680]
A549	GI₅₀	1.02 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 27344487]
A549	EC₅₀	12 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by WST1 assay Antiproliferative activity against human A549 cells measured after 72 hrs by WST1 assay	[PMID: 27597246]
A549	IC₅₀	0.63 μM Compound: 8	Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
A549	IC₅₀	476.86 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human A549 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
A549	IC₅₀	5 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
A549	IC₅₀	1.5 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
A549	GI₅₀	1.73 μM Compound: 1; SAHA	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
A549	GI₅₀	19.45 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28629630]
A549	IC₅₀	0.86 μM Compound: SAHA	Anti-proliferative activity against human A549 cells after 48 hrs by MTT assay Anti-proliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28947154]
A549	IC₅₀	2.39 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
A549	IC₅₀	1.7 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 29223096]
A549	IC₅₀	4.4 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
A549	GI₅₀	5.02 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 29500130]
A549	IC₅₀	3.7 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
A549	GI₅₀	1.02 μM Compound: SAHA; 1	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
A549	IC₅₀	2.63 μM Compound: 4; SAHA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
A549	IC₅₀	2.01 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
A549	IC₅₀	1746.95 nM Compound: SAHA	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30115492]
A549	IC₅₀	1.08 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
A549	IC₅₀	2.24 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30525585]
A549	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 30660827]
A549	IC₅₀	4.12 μM Compound: 1; SAHA	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	[PMID: 31223439]
A549	IC₅₀	2.61 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
A549	IC₅₀	2.42 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
A549	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	GI₅₀	1.02 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
A549	GI₅₀	2.62 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
A549	GI₅₀	1.02 μM Compound: 1; SAHA	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	[PMID: 32058238]
A549	IC₅₀	15.73 μM Compound: SAHA	Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
A549	IC₅₀	2.93 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
A549	IC₅₀	7.06 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
A549	IC₅₀	3.14 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
A549	IC₅₀	12.5 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay	[PMID: 32679451]
A549	IC₅₀	2651.1 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
A549	IC₅₀	1.7 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
A549	GI₅₀	>410 nM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
A549	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
A549	IC₅₀	2.36 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
A549	IC₅₀	2.57 μM Compound: SAHA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 32961382]
A549	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 33045329]
A549	IC₅₀	4.25 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
A549	IC₅₀	1.67 μM Compound: SAHA	Dark toxicity in human A549 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay Dark toxicity in human A549 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	[PMID: 33744687]
A549	IC₅₀	1.7 μM Compound: SAHA	Phototoxicity in human A549 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay Phototoxicity in human A549 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	[PMID: 33744687]
A549	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
A549	IC₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
A549	IC₅₀	1.1 μM Compound: 4; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 34314844]
A549	IC₅₀	4.372 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
A549	GI₅₀	5.4 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
A549	IC₅₀	>100 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
A549	IC₅₀	4.3 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
A549	IC₅₀	3.5 μM Compound: 2; SAHA	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
A549	IC₅₀	7.32 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
A549	IC₅₀	2.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
A549	IC₅₀	7.44 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
A549	IC₅₀	0.89 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
A549	IC₅₀	5.74 μM Compound: I-1; SAHA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 35245830]
A549	IC₅₀	9.13 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
A549	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
A549	IC₅₀	4.4 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
A549	IC₅₀	0.64 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 35643262]
A549	IC₅₀	7.49 μM Compound: SAHA	Antiproliferative activity against human A549 cells measured after 72 hrs Antiproliferative activity against human A549 cells measured after 72 hrs	[PMID: 35697181]
A549	IC₅₀	1.69 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
A549	IC₅₀	2.47 μM Compound: 1; SAHA	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
A549	IC₅₀	1.23 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
A549	IC₅₀	1862 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
A549	IC₅₀	1.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
A549	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
A549	IC₅₀	0.427 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
A549	IC₅₀	0.84 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human A549 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
A549	IC₅₀	4.33 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
A549	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A549	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 37875056]
A549	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	1.02 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 37875056]
A549	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A549	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	3.29 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
A549	IC₅₀	4.11 μM Compound: SAHA	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
A549	IC₅₀	1.62 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
A549	IC₅₀	1.91 μM Compound: XII; SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
A549	IC₅₀	9.484 μM Compound: SAHA	Anticancer activity against human A549 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay	[PMID: 38897139]
A549	IC₅₀	1.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38964169]
A549	IC₅₀	35 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
A549	IC₅₀	5.48 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
A549	IC₅₀	6.74 μM Compound: SAHA; 6	Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
A549	IC₅₀	4.97 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
A549	IC₅₀	12.46 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
A549	IC₅₀	5.37 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
A549	IC₅₀	78.76 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
ACHN	GI₅₀	0.73 μM Compound: 2, SAHA	Antiproliferative activity against human ACHN cells by SRB assay Antiproliferative activity against human ACHN cells by SRB assay	[PMID: 16723227]
ACHN	GI₅₀	0.73 μM Compound: 1, SAHA	Growth inhibition of ACHN cells by SRB assay Growth inhibition of ACHN cells by SRB assay	[PMID: 17477518]
ACHN	GI₅₀	0.65 μM Compound: SAHA	Growth inhibition of human ACHN cells after 21 hrs by MTT assay Growth inhibition of human ACHN cells after 21 hrs by MTT assay	[PMID: 17662606]
ACHN	GI₅₀	2.22 μM Compound: 2, SAHA	Growth inhibition of human ACHN cells by SRB assay Growth inhibition of human ACHN cells by SRB assay	[PMID: 17904843]
ACHN	GI₅₀	4.22 μM Compound: 1, SAHA	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 20850971]
ACHN	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human ACHN cells after 72 hrs by MTS assay Growth inhibition of human ACHN cells after 72 hrs by MTS assay	[PMID: 22435669]
ACHN	GI₅₀	4.22 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human ACHN cells assessed as growth inhibition by SRB assay Cytotoxicity against human ACHN cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
ACHN	GI₅₀	4.22 μM Compound: SAHA	Growth inhibition of human ACHN cells after 5 days by sulforhodamine B assay Growth inhibition of human ACHN cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
ACHN	GI₅₀	4.22 μM Compound: SAHA	Growth inhibition of human ACHN cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human ACHN cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
ACHN	IC₅₀	2.08 μM Compound: SAHA	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	4 μM Compound: SAHA	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
AGS	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human AGS cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human AGS cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
AML12	IC₅₀	>5 μM Compound: SAHA	Cytotoxicity against AML12 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against AML12 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
ASPC1	IC₅₀	100 μM Compound: 2	Cytotoxicity against human AsPC1 cells Cytotoxicity against human AsPC1 cells	[PMID: 17691763]
ASPC1	IC₅₀	0.69 μg/mL Compound: SAHA	Cytotoxicity against human AsPC1 cells Cytotoxicity against human AsPC1 cells	[PMID: 22036991]
ASPC1	IC₅₀	3.66 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human AsPC1 cells after 48 hrs by SRB assay Antiproliferative activity against human AsPC1 cells after 48 hrs by SRB assay	[PMID: 24185378]
ASPC1	GI₅₀	2.09 μM Compound: 1, SAHA	Growth inhibition of human Aspc-1 cells after 96 hrs by MTT assay Growth inhibition of human Aspc-1 cells after 96 hrs by MTT assay	[PMID: 26814680]
ASPC1	GI₅₀	5.44 μM Compound: 1; SAHA	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
ASPC1	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human Aspc-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Aspc-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
ASPC1	IC₅₀	>411 nM Compound: Vorinostat	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
ASPC1	IC₅₀	3.2 μM Compound: Vorinostat	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
ASPC1	IC₅₀	3.09 μM Compound: SAHA	Antiproliferative activity against human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
B16	IC₅₀	4.44 μM Compound: 1, SAHA	Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
B16	IC₅₀	2.26 μM Compound: I-1; SAHA	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 35245830]
B16-F10	IC₅₀	13.1 μM Compound: SAHA	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
B16-F10	IC₅₀	2.067 μM Compound: SAHA	Cytotoxicity against human B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
B16-F10	IC₅₀	11.36 μM Compound: SAHA	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
B16-F10	IC₅₀	13.52 μM Compound: SAHA	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
BaF3	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
BaF3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Bcap37	IC₅₀	3.098 μM Compound: SAHA	Cytotoxicity against human Bcap37 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Bcap37 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
BE(2)-C	IC₅₀	2 μM Compound: SAHA, vorinostat	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	[PMID: 22932316]
BE(2)-C	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human BE(2)-C cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human BE(2)-C cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25238284]
BE(2)-C	IC₅₀	2.112 μM Compound: SAHA	Antiproliferative activity against human BE2C cells incubated for 48 hrs by MTT assay Antiproliferative activity against human BE2C cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
BEAS-2B	IC₅₀	>50 μM Compound: 1; SAHA	Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
Bel-7402	IC₅₀	4.72 μM Compound: SAHA	Antiproliferative activity against human Bel7402 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Bel7402 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
Bel-7402	IC₅₀	7.1 μM Compound: 5; SAHA	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 31117517]
Bel-7402	IC₅₀	4.7 μM Compound: SAHA	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 31120744]
Bel-7402	IC₅₀	4.207 μM Compound: SAHA	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
Bel-7402	IC₅₀	27.35 μM Compound: SAHA	Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
Bel-7402	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human Bel-7402 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human Bel-7402 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
Bel7402/5-FU	IC₅₀	9.83 μM Compound: SAHA	Antiproliferative activity against human Bel7402/5-FU cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
BGC-823	GI₅₀	3.09 μM Compound: SAHA, Vorinostat	Growth inhibition of human BGC823 cells by MTT assay Growth inhibition of human BGC823 cells by MTT assay	[PMID: 23601706]
BGC-823	GI₅₀	4.26 μM Compound: vorinostat, SAHA	Antiproliferative activity against human BGC823 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human BGC823 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
BGC-823	IC₅₀	2.94 μM Compound: SAHA	Antiproliferative activity against human BGC823 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
BGC-823	IC₅₀	12.98 μM Compound: SAHA	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
BGC-823	IC₅₀	9.34 μM Compound: SAHA	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
BJ	IC₅₀	>100 μM Compound: SAHA	Growth inhibition of human BJ cells after 48 hrs by MTT assay Growth inhibition of human BJ cells after 48 hrs by MTT assay	[PMID: 20143840]
BMDM	CC₅₀	5 μM Compound: 1	Cytotoxicity against Swiss mouse BMDM assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay Cytotoxicity against Swiss mouse BMDM assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay	[PMID: 32392053]
BT-474	IC₅₀	2.67 μM Compound: 8	Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
BT-549	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human BT549 cells after 72 hrs by MTS assay Growth inhibition of human BT549 cells after 72 hrs by MTS assay	[PMID: 22435669]
BT-549	IC₅₀	8.67 μM Compound: SAHA	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
BT-549	IC₅₀	2.96 μM Compound: SAHA	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
BT-549	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human BT-549 cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability Cytotoxicity against human BT-549 cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 18494463]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 18642892]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells by MTT assay Antiproliferative activity against human BxPC3 cells by MTT assay	[PMID: 19419863]
BXPC-3	IC₅₀	5 μM Compound: 1a, SAHA	Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay	[PMID: 20055418]
BXPC-3	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay	[PMID: 20143778]
BXPC-3	GI₅₀	5.56 μM Compound: Vorin	Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 24900743]
BXPC-3	IC₅₀	4.74 μM Compound: SAHA	Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
BXPC-3	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human BXPC-3 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human BXPC-3 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
C6	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
C6	IC₅₀	2.97 μM Compound: Vorinostat	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37875056]
Caco-2	IC₅₀	0.037 μM Compound: SAHA	Induction of HDAC-mediated histone acetylation in human Caco-2 cells at 5 uM after 6 hrs by indirect ELISA Induction of HDAC-mediated histone acetylation in human Caco-2 cells at 5 uM after 6 hrs by indirect ELISA	[PMID: 20143840]
Caco-2	IC₅₀	0.119 μM Compound: SAHA	Ex vivo inhibition of human HDAC1 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC1 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	0.147 μM Compound: SAHA	Ex vivo inhibition of human HDAC3 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC3 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	12.6 μM Compound: SAHA	Ex vivo inhibition of human HDAC5 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC5 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	41 μM Compound: SAHA	Ex vivo inhibition of human HDAC7 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC7 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	8.1 μM Compound: SAHA	Growth inhibition of human Caco-2 cells after 48 hrs by MTT assay Growth inhibition of human Caco-2 cells after 48 hrs by MTT assay	[PMID: 20143840]
Caco-2	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human Caco2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
CAKI-1	GI₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
CAKI-1	IC₅₀	32.46 μM Compound: SAHA	Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 34111829]
CAKI-1	IC₅₀	517 nM Compound: 1; SAHA	Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
CAL-27	IC₅₀	3.2 μM Compound: 2	Cytotoxicity against human Cal27 cells Cytotoxicity against human Cal27 cells	[PMID: 17691763]
CAL-27	IC₅₀	3.72 μM Compound: SAHA	Antiproliferative activity against human CAL27 cells Antiproliferative activity against human CAL27 cells	[PMID: 20143778]
CAL-27	IC₅₀	3.2 μM Compound: 2a	Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay	[PMID: 21080629]
CAL-27	IC₅₀	0.36 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	2.08 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
CAL-27	IC₅₀	2.64 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
CAL-27	IC₅₀	1.98 μM Compound: Vorinostat	Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay	[PMID: 28581289]
CAL-27	IC₅₀	1.99 μM Compound: Vorinostat	Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
CAL-27	IC₅₀	1.96 μM Compound: Vorinostat	Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM) Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)	[PMID: 31762274]
CAL-27	IC₅₀	2.64 μM Compound: Vorinostat	Cytotoxicity against human CAL27 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay Cytotoxicity against human CAL27 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	[PMID: 31762274]
CAL-27	IC₅₀	0.59 μM Compound: 1	Inhibition of HDAC in human Cal27 cells Inhibition of HDAC in human Cal27 cells	[PMID: 31787463]
CAL-27	IC₅₀	1.5 μM Compound: 1	Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
CAL-27	IC₅₀	1.98 μM Compound: Vorinostat	Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33360560]
CAL-51	IC₅₀	1.04 μM Compound: SAHA	Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
Calu-3	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human Calu-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Calu-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
CAPAN-1	IC₅₀	7.3 μM Compound: SAHA	Antiproliferative activity against human Capan1 cells after hrs by ATP content assay Antiproliferative activity against human Capan1 cells after hrs by ATP content assay	[PMID: 20143778]
CAPAN-1	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay	[PMID: 29150335]
CAPAN-1	IC₅₀	5.4 μM Compound: SAHA	Anticancer activity against human CAPAN-1 cells Anticancer activity against human CAPAN-1 cells	[PMID: 34107385]
CAPAN-1	IC₅₀	1.89 μM Compound: SAHA	Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability	[PMID: 35643262]
CAPAN-1	IC₅₀	5.4 μM Compound: Vorinostat	Antiproliferative activity against human CAPAN-1 cells Antiproliferative activity against human CAPAN-1 cells	[PMID: 37875056]
Capan-2	IC₅₀	3 μM Compound: 5; SAHA	Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay	[PMID: 31117517]
CCRF-CEM	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC in human leukemic CEM cells Inhibition of HDAC in human leukemic CEM cells	[PMID: 16420064]
CCRF-CEM	IC₅₀	1.9 μM Compound: SAHA	Inhibition of human leukemic CEM cell viability Inhibition of human leukemic CEM cell viability	[PMID: 16420064]
CCRF-CEM	IC₅₀	0.8 μM Compound: 2	Cytotoxicity against human CCRF-CEM cells Cytotoxicity against human CCRF-CEM cells	[PMID: 17691763]
CCRF-CEM	IC₅₀	0.95 μM Compound: 2	Cytotoxicity against vincristine resistant human CCRF-CEM cells Cytotoxicity against vincristine resistant human CCRF-CEM cells	[PMID: 17691763]
CCRF-CEM	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC in human CEM cells Inhibition of HDAC in human CEM cells	[PMID: 18247554]
CCRF-CEM	IC₅₀	1.9 μM Compound: SAHA	Inhibition of human CEM cells assessed as viability Inhibition of human CEM cells assessed as viability	[PMID: 18247554]
CCRF-CEM	IC₅₀	0.8 μM Compound: 6, SAHA	Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
CCRF-CEM	GI₅₀	0.8 μM Compound: SAHA, Zolinza	Growth inhibition of human CCRF-CEM cells after 72 hrs by MTS assay Growth inhibition of human CCRF-CEM cells after 72 hrs by MTS assay	[PMID: 22435669]
CCRF-CEM	GI₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
CCRF-CEM	CC₅₀	2.5 μM Compound: SAHA	Cytotoxicity against human CEM cells assessed as cell death incubated for 20 hrs measured by DNS assay Cytotoxicity against human CEM cells assessed as cell death incubated for 20 hrs measured by DNS assay	[PMID: 34006099]
CESS	IC₅₀	1.78 μM Compound: SAHA; 6	Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
CHP-134	IC₅₀	1.74 μM Compound: Vorinostat	Antiproliferative activity against human CHP134 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human CHP134 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
CMK	IC₅₀	439.3 nM Compound: SAHA	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CMK	IC₅₀	490.2 nM Compound: SAHA	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CNE-2	IC₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
COLO 205	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter assay Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter assay	[PMID: 19181524]
COLO 205	IC₅₀	2.2 μM Compound: SAHA	Inhibition of HDAC1 in human COLO205 cells assessed as induction of histone H3 acetylation Inhibition of HDAC1 in human COLO205 cells assessed as induction of histone H3 acetylation	[PMID: 20451378]
COLO 205	IC₅₀	2.12 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
COLO 205	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
COR-L23	GI₅₀	1100 nM Compound: SAHA, vorinostat	Antiproliferative activity against human COR-L23 cells after 72 hrs by WST-1 assay Antiproliferative activity against human COR-L23 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
COR-L23	GI₅₀	3300 nM Compound: SAHA, vorinostat	Antiproliferative activity against doxorubicin-resistant human COR-L23 cells after 72 hrs by WST-1 assay Antiproliferative activity against doxorubicin-resistant human COR-L23 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
CT26	IC₅₀	5.97 μM Compound: 4; SAHA	Antiproliferative activity against mouse CT26 cells after 48 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
CT26	GI₅₀	2.7 μM Compound: 7; SAHA	Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay	[PMID: 34783558]
CT26	IC₅₀	5.65 μM Compound: I-1; SAHA	Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 35245830]
CT26	GI₅₀	2.35 μM Compound: 3; SAHA	Antiproliferative activity against mouse CT26 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells after 72 hrs by CCK-8 assay	[PMID: 35390714]
Daudi	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human Daudi cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human Daudi cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
DG-75	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay	[PMID: 29150335]
DLD-1	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
DLD-1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
DMS-114	GI₅₀	2.9 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human DMS114 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DMS114 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
DOHH-2	IC₅₀	366 nM Compound: 1; SAHA	Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
DOHH-2	IC₅₀	0.58 μM Compound: SAHA	Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
DU-145	EC₅₀	1.6 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human DU-145 cells Effective Concentration of compound to inhibit the growth of human DU-145 cells	[PMID: 15715470]
DU-145	EC₅₀	1.6 μM Compound: SAHA	Inhibition of human DU145 cells Inhibition of human DU145 cells	[PMID: 18247554]
DU-145	EC₅₀	2.11 μM Compound: SAHA	Viability of human DU145 cells after 72 hrs by MTS assay Viability of human DU145 cells after 72 hrs by MTS assay	[PMID: 18397827]
DU-145	EC₅₀	2.12 μM Compound: SAHA	Viability of human DU145 cells after 72 hrs by trypan blue staining Viability of human DU145 cells after 72 hrs by trypan blue staining	[PMID: 18397827]
DU-145	EC₅₀	2.12 μM Compound: SAHA	Cytotoxicity against human DU145 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human DU145 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
DU-145	GI₅₀	1050 nM Compound: SAHA, vorinostat	Antiproliferative activity against human DU145 cells after 72 hrs by WST-1 assay Antiproliferative activity against human DU145 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
DU-145	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay	[PMID: 22260166]
DU-145	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human DU145 cells after 72 hrs by MTS assay Growth inhibition of human DU145 cells after 72 hrs by MTS assay	[PMID: 22435669]
DU-145	GI₅₀	6.86 μM Compound: SAHA, Vorinostat	Growth inhibition of human DU145 cells by MTT assay Growth inhibition of human DU145 cells by MTT assay	[PMID: 23601706]
DU-145	IC₅₀	2.12 μM Compound: SAHA, Vorinostat	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 23622981]
DU-145	IC₅₀	27.2 μM Compound: SAHA, vorinostat	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
DU-145	IC₅₀	3.7 μM Compound: SAHA, vorinostat	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	2.58 μM Compound: Vorinostat	Cytotoxicity against human DU145 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human DU145 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
DU-145	GI₅₀	1.36 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 24015327]
DU-145	IC₅₀	2.49 μM Compound: SAHA	Cytotoxicity against androgen-independent human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against androgen-independent human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
DU-145	IC₅₀	2.49 μM Compound: SAHA	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 25240614]
DU-145	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
DU-145	GI₅₀	1590 nM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
DU-145	IC₅₀	3.45 μM Compound: SAHA	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
DU-145	IC₅₀	0.87 μM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	[PMID: 29150335]
DU-145	IC₅₀	1.8 μM Compound: 5; SAHA	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 31117517]
DU-145	IC₅₀	0.79 μM Compound: 1; SAHA	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method	[PMID: 33077264]
DU-145	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
DU-145	IC₅₀	0.47 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability	[PMID: 35643262]
DU-145	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
DU-145	IC₅₀	24.19 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay	[PMID: 38367494]
DU-145	IC₅₀	0.64 μM Compound: 1; SAHA	Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
EA.hy 926	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
EB-3	GI₅₀	2.8 μM Compound: 1, SAHA	Cytotoxic activity against human EB3 cells after 3 days by MTT assay Cytotoxic activity against human EB3 cells after 3 days by MTT assay	[PMID: 25380299]
EB-3	GI₅₀	2.8 μM Compound: SAHA, Zolinza	Antiproliferative activity against human EB3 cells assessed as growth inhibition incubated for 3 days by MTT assay Antiproliferative activity against human EB3 cells assessed as growth inhibition incubated for 3 days by MTT assay	10.1039/C4MD00252K
EBC-1	IC₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	[PMID: 28835797]
EJ	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
EKVX	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human EKVX cells after 72 hrs by MTS assay Growth inhibition of human EKVX cells after 72 hrs by MTS assay	[PMID: 22435669]
EL4	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse EL4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse EL4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
EL4	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
EOL1	IC₅₀	1 μM Compound: 2	Cytotoxicity against human EOL1cells Cytotoxicity against human EOL1cells	[PMID: 17691763]
EOL1	IC₅₀	1 μM Compound: 6, SAHA	Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
Epithelial cell	IC₅₀	14000 nM Compound: 1, vorinostat	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
Epithelial cell	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against nontransformed human microvascular epithelial cells Cytotoxicity against nontransformed human microvascular epithelial cells	[PMID: 18494463]
Erythrocyte	IC₅₀	>2.2 μM Compound: SAHA, Vorinostat	Cytotoxicity against erythrocytes (unknown origin) Cytotoxicity against erythrocytes (unknown origin)	[PMID: 24904967]
Erythroleukemia cell line	IC₅₀	2 μM Compound: SAHA	Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth	[PMID: 34591474]
ES-2	IC₅₀	0.53 μM Compound: SAHA	Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
ES-2	IC₅₀	414 nM Compound: 1; SAHA	Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
FaDu	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
FaDu	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human FaDu cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
FaDu	IC₅₀	5.42 μM Compound: XII; SAHA	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
FHC	IC₅₀	2.59 μM Compound: Vorinostat	Cytotoxicity against human FHC cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human FHC cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	[PMID: 33493830]
Fibroblast	IC₅₀	>300 μM Compound: SBHA	Toxicity in neonatal foreskin fibroblasts Toxicity in neonatal foreskin fibroblasts	[PMID: 18212103]
Fibroblast	EC₅₀	>10 μM Compound: SAHA	Cytotoxicity against human primary lung fibroblasts after 72 hrs by trypan blue exclusion assay Cytotoxicity against human primary lung fibroblasts after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
Friend leukemia cell line	IC₅₀	0.99 μM Compound: 6a	Tested in vivo for the inhibition of proliferation of friend leukemic cells Tested in vivo for the inhibition of proliferation of friend leukemic cells	[PMID: 12109913]
Friend leukemia cell line	IC₅₀	0.99 μM Compound: 1 (SAHA)	Inhibitory concentration against friend cells proliferation Inhibitory concentration against friend cells proliferation	[PMID: 14613312]
Friend leukemia cell line	IC₅₀	0.11 μM Compound: SAHA	Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
G-401	IC₅₀	1000 nM Compound: 1, vorinostat	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
G-401	CC₅₀	1000 nM Compound: 1	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
G55T2	IC₅₀	0.78 μM Compound: Vorinostat	Antiproliferative activity against human G55T2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human G55T2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 31391882]
GES1	IC₅₀	4690 nM Compound: SAHA	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
GES1	IC₅₀	233 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
GES1	IC₅₀	9.18 μM Compound: SAHA	Cytotoxicity against human GES1 cells harboring low LSD1 expression assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Cytotoxicity against human GES1 cells harboring low LSD1 expression assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
GES1	IC₅₀	0.61 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay	[PMID: 37796543]
GES1	IC₅₀	48.3 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37796543]
HaCaT	IC₅₀	1.85 μM Compound: SAHA	Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth	[PMID: 34742014]
HAL-01	IC₅₀	0.299 μM Compound: Vorinostat	Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HAL-01	IC₅₀	0.3 μM Compound: Vorinostat	Cytotoxicity against human HAL-01 cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human HAL-01 cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
HCC 2998	GI₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
HCC1937	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay	[PMID: 28601509]
HCC1937	IC₅₀	3.73 μM Compound: SAHA	Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability	[PMID: 35643262]
HCC827	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human HCC827 cells after hrs by ATP content assay Antiproliferative activity against human HCC827 cells after hrs by ATP content assay	[PMID: 20143778]
HCC827	IC₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 28601509]
HCCLM3	IC₅₀	6.52 μM Compound: 1; SAHA	Antiproliferative activity against human HCCLM3 cells after 48 hrs by MTT assay Antiproliferative activity against human HCCLM3 cells after 48 hrs by MTT assay	[PMID: 30455152]
HCT-116	IC₅₀	1.9 μM Compound: 4	Concentration required to inhibit the HCT116 cell growth by 50%. Concentration required to inhibit the HCT116 cell growth by 50%.	[PMID: 11831887]
HCT-116	IC₅₀	1930 nM Compound: SAHA (1)	Inhibitory activity against HCT116 human colon cell growth Inhibitory activity against HCT116 human colon cell growth	[PMID: 14521422]
HCT-116	EC₅₀	0.58 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human HCT116 cells Effective Concentration of compound to inhibit the growth of human HCT116 cells	[PMID: 15715470]
HCT-116	IC₅₀	1.93 μM Compound: 3, SAHA	Antiproliferative activity against HCT116 cells Antiproliferative activity against HCT116 cells	[PMID: 16904890]
HCT-116	IC₅₀	2.52 μM Compound: SAHA	Inhibition of HCT116 cell proliferation (mean of two experiments) Inhibition of HCT116 cell proliferation (mean of two experiments)	[PMID: 17095213]
HCT-116	IC₅₀	2.52 μM Compound: SAHA	Inhibition of HCT116 cell proliferation (mean of two experiments) Inhibition of HCT116 cell proliferation (mean of two experiments)	[PMID: 17107790]
HCT-116	IC₅₀	1.2 μM Compound: SAHA, vorinostat	Growth inhibition of human HCT116 cells by SRB assay Growth inhibition of human HCT116 cells by SRB assay	[PMID: 17892933]
HCT-116	EC₅₀	0.58 μM Compound: SAHA	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	IC₅₀	0.9 μM Compound: SAHA	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	IC₅₀	1.8 μM Compound: SAHA, 3	Cytotoxicity against human HCT116 cells assessed as cell viability after 96 hrs by MTS reduction assay Cytotoxicity against human HCT116 cells assessed as cell viability after 96 hrs by MTS reduction assay	[PMID: 18348516]
HCT-116	IC₅₀	1000 nM Compound: 1, vorinostat	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HCT-116	IC₅₀	1000 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
HCT-116	EC₅₀	1.6 μM Compound: 1, SAHA	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18954984]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs	[PMID: 19084294]
HCT-116	IC₅₀	1.2 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay	[PMID: 19359173]
HCT-116	IC₅₀	1000 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19410459]
HCT-116	GI₅₀	0.58 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
HCT-116	CC₅₀	1000 nM Compound: 1	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HCT-116	IC₅₀	0.08 mM Compound: Vorinostat	Antiproliferative activity against human HCT116 cells after 2 days by MTT assay Antiproliferative activity against human HCT116 cells after 2 days by MTT assay	[PMID: 19608304]
HCT-116	GI₅₀	2.69 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 19822426]
HCT-116	IC₅₀	0.79 mM Compound: vorinostat, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20171895]
HCT-116	EC₅₀	2 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 71 hrs by MTS assay Cytotoxicity against human HCT116 cells after 71 hrs by MTS assay	[PMID: 20392638]
HCT-116	IC₅₀	1.43 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 20451378]
HCT-116	GI₅₀	0.6 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20605448]
HCT-116	GI₅₀	750 nM Compound: SAHA	Growth inhibition of human HCT116 cells after 72 hrs by SRB assay Growth inhibition of human HCT116 cells after 72 hrs by SRB assay	[PMID: 20884208]
HCT-116	IC₅₀	1.2 μM Compound: 2, SAHA	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 21073160]
HCT-116	GI₅₀	740 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HCT116 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar blue assay	[PMID: 21420859]
HCT-116	IC₅₀	2.85 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
HCT-116	IC₅₀	810 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition Antiproliferative activity against human HCT116 cells assessed as growth inhibition	[PMID: 21650221]
HCT-116	IC₅₀	0.34 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 21733698]
HCT-116	IC₅₀	0.81 μM Compound: 1, SAHA, Zolinza	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 21742496]
HCT-116	IC₅₀	0.7 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21745740]
HCT-116	GI₅₀	0.6 μM Compound: SAHA	Growth inhibition of human HCT116 cells after 5 days by alamar blue assay Growth inhibition of human HCT116 cells after 5 days by alamar blue assay	[PMID: 21978679]
HCT-116	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human HCT116 cells after 72 hrs by MTS assay Growth inhibition of human HCT116 cells after 72 hrs by MTS assay	[PMID: 22435669]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	[PMID: 22877635]
HCT-116	IC₅₀	6 μM Compound: 1, SAHA	Inhibition of human HCT116 cell proliferation after 48 hrs by MTT assay Inhibition of human HCT116 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
HCT-116	GI₅₀	1 μM Compound: SAHA	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23538115]
HCT-116	GI₅₀	0.878 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 48 hrs by Sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by Sulforhodamine B assay	[PMID: 23639537]
HCT-116	IC₅₀	0.757 μM Compound: SAHA	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 23644210]
HCT-116	IC₅₀	0.76 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
HCT-116	EC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 23820574]
HCT-116	IC₅₀	1.39 μM Compound: Vorinostat	Cytotoxicity against human HCT116 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human HCT116 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
HCT-116	GI₅₀	0.37 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 24015327]
HCT-116	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24095018]
HCT-116	GI₅₀	0.94 μM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
HCT-116	GI₅₀	0.4 μM Compound: 2, SAHA, Vorinostat	Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay	[PMID: 24164245]
HCT-116	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24296013]
HCT-116	IC₅₀	2.81 μM Compound: SA, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24694055]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
HCT-116	IC₅₀	0.61 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 24766560]
HCT-116	GI₅₀	2.5 μM Compound: Vorin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 24900743]
HCT-116	GI₅₀	0.65 μM Compound: Vorinostat	Growth inhibition of human HCT116 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human HCT116 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
HCT-116	IC₅₀	3.45 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay	[PMID: 25261927]
HCT-116	IC₅₀	2.81 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 25462271]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	[PMID: 25746815]
HCT-116	GI₅₀	1.04 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
HCT-116	IC₅₀	3.7 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25815139]
HCT-116	IC₅₀	1.28 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
HCT-116	IC₅₀	4.25 μM Compound: 6, SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HCT-116	IC₅₀	0.33 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26100440]
HCT-116	IC₅₀	4.25 μM Compound: 1, SAHA	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HCT-116	IC₅₀	1.81 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
HCT-116	IC₅₀	6.15 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
HCT-116	IC₅₀	1.2 μM Compound: SAHA	Growth inhibition of human HCT116 cells after 72 hrs Growth inhibition of human HCT116 cells after 72 hrs	[PMID: 26376355]
HCT-116	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26443078]
HCT-116	GI₅₀	4.64 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	0.757 μM Compound: vorinostat	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
HCT-116	GI₅₀	2.03 μM Compound: 1, SAHA	Growth inhibition of human HCT116 cells after 96 hrs by MTT assay Growth inhibition of human HCT116 cells after 96 hrs by MTT assay	[PMID: 26814680]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity human HCT116 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity human HCT116 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
HCT-116	IC₅₀	1450 nM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
HCT-116	GI₅₀	0.15 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 27344487]
HCT-116	IC₅₀	1.85 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27541357]
HCT-116	EC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HCT116 cells measured after 72 hrs by WST1 assay Antiproliferative activity against human HCT116 cells measured after 72 hrs by WST1 assay	[PMID: 27597246]
HCT-116	IC₅₀	1488.6 nM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human HCT116 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
HCT-116	IC₅₀	1.4 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
HCT-116	IC₅₀	1.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	[PMID: 28213282]
HCT-116	IC₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 28835797]
HCT-116	IC₅₀	3.1 μM Compound: 1; SAHA	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HCT-116	IC₅₀	2.35 μM Compound: SAHA	Anti-proliferative activity against human HCT116 cells after 48 hrs by MTT assay Anti-proliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28947154]
HCT-116	IC₅₀	1.85 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28953386]
HCT-116	IC₅₀	0.877 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29288941]
HCT-116	IC₅₀	9.6 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
HCT-116	GI₅₀	0.15 μM Compound: SAHA; 1	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
HCT-116	IC₅₀	3.07 μM Compound: 4; SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
HCT-116	IC₅₀	1.85 μM Compound: 4	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 29945795]
HCT-116	IC₅₀	<1 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29954683]
HCT-116	IC₅₀	1.18 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108831]
HCT-116	IC₅₀	561.32 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30115492]
HCT-116	IC₅₀	2.2 μM Compound: 4	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30243158]
HCT-116	IC₅₀	0.76 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
HCT-116	IC₅₀	882.5 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30629434]
HCT-116	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
HCT-116	IC₅₀	1617.76 nM Compound: SAHA	Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay	[PMID: 30819618]
HCT-116	IC₅₀	4.97 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HCT-116	IC₅₀	1.9 μM Compound: 5; SAHA	Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 31117517]
HCT-116	IC₅₀	720 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31177073]
HCT-116	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
HCT-116	IC₅₀	1.81 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
HCT-116	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 31546197]
HCT-116	GI₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
HCT-116	GI₅₀	0.44 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
HCT-116	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HCT-116	IC₅₀	4.9 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
HCT-116	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
HCT-116	IC₅₀	11.8 nM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay	[PMID: 32679451]
HCT-116	IC₅₀	895 nM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
HCT-116	IC₅₀	0.55 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
HCT-116	GI₅₀	>410 nM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
HCT-116	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HCT-116	IC₅₀	4.2 μM Compound: 1; SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
HCT-116	IC₅₀	3.7 μM Compound: SAHA	Phototoxicity in human HCT-116 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay Phototoxicity in human HCT-116 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	[PMID: 33744687]
HCT-116	IC₅₀	3.75 μM Compound: SAHA	Dark toxicity in human HCT-116 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay Dark toxicity in human HCT-116 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	[PMID: 33744687]
HCT-116	IC₅₀	1.85 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 33957387]
HCT-116	IC₅₀	2.59 μM Compound: SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HCT-116	IC₅₀	0.89 μM Compound: 4; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 34314844]
HCT-116	IC₅₀	0.67 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HCT-116	IC₅₀	3.59 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
HCT-116	IC₅₀	1.08 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HCT-116	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HCT-116	IC₅₀	1.55 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HCT-116	IC₅₀	2.41 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
HCT-116	IC₅₀	0.27 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HCT-116	IC₅₀	0.797 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
HCT-116	IC₅₀	1.47 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 72 hrs Antiproliferative activity against human HCT-116 cells measured after 72 hrs	[PMID: 35697181]
HCT-116	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HCT-116	IC₅₀	1.31 μM Compound: SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
HCT-116	IC₅₀	1.27 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HCT-116	IC₅₀	2.7 μM Compound: 1; SAHA	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HCT-116	IC₅₀	1.18 μM Compound: SAHA	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HCT-116	IC₅₀	0.49 μM Compound: 3; SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
HCT-116	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HCT-116	IC₅₀	0.3 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	3.05 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
HCT-116	IC₅₀	5.66 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
HCT-116	IC₅₀	1.489 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
HCT-116	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HCT-116	IC₅₀	0.15 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 37875056]
HCT-116	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human wild type HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human wild type HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	1.03 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells Antiproliferative activity against human HCT-116 cells	[PMID: 37875056]
HCT-116	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells by MTT assay Antiproliferative activity against human HCT-116 cells by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	4.2 μM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
HCT-116	IC₅₀	0.69 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HCT-116	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HCT-116	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
HCT-116	IC₅₀	<1.18 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HCT-116	IC₅₀	32.46 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HCT-116	IC₅₀	5.06 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HCT-15	GI₅₀	0.82 μM Compound: 2, SAHA	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 16723227]
HCT-15	GI₅₀	0.82 μM Compound: 1, SAHA	Growth inhibition of HCT15 cells by SRB assay Growth inhibition of HCT15 cells by SRB assay	[PMID: 17477518]
HCT-15	GI₅₀	0.95 μM Compound: SAHA	Growth inhibition of human HCT15 cells after 21 hrs by MTT assay Growth inhibition of human HCT15 cells after 21 hrs by MTT assay	[PMID: 17662606]
HCT-15	IC₅₀	3.9 μM Compound: 2	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 17691763]
HCT-15	GI₅₀	2.49 μM Compound: 2, SAHA	Growth inhibition of human HCT15 cells by SRB assay Growth inhibition of human HCT15 cells by SRB assay	[PMID: 17904843]
HCT-15	GI₅₀	2.49 μM Compound: 1, SAHA	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 20850971]
HCT-15	GI₅₀	2.5 μM Compound: SAHA, Zolinza	Growth inhibition of human HCT15 cells after 72 hrs by MTS assay Growth inhibition of human HCT15 cells after 72 hrs by MTS assay	[PMID: 22435669]
HCT-15	GI₅₀	2.49 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
HCT-15	GI₅₀	2.49 μM Compound: SAHA	Growth inhibition of human HCT15 cells after 5 days by sulforhodamine B assay Growth inhibition of human HCT15 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
HCT-15	GI₅₀	2.49 μM Compound: SAHA	Growth inhibition of human HCT15 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human HCT15 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
HCT-8	IC₅₀	0.35 μM Compound: 5; SAHA	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 31117517]
HEC-1-A	IC₅₀	1 μM Compound: 2	Cytotoxicity against human Hec-1-A cells Cytotoxicity against human Hec-1-A cells	[PMID: 17691763]
HEK293	IC₅₀	30 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC1 in HEK293 cells Inhibition of HDAC1 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	43 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC6 in HEK293 cells Inhibition of HDAC6 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	57 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC3 in HEK293 cells Inhibition of HDAC3 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	0.019 μM Compound: SAHA	Inhibition of recombinant HDAC6 expressed in HEK293 cells Inhibition of recombinant HDAC6 expressed in HEK293 cells	[PMID: 18558669]
HEK293	IC₅₀	0.033 μM Compound: SAHA	Inhibition of recombinant HDAC1 expressed in HEK293 cells Inhibition of recombinant HDAC1 expressed in HEK293 cells	[PMID: 18558669]
HEK293	IC₅₀	0.02 μM Compound: 6, SAHA	Inhibition of human recombinant HDAC1 expressed in HEK293 cells Inhibition of human recombinant HDAC1 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	0.052 μM Compound: 6, SAHA	Inhibition of human recombinant HDAC6 expressed in HEK293 cells Inhibition of human recombinant HDAC6 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	30 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	57 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	82 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	0.021 μM Compound: 2a	Inhibition of human recombinant HDAC1 expressed in HEK293 cells Inhibition of human recombinant HDAC1 expressed in HEK293 cells	[PMID: 21080629]
HEK293	IC₅₀	0.025 μM Compound: 2a	Inhibition of human recombinant HDAC6 expressed in HEK293 cells Inhibition of human recombinant HDAC6 expressed in HEK293 cells	[PMID: 21080629]
HEK293	GI₅₀	13 μM Compound: 1, SAHA	Growth inhibition of human HEK293 cells after 72 hrs by XTT assay Growth inhibition of human HEK293 cells after 72 hrs by XTT assay	[PMID: 24900500]
HEK293	CC₅₀	100 μM Compound: SAHA, Vorinostat	Cytotoxicity against HEK293 cells assessed as reduction in cell viability Cytotoxicity against HEK293 cells assessed as reduction in cell viability	[PMID: 26264503]
HEK293	GI₅₀	3.38 μM Compound: 1, SAHA	Cytotoxicity against HEK293 cells assessed as growth inhibition after 96 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as growth inhibition after 96 hrs by MTT assay	[PMID: 26814680]
HEK293	IC₅₀	>30 μM Compound: SAHA	Inhibition of recombinant human ERG expressed in HEK293 cells at -80 mV holding potential measured for 9 mins by Qpatch clamp method Inhibition of recombinant human ERG expressed in HEK293 cells at -80 mV holding potential measured for 9 mins by Qpatch clamp method	[PMID: 28947154]
HEK293	IC₅₀	0.01 μM Compound: SAHA	Inhibition of recombinant human GST-fused HDAC1 expressed in HEK293 cells Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human GST-fused HDAC1 expressed in HEK293 cells Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HEK293	IC₅₀	5170 nM Compound: SAHA	Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay	[PMID: 30245402]
HEK293	IC₅₀	0.016 μM Compound: SAHA	Inhibition of full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells preincubated for 15 mins followed by acetyl-Gly-Ala-[acetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method Inhibition of full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells preincubated for 15 mins followed by acetyl-Gly-Ala-[acetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	[PMID: 30613344]
HEK293	IC₅₀	0.669 μM Compound: SAHA	Inhibition of full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells preincubated for 15 mins followed by Boc-[trifluoroacetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method Inhibition of full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells preincubated for 15 mins followed by Boc-[trifluoroacetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	[PMID: 30613344]
HEK293	CC₅₀	2.3 μM Compound: Vorinostat	Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	[PMID: 30973727]
HEK293	IC₅₀	0.122 μM Compound: SAHA	Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	[PMID: 31414801]
HEK293	IC₅₀	0.241 μM Compound: SAHA	Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	[PMID: 31414801]
HEK293	IC₅₀	2.48 μM Compound: SAHA	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 34107385]
HEK293	IC₅₀	1637 nM Compound: 1; SAHA	Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HEK293	IC₅₀	2.48 μM Compound: SAHA	Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 38056296]
HEK293	IC₅₀	>250 μM Compound: SAHA	Cytotoxicity against HEK293 cells incubated for 24 hrs by Neutral Red Uptake assay Cytotoxicity against HEK293 cells incubated for 24 hrs by Neutral Red Uptake assay	[PMID: 39208744]
HEK293	IC₅₀	0.013 μM Compound: 2, SAHA	Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HEK-293T	IC₅₀	8.221 μM Compound: SAHA	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
HEK-293T	EC₅₀	>1 μM Compound: SAHA	Cytotoxicity against human HEK293T cells assessed as cell growth inhibition Cytotoxicity against human HEK293T cells assessed as cell growth inhibition	[PMID: 33356214]
HEK-293T	IC₅₀	4.5 μM Compound: Vorinostat	Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay	[PMID: 35175762]
HEL	IC₅₀	0.49 μM Compound: SA, SAHA	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 24694055]
HEL	IC₅₀	0.49 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 25462271]
HEL	GI₅₀	0.76 μM Compound: SAHA	Antiproliferative activity against human HEL cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human HEL cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
HEL	IC₅₀	2.42 μM Compound: 6, SAHA	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HEL	IC₅₀	1.74 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 26100440]
HEL	IC₅₀	2.42 μM Compound: 1, SAHA	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HEL	IC₅₀	1.27 μM Compound: SAHA	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
HEL	IC₅₀	0.21 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28336407]
HEL	IC₅₀	0.25 μM Compound: Vorinostat	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28371677]
HEL	IC₅₀	0.79 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 29500131]
HEL	IC₅₀	0.15 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 29533873]
HEL	IC₅₀	0.19 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	[PMID: 29787262]
HEL	IC₅₀	0.86 μM Compound: 2; SAHA	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HEL	IC₅₀	0.89 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 30879863]
HEL	IC₅₀	0.3 μM Compound: 3; SAHA	Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	[PMID: 30901208]
HEL	IC₅₀	0.65 μM Compound: 3; SAHA	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
HEL	IC₅₀	0.02 μM Compound: SAHA	Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
HEL	IC₅₀	0.65 μM Compound: 1	Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HEL	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HEL	IC₅₀	0.4 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
HEL	IC₅₀	0.5 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
HEL	IC₅₀	0.18 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HEL cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HEL	IC₅₀	0.18 μM Compound: SAHA	Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HEL	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human HEL cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HEL	IC₅₀	0.21 μM Compound: Vorinostat	Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay	[PMID: 38107170]
HEL	IC₅₀	0.18 μM Compound: SAHA	Cytotoxicity against HEL cells assessed as reduction in cell growth incubated for 72 hrs by WST assay Cytotoxicity against HEL cells assessed as reduction in cell growth incubated for 72 hrs by WST assay	[PMID: 38964169]
HEL	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 1; SAHA	Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay	[PMID: 27541357]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 2	Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay	[PMID: 28953386]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 4	Antiproliferative activity against human HEL 92.1.7 cells after 72 hrs by MTT assay Antiproliferative activity against human HEL 92.1.7 cells after 72 hrs by MTT assay	[PMID: 30243158]
HeLa	IC₅₀	0.28 μM Compound: SAHA	Inhibitory concentration against histone deacetylase of HeLa cells Inhibitory concentration against histone deacetylase of HeLa cells	[PMID: 15603949]
HeLa	IC₅₀	0.11 μM Compound: 2, SAHA	Inhibition of HeLa cell HDAC Inhibition of HeLa cell HDAC	[PMID: 16723227]
HeLa	IC₅₀	460 nM Compound: SAHA	Inhibition of HeLa cell proliferation Inhibition of HeLa cell proliferation	[PMID: 16987657]
HeLa	IC₅₀	0.11 μM Compound: 1, SAHA	Inhibition of HDAC in HeLa cells by fluorescent activity assay Inhibition of HDAC in HeLa cells by fluorescent activity assay	[PMID: 17477518]
HeLa	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC in HeLa cells Inhibition of HDAC in HeLa cells	[PMID: 17662606]
HeLa	EC₅₀	6.67 μM Compound: 2	Inhibition of HDAC in HeLa cells assessed as induction of human histone H3 hyperacetylation Inhibition of HDAC in HeLa cells assessed as induction of human histone H3 hyperacetylation	[PMID: 17691763]
HeLa	IC₅₀	0.02 μM Compound: 2	Inhibition of recombinant HDAC1 in HeLa cells Inhibition of recombinant HDAC1 in HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	0.07 μM Compound: 2	Inhibition of HDAC in HeLa cells Inhibition of HDAC in HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	1.75 μM Compound: 2	Cytotoxicity against HeLa cells Cytotoxicity against HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	>=0.05 μM Compound: SAHA, vorinostat	Inhibition of HDAC2 in HeLa cell lysates Inhibition of HDAC2 in HeLa cell lysates	[PMID: 17892933]
HeLa	IC₅₀	0.11 μM Compound: 2, SAHA	Inhibition of HDAC in HeLa cell lysates Inhibition of HDAC in HeLa cell lysates	[PMID: 17904843]
HeLa	IC₅₀	0.28 μM Compound: SAHA	Inhibition of HDAC from human HeLa cells Inhibition of HDAC from human HeLa cells	[PMID: 18247554]
HeLa	IC₅₀	460 nM Compound: 1, vorinostat	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of human HDAC in HeLa cells by flour de lys assay Inhibition of human HDAC in HeLa cells by flour de lys assay	[PMID: 18397827]
HeLa	EC₅₀	4.8 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells assessed as induction of histone H3 hyperacetylation after 24 hrs Inhibition of HDAC in human HeLa cells assessed as induction of histone H3 hyperacetylation after 24 hrs	[PMID: 18558669]
HeLa	IC₅₀	0.083 μM Compound: SAHA	Inhibition of nuclear HDAC isolated from human HeLa cells Inhibition of nuclear HDAC isolated from human HeLa cells	[PMID: 18558669]
HeLa	IC₅₀	4.5 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells Inhibition of HDAC in human HeLa cells	[PMID: 18558669]
HeLa	IC₅₀	3.1 μM Compound: II, SAHA	Antiproliferative activity against human HeLa cells after 4 hrs by WST-1 assay Antiproliferative activity against human HeLa cells after 4 hrs by WST-1 assay	[PMID: 18672316]
HeLa	IC₅₀	87 nM Compound: II, SAHA	Inhibition of HDAC from human HeLa cells Inhibition of HDAC from human HeLa cells	[PMID: 18672316]
HeLa	IC₅₀	460 nM Compound: 1, SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human HeLa cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
HeLa	EC₅₀	0.55 μM Compound: 1, SAHA	Inhibition of histone deacetylase in human HeLa cells assessed as induction of histone H3 hyperacetylation Inhibition of histone deacetylase in human HeLa cells assessed as induction of histone H3 hyperacetylation	[PMID: 18954984]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa cells Inhibition of HDAC2 in human HeLa cells	[PMID: 19084294]
HeLa	IC₅₀	1860 nM Compound: SAHA	Inhibition of HDAC8 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC8 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC1/2 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC1/2 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	85.5 nM Compound: SAHA	Inhibition of HDAC6 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC6 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	80 nM Compound: SAHA	Inhibition of human HDAC in HeLa cells by fluorescent activity assay Inhibition of human HDAC in HeLa cells by fluorescent activity assay	[PMID: 19223622]
HeLa	EC₅₀	6.7 μM Compound: 6, SAHA	Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation	[PMID: 19301902]
HeLa	IC₅₀	2.2 μM Compound: 6, SAHA	Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HeLa	IC₅₀	0.28 μM Compound: 2, (SAHA, vorinostat)	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetry Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetry	[PMID: 19419205]
HeLa	CC₅₀	460 nM Compound: 1	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HeLa	IC₅₀	0.7 μM Compound: SAHA	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	[PMID: 19457659]
HeLa	IC₅₀	49 nM Compound: SAHA	Inhibition of HDAC1/2 from human HeLa cells Inhibition of HDAC1/2 from human HeLa cells	[PMID: 19854643]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	[PMID: 19914074]
HeLa	IC₅₀	1.1 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract by fluorescence assay	[PMID: 20036560]
HeLa	IC₅₀	40 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract Inhibition of HDAC in human HeLa cell nuclear extract	[PMID: 20143778]
HeLa	IC₅₀	196 nM Compound: SAHA	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	[PMID: 20167479]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay	[PMID: 20576572]
HeLa	IC₅₀	29 nM Compound: SAHA	Selectivity ratio IC50 for HDAC8 to IC50 for HDAC in human HeLa cells nuclear extract Selectivity ratio IC50 for HDAC8 to IC50 for HDAC in human HeLa cells nuclear extract	[PMID: 20669972]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts Inhibition of HDAC in human HeLa cell nuclear extracts	[PMID: 20669972]
HeLa	GI₅₀	1460 nM Compound: SAHA	Growth inhibition of human HeLa cells after 72 hrs by SRB assay Growth inhibition of human HeLa cells after 72 hrs by SRB assay	[PMID: 20884208]
HeLa	IC₅₀	87 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetric assay Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetric assay	[PMID: 20884208]
HeLa	IC₅₀	0.07 μM Compound: 2a	Inhibition of HDAC in human HeLa cell nuclear extracts Inhibition of HDAC in human HeLa cell nuclear extracts	[PMID: 21080629]
HeLa	IC₅₀	1.5 μM Compound: 2a	Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay	[PMID: 21080629]
HeLa	IC₅₀	87 nM Compound: SAHA, vorinostat	Inhibition of HDAC in human HeLa cells nuclear extract using fluor de Lys as substrate preincubated for 5 mins by fluorometric analysis Inhibition of HDAC in human HeLa cells nuclear extract using fluor de Lys as substrate preincubated for 5 mins by fluorometric analysis	[PMID: 21080647]
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells by fluorescent activity assay Inhibition of HDAC in human HeLa cells by fluorescent activity assay	[PMID: 21420859]
HeLa	IC₅₀	0.107 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 21476600]
HeLa	IC₅₀	0.195 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC6 in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC6 in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 21476600]
HeLa	IC₅₀	147 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21476600]
HeLa	EC₅₀	14.2 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by XTT assay Antiproliferative activity against human HeLa cells after 48 hrs by XTT assay	[PMID: 21548582]
HeLa	EC₅₀	4.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by XTT assay Antiproliferative activity against human HeLa cells after 72 hrs by XTT assay	[PMID: 21548582]
HeLa	EC₅₀	43 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 24 hrs by XTT assay Antiproliferative activity against human HeLa cells after 24 hrs by XTT assay	[PMID: 21548582]
HeLa	IC₅₀	67 nM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	[PMID: 21621883]
HeLa	IC₅₀	0.09 μM Compound: SAHA, Vorinostat	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	[PMID: 21889343]
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release by fluorescence spectrophotometry Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release by fluorescence spectrophotometry	[PMID: 21978679]
HeLa	IC₅₀	18 nM Compound: 2, SAHA	Inhibition of HDAC6 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC6 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	2000 nM Compound: 2, SAHA	Inhibition of HDAC8 in human HeLa cells nuclear extract using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry Inhibition of HDAC8 in human HeLa cells nuclear extract using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	41 nM Compound: 2, SAHA	Inhibition of HDAC1 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC1 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	41 nM Compound: 2, SAHA	Inhibition of HDAC3-NCoR2 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC3-NCoR2 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	1989 nM Compound: SAHA	Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	27 nM Compound: SAHA	Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	38 nM Compound: SAHA	Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	67 nM Compound: SAHA, Zolinza	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorimetry Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorimetry	[PMID: 22435669]
HeLa	IC₅₀	96.4 nM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 22439863]
HeLa	IC₅₀	0.98 μM Compound: Zolinza, SAHA	Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry	[PMID: 22698782]
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate by fluorescence assay	[PMID: 22877635]
HeLa	IC₅₀	86 nM Compound: SAHA	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	[PMID: 23089527]
HeLa	IC₅₀	0.17 μM Compound: 2	Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay	[PMID: 23116147]
HeLa	IC₅₀	0.19 μM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 23493449]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC1/3/5/8 in human HeLa cell extract using Boc-Lys-(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorometric analysis Inhibition of HDAC1/3/5/8 in human HeLa cell extract using Boc-Lys-(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorometric analysis	[PMID: 23510562]
HeLa	GI₅₀	3.36 μM Compound: SAHA, Vorinostat	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 23601706]
HeLa	IC₅₀	1989 nM Compound: SAHA, Vorinostat	Inhibition of HDAC8 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC8 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	27 nM Compound: SAHA, Vorinostat	Inhibition of HDAC6 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC6 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	38 nM Compound: SAHA, Vorinostat	Inhibition of HDAC1 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC1 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	65 nM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	0.122 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay	[PMID: 23639537]
HeLa	IC₅₀	0.102 μM Compound: SAHA	Inhibition of HDAC in human Hela cell nuclear extract after 15 mins Inhibition of HDAC in human Hela cell nuclear extract after 15 mins	[PMID: 23644210]
HeLa	IC₅₀	2.8 μM Compound: SAHA, vorinostat	Inhibition of HDAC isolated from human HeLa cell nuclear extract after 30 mins by fluorescence assay Inhibition of HDAC isolated from human HeLa cell nuclear extract after 30 mins by fluorescence assay	[PMID: 23707260]
HeLa	IC₅₀	0.13 μM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 23792316]
HeLa	IC₅₀	0.053 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract using Fluor deLys as substrate by fluorimetric assay Inhibition of HDAC in human HeLa cell extract using Fluor deLys as substrate by fluorimetric assay	[PMID: 23820574]
HeLa	IC₅₀	0.106 μM Compound: Vorinostat, SAHA, Zolinza	Inhibition of full length FLAG-tagged recombinant HDAC3 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis Inhibition of full length FLAG-tagged recombinant HDAC3 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	[PMID: 23964961]
HeLa	IC₅₀	0.119 μM Compound: Vorinostat, SAHA, Zolinza	Inhibition of full length FLAG-tagged recombinant HDAC1 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis Inhibition of full length FLAG-tagged recombinant HDAC1 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	[PMID: 23964961]
HeLa	IC₅₀	2.59 μM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extracts using Color de LysTM after 30 mins Inhibition of HDAC in human HeLa cell nuclear extracts using Color de LysTM after 30 mins	[PMID: 24095016]
HeLa	IC₅₀	9.69 μM Compound: SAHA, Vorinostat	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 24095016]
HeLa	IC₅₀	141 nM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate by fluorescence assay	[PMID: 24119555]
HeLa	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs Antiproliferative activity against human HeLa cells after 48 hrs	[PMID: 24262004]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24296013]
HeLa	IC₅₀	0.13 μM Compound: 1, SAHA	Inhibition of HDAC1/2 in human HeLa cell extracts using acetylated histone peptide as substrate after 30 mins Inhibition of HDAC1/2 in human HeLa cell extracts using acetylated histone peptide as substrate after 30 mins	[PMID: 24525003]
HeLa	IC₅₀	0.26 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine as substrate after 30 mins by spectrophotometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine as substrate after 30 mins by spectrophotometric analysis	[PMID: 24702857]
HeLa	IC₅₀	0.72 μM Compound: SAHA	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 24702857]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa cells using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC2 in human HeLa cells using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 24742384]
HeLa	IC₅₀	0.48 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorimetric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorimetric analysis	[PMID: 24766560]
HeLa	GI₅₀	2.5 μM Compound: 1, SAHA	Growth inhibition of human HeLa cells after 72 hrs by XTT assay Growth inhibition of human HeLa cells after 72 hrs by XTT assay	[PMID: 24900500]
HeLa	GI₅₀	3.2 μM Compound: vorinostat, SAHA	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
HeLa	IC₅₀	416 nM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cell extract incubated for 5 mins prior to substrate addition measured after 30 mins by microtitre plate reader analysis Inhibition of HDAC1/HDAC2 in human HeLa cell extract incubated for 5 mins prior to substrate addition measured after 30 mins by microtitre plate reader analysis	[PMID: 25311567]
HeLa	IC₅₀	144.8 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract using Boc-Lys (acetyl)-AMC as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell extract using Boc-Lys (acetyl)-AMC as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 25462271]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Fluor de Lys as substrate incubated with compound for 30 mins by microtiter-plate reading flourimeter analysis Inhibition of HDAC in human HeLa cell nuclear extract using Fluor de Lys as substrate incubated with compound for 30 mins by microtiter-plate reading flourimeter analysis	[PMID: 25811792]
HeLa	IC₅₀	3.7 μM Compound: SAHA	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25899338]
HeLa	IC₅₀	0.11 μM Compound: 6, SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay Inhibition of HDAC1/HDAC2 in human HeLa cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
HeLa	IC₅₀	12.28 μM Compound: 6, SAHA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HeLa	IC₅₀	0.11 μM Compound: SAHA, Zolinza	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	[PMID: 26100440]
HeLa	IC₅₀	5.45 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26100440]
HeLa	IC₅₀	107.8 nM Compound: 1, SAHA	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 26122774]
HeLa	IC₅₀	12.28 μM Compound: 1, SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HeLa	IC₅₀	161 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts preincubated for 5 mins followed by substrate addition measured after 0.5 hrs by Color de Lys assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts preincubated for 5 mins followed by substrate addition measured after 0.5 hrs by Color de Lys assay	[PMID: 26149591]
HeLa	IC₅₀	0.193 μM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cells nuclear extracts using acetylated histone peptide as substrate after 30 mins by Color de Lys assay Inhibition of HDAC1/2 in human HeLa cells nuclear extracts using acetylated histone peptide as substrate after 30 mins by Color de Lys assay	[PMID: 26216016]
HeLa	IC₅₀	154.8 nM Compound: SAHA	Inhibition of Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 26349626]
HeLa	IC₅₀	176.6 μM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 26386821]
HeLa	IC₅₀	711 nM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26443078]
HeLa	IC₅₀	12 nM Compound: Vorinostat	Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate	[PMID: 26475519]
HeLa	IC₅₀	0.076 μM Compound: SAHA	Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.19 μM Compound: SAHA	Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.56 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	EC₅₀	0.0217 μM Compound: 1; SAHA; vorinostat	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	[PMID: 26611919]
HeLa	IC₅₀	0.12 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis	[PMID: 26629857]
HeLa	IC₅₀	0.102 μM Compound: vorinostat	Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis	[PMID: 26629860]
HeLa	IC₅₀	15 nM Compound: Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay	[PMID: 26741358]
HeLa	IC₅₀	0.055 μM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	[PMID: 26814680]
HeLa	IC₅₀	91 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using color de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 30 min by microtiter plate reader analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using color de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 30 min by microtiter plate reader analysis	[PMID: 26907204]
HeLa	IC₅₀	11.5 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 27186676]
HeLa	IC₅₀	11 nM Compound: Vorinostat	Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract preincubated for 20 mins followed by addition of HDAC green as substrate measured after 60 mins by fluorescence analysis Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract preincubated for 20 mins followed by addition of HDAC green as substrate measured after 60 mins by fluorescence analysis	[PMID: 27597246]
HeLa	IC₅₀	120.06 nM Compound: 1; SAHA	Inhibition of HDAC activity in human HeLa cell nuclear extract using fluorometric substrate measured after 30 mins by fluorescence assay Inhibition of HDAC activity in human HeLa cell nuclear extract using fluorometric substrate measured after 30 mins by fluorescence assay	[PMID: 27886544]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine side chain of histone as substrate measured after 30 mins by fluorometric assay Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine side chain of histone as substrate measured after 30 mins by fluorometric assay	[PMID: 28011426]
HeLa	IC₅₀	2.12 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
HeLa	IC₅₀	1.72 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28336407]
HeLa	IC₅₀	160.8 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using (Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using (Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 28336407]
HeLa	IC₅₀	159 nM Compound: Vorinostat	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using COLOR DE LYS as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins by UV-absorption method Inhibition of HDAC1/2 in human HeLa cell nuclear extract using COLOR DE LYS as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins by UV-absorption method	[PMID: 28371677]
HeLa	IC₅₀	3.55 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28371677]
HeLa	IC₅₀	131.26 nM Compound: 1; SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	[PMID: 28395150]
HeLa	IC₅₀	2.06 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28601509]
HeLa	GI₅₀	19.21 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28629630]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 29150335]
HeLa	IC₅₀	1.84 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29500131]
HeLa	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29533873]
HeLa	IC₅₀	2.06 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29787262]
HeLa	IC₅₀	0.147 μM Compound: SAHA	Inhibition of HDAC in human HeLa cytosolic extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa cytosolic extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.16 μM Compound: SAHA	Inhibition of HDAC6 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC6 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.18 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.19 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa nuclear extract Inhibition of HDAC1/HDAC2 in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	0.231 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.48 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract Inhibition of HDAC in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	1.41 μM Compound: SAHA	Inhibition of HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 30660827]
HeLa	IC₅₀	0.16 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 30879863]
HeLa	IC₅₀	4.61 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30879863]
HeLa	IC₅₀	0.168 μM Compound: 3; SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 30901208]
HeLa	IC₅₀	1.17 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
HeLa	IC₅₀	73.2 nM Compound: SAHA	Inhibition of HDAC in human HeLA cell nuclear extracts Inhibition of HDAC in human HeLA cell nuclear extracts	[PMID: 31400938]
HeLa	IC₅₀	98.35 μM Compound: 1; SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 31655430]
HeLa	IC₅₀	2.41 μM Compound: SAHA	Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HeLa	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
HeLa	IC₅₀	135 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (acetyl)-AMC as substrate by fluorescence based assay Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (acetyl)-AMC as substrate by fluorescence based assay	[PMID: 32247729]
HeLa	IC₅₀	0.35 μM Compound: SAHA	Inhibition of class 1 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of class 1 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	121 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	18.9 μM Compound: SAHA	Inhibition of class 2 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of class 2 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	2.65 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	4.66 μM Compound: SAHA	Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
HeLa	CC₅₀	2.8 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as cell death incubated for 20 hrs measured by DNS assay Cytotoxicity against human HeLa cells assessed as cell death incubated for 20 hrs measured by DNS assay	[PMID: 34006099]
HeLa	IC₅₀	3.823 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
HeLa	GI₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
HeLa	IC₅₀	2.85 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
HeLa	IC₅₀	0.48 μM Compound: SAHA	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
HeLa	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HeLa	IC₅₀	4.52 μM Compound: SAHA	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 35944852]
HeLa	IC₅₀	5.21 μM Compound: 1; SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HeLa	IC₅₀	2.04 μM Compound: SAHA	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HeLa	IC₅₀	1270 nM Compound: 1; SAHA	Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HeLa	IC₅₀	2.59 μM Compound: SAHA	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HeLa	IC₅₀	3.56 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HeLa	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HeLa	IC₅₀	1.72 μM Compound: Vorinostat	Cytotoxicity against human HeLa cells assessed as cell growth inhibition Cytotoxicity against human HeLa cells assessed as cell growth inhibition	[PMID: 38107170]
HeLa	IC₅₀	2.74 μM Compound: SAHA	Antiproliferative activity against human HeLa cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
HeLa	IC₅₀	0.063 μM Compound: 2, SAHA	Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	0.079 μM Compound: 2, SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 isolated from human HeLa cells incubated for 30 mins by Color de Lys assay Inhibition of HDAC1/HDAC2 isolated from human HeLa cells incubated for 30 mins by Color de Lys assay	10.1039/C4MD00203B
HeLa	IC₅₀	6.07 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
HeLa	IC₅₀	0.6 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay	10.1039/C4MD00350K
HeLa	IC₅₀	7.13 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HeLa	IC₅₀	8.96 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HeLa	IC₅₀	9.19 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HeLa S3	IC₅₀	0.02 μM Compound: SAHA	Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.033 μM Compound: SAHA	Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.033 μM Compound: SAHA	Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.096 μM Compound: SAHA	Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
Hep 3B2	IC₅₀	2.44 μM Compound: SAHA	Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay	[PMID: 20143778]
Hep 3B2	GI₅₀	1.21 μM Compound: SAHA	Antiproliferative activity against human Hep3B cells after 48 hrs by SRB assay Antiproliferative activity against human Hep3B cells after 48 hrs by SRB assay	[PMID: 21712146]
Hep 3B2	GI₅₀	0.69 μM Compound: 1, SAHA	Growth inhibition of human Hep3B cells after 48 hrs by SRB assay Growth inhibition of human Hep3B cells after 48 hrs by SRB assay	[PMID: 22439863]
Hep 3B2	IC₅₀	5.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
Hep 3B2	IC₅₀	2.1 μM Compound: SAHA	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 23906422]
Hep 3B2	IC₅₀	2.6 μM Compound: Vor; SAHA	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Hep 3B2	IC₅₀	2.3 μM Compound: Vorinostat	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
Hep 3B2	GI₅₀	>410 nM Compound: Vorinostat	Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
Hep 3B2	IC₅₀	5.58 μM Compound: SAHA	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
Hepatocyte	EC₅₀	>500 μM Compound: SAHA	Compound was tested for anti-proliferative activity in human hepatocytes Compound was tested for anti-proliferative activity in human hepatocytes	[PMID: 14698179]
Hepatocyte	GI₅₀	>500 μM Compound: SAHA	Growth inhibition of human hepatocytes after 21 hrs by MTT assay Growth inhibition of human hepatocytes after 21 hrs by MTT assay	[PMID: 17662606]
HepG2	IC₅₀	0.6 nM Compound: SAHA	Inhibition of human HepG2 cells Inhibition of human HepG2 cells	[PMID: 18247554]
HepG2	GI₅₀	63.48 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 19822426]
HepG2	IC₅₀	1.66 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after hrs by ATP content assay Antiproliferative activity against human HepG2 cells after hrs by ATP content assay	[PMID: 20143778]
HepG2	IC₅₀	9.3 μM Compound: SAHA	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 20143840]
HepG2	EC₅₀	2.5 μM Compound: suberoylanilide	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	35.5 μM Compound: suberoylanilide	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	GI₅₀	4600 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HepG2 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HepG2 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HepG2	EC₅₀	>50 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 24 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by XTT assay	[PMID: 21548582]
HepG2	EC₅₀	3.8 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay	[PMID: 21548582]
HepG2	EC₅₀	8.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by XTT assay	[PMID: 21548582]
HepG2	GI₅₀	3.5 μM Compound: SAHA, Zolinza	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 22435669]
HepG2	EC₅₀	12.2 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23820574]
HepG2	IC₅₀	0.14 μM Compound: SAHA, Vorinostat	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	0.15 μM Compound: SAHA, Vorinostat	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells	[PMID: 24904967]
HepG2	IC₅₀	1.49 μM Compound: SAHA, Vorinostat	Cytotoxicity against human HepG2 cells after 48 hrs Cytotoxicity against human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	23.62 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
HepG2	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 26443078]
HepG2	IC₅₀	4.1 μM Compound: 1; SAHA	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HepG2	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 29150335]
HepG2	IC₅₀	6.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29288941]
HepG2	IC₅₀	9.1 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
HepG2	IC₅₀	1.27 μM Compound: Vor; SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
HepG2	IC₅₀	3.33 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29396364]
HepG2	GI₅₀	21.96 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 29500130]
HepG2	IC₅₀	2.57 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
HepG2	IC₅₀	6.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108831]
HepG2	IC₅₀	4.5 μM Compound: 1; SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30455152]
HepG2	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	[PMID: 30660827]
HepG2	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells by CCK8 assay Antiproliferative activity against human HepG2 cells by CCK8 assay	[PMID: 30660827]
HepG2	IC₅₀	5.94 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HepG2	CC₅₀	12 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay	[PMID: 30973727]
HepG2	IC₅₀	2 μM Compound: 5; SAHA	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 31117517]
HepG2	IC₅₀	5.9 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31120744]
HepG2	IC₅₀	514.5 nM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31177073]
HepG2	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
HepG2	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 31945642]
HepG2	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
HepG2	IC₅₀	0.18 μg/mL Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HepG2	IC₅₀	0.18 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HepG2	IC₅₀	2.265 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
HepG2	IC₅₀	7.6 μM Compound: SAHA	Cytotoxicity against human HepG2-A16-CD81EGFP cells assessed as inhibition of cell growth incubated for 24 hrs followed by medium transfer and incubation in multimode plate for 48 hrs by CellTiterGlo reagent based luminescence assay Cytotoxicity against human HepG2-A16-CD81EGFP cells assessed as inhibition of cell growth incubated for 24 hrs followed by medium transfer and incubation in multimode plate for 48 hrs by CellTiterGlo reagent based luminescence assay	[PMID: 33360801]
HepG2	IC₅₀	0.85 μM Compound: SAHA	Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	[PMID: 34185525]
HepG2	IC₅₀	1.43 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
HepG2	IC₅₀	3385 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
HepG2	GI₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
HepG2	IC₅₀	2.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HepG2	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
HepG2	IC₅₀	>50 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HepG2	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HepG2	IC₅₀	7.19 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HepG2	IC₅₀	2.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
HepG2	IC₅₀	1.18 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35175762]
HepG2	IC₅₀	0.41 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HepG2	IC₅₀	9.06 μM Compound: I-1; SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 35245830]
HepG2	IC₅₀	3.2 ng/mL Compound: SAHA; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay	[PMID: 35586423]
HepG2	IC₅₀	13 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
HepG2	IC₅₀	6 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HepG2	IC₅₀	1.54 μM Compound: 1; SAHA	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
HepG2	IC₅₀	5.75 μM Compound: 1; SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HepG2	IC₅₀	1.14 μM Compound: SAHA	Cytotoxicity against human HepG2 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
HepG2	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
HepG2	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 37875056]
HepG2	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
HepG2	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
HepG2	IC₅₀	2.1 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	3.81 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
HepG2	IC₅₀	10.52 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HepG2	IC₅₀	10.77 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HepG2	IC₅₀	8.78 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HET-1A	IC₅₀	960 nM Compound: SAHA	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HGC-27	IC₅₀	5.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
HGC-27	IC₅₀	0.35 μM Compound: 5; SAHA	Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay	[PMID: 31117517]
HGC-27	IC₅₀	5.79 μM Compound: SAHA	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HGC-27	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HGC-27	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
HH	EC₅₀	1.03 μM Compound: SAHA	Cytotoxicity against human HH cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against human HH cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
HH	IC₅₀	0.86 μM Compound: 1; SAHA	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HH	IC₅₀	2.53 μM Compound: XII; SAHA	Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	IC₅₀	>3.78 mM Compound: vorinostat, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20171895]
HL-60	EC₅₀	1.2 μM Compound: 1a, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human HL60 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
HL-60	IC₅₀	>200 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21476600]
HL-60	IC₅₀	76.5 μM Compound: Zolinza, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22698782]
HL-60	IC₅₀	4.26 μM Compound: SA, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 24694055]
HL-60	GI₅₀	0.93 μM Compound: 1, SAHA	Growth inhibition of human HL60 cells after 72 hrs by XTT assay Growth inhibition of human HL60 cells after 72 hrs by XTT assay	[PMID: 24900500]
HL-60	GI₅₀	0.75 μM Compound: Vorinostat	Growth inhibition of human HL60 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human HL60 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
HL-60	IC₅₀	4.26 μM Compound: SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25462271]
HL-60	GI₅₀	0.55 μM Compound: SAHA	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
HL-60	GI₅₀	0.08 μM Compound: SAHA	Cytotoxicity against human HL60 cells after 72 hrs by cell titre 96 aqueous cell proliferation assay Cytotoxicity against human HL60 cells after 72 hrs by cell titre 96 aqueous cell proliferation assay	[PMID: 26653328]
HL-60	GI₅₀	1.74 μM Compound: SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay	[PMID: 27344487]
HL-60	IC₅₀	1331 nM Compound: SAHA	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	570.5 nM Compound: SAHA	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	2.28 μM Compound: 1; SAHA	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 27541357]
HL-60	IC₅₀	1 μM Compound: SAHA	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
HL-60	EC₅₀	1.3 μM Compound: SAHA	Induction of ATRA-induced human HL60 cell differentiation pretreated for 1 hr followed by ATRA addition measured after 3 days by Wright-Giemsa staining based microscopic analysis Induction of ATRA-induced human HL60 cell differentiation pretreated for 1 hr followed by ATRA addition measured after 3 days by Wright-Giemsa staining based microscopic analysis	[PMID: 28549889]
HL-60	IC₅₀	2.28 μM Compound: 2	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 28953386]
HL-60	GI₅₀	1.74 μM Compound: SAHA; 1	Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
HL-60	IC₅₀	1.5 μM Compound: 2; SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human HL60 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL60 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
HL-60	IC₅₀	0.42 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay	[PMID: 31883490]
HL-60	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 31945642]
HL-60	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HL-60	IC₅₀	0.69 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HL-60	IC₅₀	0.48 μM Compound: 1; SAHA	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	0.9 μM Compound: SAHA	Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	[PMID: 34185525]
HL-60	IC₅₀	0.93 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
HL-60	IC₅₀	3.04 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HL-60	IC₅₀	0.54 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HL-60	IC₅₀	2.21 μM Compound: 1; SAHA	Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
HL-60	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
HL-60	IC₅₀	0.22 μM Compound: Vorinostat	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HL-60	IC₅₀	1.3 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
HL-60	IC₅₀	1.4 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
HL-60	IC₅₀	0.69 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HL-60	IC₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HL-60	IC₅₀	0.39 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
HL-60	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
HL-60	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 37875056]
HL-60	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HL-60	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
HL-60	IC₅₀	0.22 μM Compound: Vorinostat	Cytotoxicity against human HL-60 cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human HL-60 cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
HL-60	IC₅₀	2.91 μM Compound: XII; SAHA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	IC₅₀	0.32 μM Compound: SAHA	Inhibition of cell viability in human HL-60 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human HL-60 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
HL-60	IC₅₀	0.64 μM Compound: SAHA	Inhibition of cell viability in human HL-60 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human HL-60 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
HL-60	IC₅₀	729 nM Compound: SAHA	Growth inhibition of human HL60 cells assessed as ATP level after 72 hrs by CellTiterGlo assay Growth inhibition of human HL60 cells assessed as ATP level after 72 hrs by CellTiterGlo assay	10.1039/C3MD00285C
HL-60(TB)	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human HL-60(TB) cells after 72 hrs by MTS assay Growth inhibition of human HL-60(TB) cells after 72 hrs by MTS assay	[PMID: 22435669]
HMEC	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against HMEC after 72 hrs by MTT assay Cytotoxicity against HMEC after 72 hrs by MTT assay	[PMID: 18642892]
HMEC	EC₅₀	>10 μM Compound: SAHA	Cytotoxicity against HMEC after 72 hrs by trypan blue exclusion assay Cytotoxicity against HMEC after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
HMEC	GI₅₀	5.8 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human HMEC after 72 hrs by WST1 assay Cytotoxicity against human HMEC after 72 hrs by WST1 assay	[PMID: 24015327]
HMEC	IC₅₀	10.7 μM Compound: Vorinostat	Cytotoxicity against HMEC cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Cytotoxicity against HMEC cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
HMEC	IC₅₀	4.41 μM Compound: 1; SAHA	Cytotoxicity against human HMEC cells assessed as inhibition of cell viability incubated for 3 days by AlamarBlue based fluorescence analysis Cytotoxicity against human HMEC cells assessed as inhibition of cell viability incubated for 3 days by AlamarBlue based fluorescence analysis	[PMID: 37847303]
HONE1 cell line	IC₅₀	1.18 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HONE1 cells by MTT assay Cytotoxicity against human HONE1 cells by MTT assay	[PMID: 24766560]
HOP-62	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
HOP-62	IC₅₀	2.91 μM Compound: SAHA	Cytotoxicity against human HOP-62 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HOP-62 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
HOP-92	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human HOP92 cells after 72 hrs by MTS assay Growth inhibition of human HOP92 cells after 72 hrs by MTS assay	[PMID: 22435669]
HOP-92	GI₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
Hs-578T	GI₅₀	5 μM Compound: SAHA, Zolinza	Growth inhibition of human Hs 578T cells after 72 hrs by MTS assay Growth inhibition of human Hs 578T cells after 72 hrs by MTS assay	[PMID: 22435669]
Hs-578T	GI₅₀	4.83 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay	[PMID: 24015327]
Hs-578T	GI₅₀	3.6 μM Compound: SAHA	Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
Hs68	IC₅₀	4.6 μM Compound: SAHA	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	[PMID: 23570542]
HSC-3	IC₅₀	0.71 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HSC3 cells by MTT assay Cytotoxicity against human HSC3 cells by MTT assay	[PMID: 24766560]
HT-1080	IC₅₀	2.4 μM Compound: 1	Concentration required for the antiproliferation of Human HT1080 fibrosarcoma cells Concentration required for the antiproliferation of Human HT1080 fibrosarcoma cells	[PMID: 12270175]
HT-1080	IC₅₀	2.4 μM Compound: 3 (SAHA)	Antiproliferative activity against HT1080 (human fibrosarcoma) cell line. Antiproliferative activity against HT1080 (human fibrosarcoma) cell line.	[PMID: 12749893]
HT-1080	IC₅₀	2.4 μM Compound: 1	Antiproliferative activity against human HT1080 fibrosarcoma cell line Antiproliferative activity against human HT1080 fibrosarcoma cell line	[PMID: 14552787]
HT-1080	IC₅₀	2400 nM Compound: 1 (SAHA)	Inhibitory concentration against HT1080 cells proliferation Inhibitory concentration against HT1080 cells proliferation	[PMID: 14613312]
HT-1080	IC₅₀	2.4 nM Compound: SAHA	Inhibition of human HT1080 cells Inhibition of human HT1080 cells	[PMID: 18247554]
HT-1080	GI₅₀	4.87 μM Compound: SAHA, Vorinostat	Growth inhibition of human HT1080 cells by MTT assay Growth inhibition of human HT1080 cells by MTT assay	[PMID: 23601706]
HT-1080	IC₅₀	7.5 μM Compound: SAHA	Cytotoxicity against human HT1080 cells Cytotoxicity against human HT1080 cells	[PMID: 23953690]
HT-1080	GI₅₀	1.79 μM Compound: vorinostat, SAHA	Antiproliferative activity against human HT1080 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HT1080 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
HT-1080	IC₅₀	2.54 μM Compound: SAHA	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-1080	IC₅₀	24 nM Compound: 1; SAHA	Antiproliferative activity against human HT1080 cells Antiproliferative activity against human HT1080 cells	[PMID: 31655430]
HT-1080	IC₅₀	3.56 μM Compound: SAHA	Anticancer activity against human HT-1080 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HT-1080 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HT-29	EC₅₀	2 μM Compound: 1a, SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human HT-29 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
HT-29	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human HT-29 cells after 72 hrs by MTS assay Growth inhibition of human HT-29 cells after 72 hrs by MTS assay	[PMID: 22435669]
HT-29	IC₅₀	0.72 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 24766560]
HT-29	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26443078]
HT-29	GI₅₀	2.88 μM Compound: 1, SAHA	Growth inhibition of human HT-29 cells after 96 hrs by MTT assay Growth inhibition of human HT-29 cells after 96 hrs by MTT assay	[PMID: 26814680]
HT-29	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 29150335]
HT-29	IC₅₀	1.78 μM Compound: 4; SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
HT-29	IC₅₀	1.51 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-29	IC₅₀	2.37 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30879863]
HT-29	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HT-29	IC₅₀	0.56 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HT-29	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HT-29	IC₅₀	5.01 μM Compound: Vorinostat	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 37875056]
HT-29	IC₅₀	3.33 μM Compound: SAHA	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
HT-29	IC₅₀	2.33 μM Compound: 1; SAHA	Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HT-29	IC₅₀	2.57 μM Compound: SAHA	Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay	[PMID: 38897139]
Huh-7	CC₅₀	1.9 μM Compound: 5, SAHA	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	[PMID: 25490700]
Huh-7	EC₅₀	0.36 μM Compound: 5, SAHA	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	[PMID: 25490700]
Huh-7	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 29288941]
Huh-7	IC₅₀	1.95 μM Compound: Vor; SAHA	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Huh-7	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human HuH7 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
Huh-7	IC₅₀	4.3 μM Compound: 5; SAHA	Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay	[PMID: 31117517]
Huh-7	IC₅₀	5.1 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 31120744]
Huh-7	CC₅₀	0.64 μM Compound: Vorinostat	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31201063]
Huh-7	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Huh-7	IC₅₀	3.88 μM Compound: SAHA	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
Huh-7	IC₅₀	1.65 μM Compound: SAHA	Cytotoxicity against human Huh-7 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human Huh-7 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
Huh-7	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Cytotoxicity against human Hup T3 cells after 72 hrs by MTT assay Cytotoxicity against human Hup T3 cells after 72 hrs by MTT assay	[PMID: 18494463]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HupT3 cells after 72 hrs by MTT assay Antiproliferative activity against human HupT3 cells after 72 hrs by MTT assay	[PMID: 18642892]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HUPT3 cells by MTT assay Antiproliferative activity against human HUPT3 cells by MTT assay	[PMID: 19419863]
HuP-T3	IC₅₀	0.8 μM Compound: 1a, SAHA	Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay	[PMID: 20055418]
HuT78	GI₅₀	300 nM Compound: SAHA	Growth inhibition of human HUT78 cells after 72 hrs by SRB assay Growth inhibition of human HUT78 cells after 72 hrs by SRB assay	[PMID: 20884208]
HuT78	GI₅₀	295 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HUT78 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HUT78 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HuT78	GI₅₀	3 μM Compound: 2, SAHA, Vorinostat	Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay	[PMID: 24164245]
HuT78	GI₅₀	2.1 μM Compound: Vorin	Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay	[PMID: 24900743]
HuT78	EC₅₀	290 nM Compound: 1	Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay	[PMID: 30122227]
HuT78	IC₅₀	0.71 μM Compound: 1; SAHA	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HuT78	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human HuT78 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human HuT78 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
HUVEC	GI₅₀	8.13 μM Compound: SAHA, Vorinostat	Growth inhibition of HUVEC by MTT assay Growth inhibition of HUVEC by MTT assay	[PMID: 23601706]
HUVEC	IC₅₀	3610 nM Compound: SAHA	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HUVEC	IC₅₀	0.85 μM Compound: SAHA	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	[PMID: 32347094]
HUVEC	IC₅₀	2.84 μM Compound: SAHA	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HUVEC	IC₅₀	26.4 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth Cytotoxicity against HUVEC cells assessed as inhibition of cell growth	[PMID: 35944852]
HUVEC	IC₅₀	8.58 μM Compound: SAHA	Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
HUVEC	IC₅₀	120 nM Compound: 1; SAHA	Inhibition of total HDAC in human HUVEC cells using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition measured after 6 hrs by microtiter plate reader analysis Inhibition of total HDAC in human HUVEC cells using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition measured after 6 hrs by microtiter plate reader analysis	[PMID: 37037787]
HUVEC	IC₅₀	5.9 μM Compound: 1; SAHA	Cytotoxicity against HUVECs assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against HUVECs assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HUVEC	IC₅₀	>50 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
HUVEC	IC₅₀	2.72 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against cisplatin-resistant human IGROV1 cells after 72 hrs Antiproliferative activity against cisplatin-resistant human IGROV1 cells after 72 hrs	[PMID: 19084294]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells after 72 hrs Antiproliferative activity against human IGROV1 cells after 72 hrs	[PMID: 19084294]
IGROV-1	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human IGROV1 cells after 72 hrs by MTS assay Growth inhibition of human IGROV1 cells after 72 hrs by MTS assay	[PMID: 22435669]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against p53 defective cis-platinum-resistant human IGROV1/Pt1 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against p53 defective cis-platinum-resistant human IGROV1/Pt1 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Growth inhibition of human IGROV1 cells after 72 hrs Growth inhibition of human IGROV1 cells after 72 hrs	[PMID: 26376355]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Growth inhibition of human IGROV1/Pt1 cells after 72 hrs Growth inhibition of human IGROV1/Pt1 cells after 72 hrs	[PMID: 26376355]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human IGROV1 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
IGROV-1	GI₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
IMR-32	IC₅₀	0.62 μM Compound: Vorinostat	Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
JeKo-1	IC₅₀	0.42 μM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human JeKo1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
JeKo-1	IC₅₀	3.5 μM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	[PMID: 29150335]
JeKo-1	IC₅₀	638.6 nM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	[PMID: 31177073]
JeKo-1	IC₅₀	0.18 μM Compound: SAHA	Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
JeKo-1	IC₅₀	285 nM Compound: 1; SAHA	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
Jurkat	EC₅₀	2.3 μM Compound: SAHA	Compound was tested for anti-proliferative activity in Jurkat human leukemia cell line Compound was tested for anti-proliferative activity in Jurkat human leukemia cell line	[PMID: 14698179]
Jurkat	EC₅₀	0.87 μM Compound: 1a, SAHA	Antiproliferative activity against human Jurkat JA16 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human Jurkat JA16 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23547652]
Jurkat	IC₅₀	>10 μM Compound: 4, SAHA	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-TFA as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-TFA as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	[PMID: 24261862]
Jurkat	IC₅₀	0.04 μM Compound: 4, SAHA	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-Ac as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-Ac as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	[PMID: 24261862]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
Jurkat	GI₅₀	1.1 μM Compound: 1, SAHA	Growth inhibition of human Jurkat cells after 72 hrs by XTT assay Growth inhibition of human Jurkat cells after 72 hrs by XTT assay	[PMID: 24900500]
Jurkat	GI₅₀	0.9 μM Compound: Vorin	Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay	[PMID: 24900743]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells Cytotoxicity against human Jurkat cells	[PMID: 25240614]
Jurkat	EC₅₀	1.66 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
Jurkat	IC₅₀	10 nM Compound: 5; SAHA	Inhibition of HDAC1 in human Jurkat cells extract after 30 mins by immunoprecipitation assay Inhibition of HDAC1 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	[PMID: 27177826]
Jurkat	IC₅₀	20 nM Compound: 5; SAHA	Inhibition of HDAC3 in human Jurkat cells extract after 30 mins by immunoprecipitation assay Inhibition of HDAC3 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	[PMID: 27177826]
Jurkat	IC₅₀	0.59 μM Compound: 1; SAHA	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 27541357]
Jurkat	EC₅₀	0.72 μM Compound: SAHA	Growth inhibition of human Jurkat cells after 44 hrs by MTT assay Growth inhibition of human Jurkat cells after 44 hrs by MTT assay	[PMID: 28337317]
Jurkat	IC₅₀	0.59 μM Compound: 2	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 28953386]
Jurkat	IC₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 29500131]
Jurkat	IC₅₀	0.35 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 29533873]
Jurkat	IC₅₀	0.59 μM Compound: 4	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 30243158]
Jurkat	IC₅₀	0.27 μM Compound: 3; SAHA	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
Jurkat	EC₅₀	1600 nM Compound: Vorinostat	Inhibition of class 1 HDAC in human Jurkat model of HIV latency assessed as reactivation of HIV latency incubated for 20 hrs in presence of 5% NHS by Steady-Glo luciferase assay Inhibition of class 1 HDAC in human Jurkat model of HIV latency assessed as reactivation of HIV latency incubated for 20 hrs in presence of 5% NHS by Steady-Glo luciferase assay	[PMID: 32676157]
Jurkat	IC₅₀	0.1 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	0.7 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	32 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	0.3 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35043615]
Jurkat	IC₅₀	0.47 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
Jurkat	IC₅₀	>30 μM Compound: 3; SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
Jurkat	IC₅₀	702 nM Compound: 1; SAHA	Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
Jurkat	IC₅₀	3.62 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
Jurkat	GI₅₀	2.4 μM Compound: 1	Growth inhibition of human Jurkat cells Growth inhibition of human Jurkat cells	[PMID: 37429084]
Jurkat	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Jurkat	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 37875056]
Jurkat	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
Jurkat	IC₅₀	0.1 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
Jurkat	IC₅₀	0.47 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human Jurkat cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
Jurkat	IC₅₀	0.38 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
Jurkat	IC₅₀	9.33 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
K562	IC₅₀	120 nM Compound: 1	Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells	[PMID: 12270175]
K562	IC₅₀	10 nM Compound: SAHA	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells. Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	[PMID: 12419380]
K562	IC₅₀	140 nM Compound: 1	Inhibitory activity against histone deacetylase (HDAC1 and HDAC2) isolated from K562 erythroleukemia cells Inhibitory activity against histone deacetylase (HDAC1 and HDAC2) isolated from K562 erythroleukemia cells	[PMID: 14552787]
K562	IC₅₀	0.67 μM Compound: 2	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 17691763]
K562	IC₅₀	0.75 μM Compound: 3, SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18038969]
K562	IC₅₀	140 nM Compound: SAHA	Inhibition of HDAC from human K562 cells Inhibition of HDAC from human K562 cells	[PMID: 18247554]
K562	IC₅₀	0.67 μM Compound: 6, SAHA	Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
K562	EC₅₀	2.2 μM Compound: 1a, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human K562 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
K562	IC₅₀	3.32 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21476600]
K562	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human K562 cells after 72 hrs by MTS assay Growth inhibition of human K562 cells after 72 hrs by MTS assay	[PMID: 22435669]
K562	IC₅₀	0.645 μM Compound: SAHA	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 23644210]
K562	IC₅₀	0.64 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
K562	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC in human K562 cell extract using Fluor-de-Lys deacetylase as substrate preincubated for 45 mins measured after 15 mins by fluorescence assay Inhibition of HDAC in human K562 cell extract using Fluor-de-Lys deacetylase as substrate preincubated for 45 mins measured after 15 mins by fluorescence assay	[PMID: 24328302]
K562	IC₅₀	3.77 μM Compound: 1, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 24525003]
K562	IC₅₀	3.24 μM Compound: SA, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 24694055]
K562	GI₅₀	1.97 μM Compound: vorinostat, SAHA	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
K562	IC₅₀	1 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by trypan blue dye exclusion method Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by trypan blue dye exclusion method	[PMID: 25221651]
K562	IC₅₀	1.61 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25311567]
K562	IC₅₀	3.24 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25462271]
K562	GI₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
K562	IC₅₀	1.44 μM Compound: SAHA, Zolinza	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26100440]
K562	IC₅₀	3.94 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
K562	IC₅₀	38 μM Compound: SAHA, Vorinostat	Cytotoxicity against human K562 cells assessed as reduction in cell viability Cytotoxicity against human K562 cells assessed as reduction in cell viability	[PMID: 26264503]
K562	IC₅₀	3.89 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
K562	IC₅₀	444 nM Compound: SAHA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26443078]
K562	IC₅₀	0.645 μM Compound: vorinostat	Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
K562	IC₅₀	0.17 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27142751]
K562	ED₅₀	0.45791 μM Compound: 5; SAHA	Potentiation of (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as (-)-lomaiviticin A ED50 at compound to (-)-lomaiviticin A ratio of 5000:1 after 48 hrs by cell titer-glo luminescence assay (Rvb = 0.23776 nM) Potentiation of (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as (-)-lomaiviticin A ED50 at compound to (-)-lomaiviticin A ratio of 5000:1 after 48 hrs by cell titer-glo luminescence assay (Rvb = 0.23776 nM)	[PMID: 27177826]
K562	ED₅₀	1.24803 μM Compound: 5; SAHA	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay	[PMID: 27177826]
K562	IC₅₀	1.49 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28336407]
K562	IC₅₀	1.95 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28371677]
K562	IC₅₀	1.91 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28419930]
K562	IC₅₀	1.91 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28601509]
K562	GI₅₀	3.66 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28629630]
K562	IC₅₀	0.98 μM Compound: SAHA	Anti-proliferative activity against human K562 cells after 48 hrs by MTT assay Anti-proliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28947154]
K562	IC₅₀	1.02 μM Compound: Vor; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
K562	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29533873]
K562	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29787262]
K562	IC₅₀	7.7 μM Compound: 2; SAHA	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	0.65 μM Compound: SAHA	Cytotoxicity against human K562 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human K562 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
K562	IC₅₀	3.88 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30879863]
K562	IC₅₀	1.03 μM Compound: 3; SAHA	Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	[PMID: 30901208]
K562	IC₅₀	1.11 μM Compound: 3; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
K562	IC₅₀	10 μM Compound: 5; SAHA	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	[PMID: 31117517]
K562	IC₅₀	1.45 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
K562	IC₅₀	143 nM Compound: 24; SAHA	Inhibition of HDAC in human K562 cell extracts using (QSY-7)-RGGRGLGK(Ac)-GGARRHRK(TAMRA)NH2 as substrate preincubated for 30 mins followed by addition of endoproteinase Lys-C and measured after 2 hrs by fluorescence assay Inhibition of HDAC in human K562 cell extracts using (QSY-7)-RGGRGLGK(Ac)-GGARRHRK(TAMRA)NH2 as substrate preincubated for 30 mins followed by addition of endoproteinase Lys-C and measured after 2 hrs by fluorescence assay	[PMID: 31536895]
K562	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 31546197]
K562	IC₅₀	140 nM Compound: 1; SAHA	Inhibition of HDAC in human K562 nuclear extract Inhibition of HDAC in human K562 nuclear extract	[PMID: 31655430]
K562	IC₅₀	1.51 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
K562	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
K562	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
K562	IC₅₀	1.35 μM Compound: SAHA	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 33132117]
K562	GI₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
K562	IC₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
K562	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
K562	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
K562	IC₅₀	0.56 μM Compound: SAHA	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
K562	IC₅₀	0.11 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
K562	IC₅₀	0.52 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
K562	IC₅₀	1.391 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 35926141]
K562	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
K562	IC₅₀	1.17 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
K562	IC₅₀	2.24 μM Compound: 3; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
K562	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
K562	IC₅₀	0.21 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
K562	IC₅₀	1.8 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
K562	IC₅₀	828 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
K562	IC₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
K562	IC₅₀	1.29 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
K562	IC₅₀	0.35 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human K562 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
K562	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
K562	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
K562	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
K562	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
K562	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 37875056]
K562	IC₅₀	1.49 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as cell growth inhibition Cytotoxicity against human K562 cells assessed as cell growth inhibition	[PMID: 38107170]
K562	IC₅₀	2.26 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
K562	IC₅₀	2.93 μM Compound: XII; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
K562	IC₅₀	370 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
K562/A02	IC₅₀	3.13 μM Compound: SAHA	Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay	[PMID: 33132117]
Kasumi 1	IC₅₀	620 nM Compound: Vorinostat	Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
Kasumi 1	IC₅₀	0.38 μM Compound: SAHA	Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
Kasumi 1	IC₅₀	0.65 μM Compound: SAHA	Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
KATO III stomach cancer cell line	IC₅₀	0.25 μM Compound: 3; SAHA	Antiproliferative activity against human KATO III stomach cancer cell line assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human KATO III stomach cancer cell line assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
KB	IC₅₀	0.75 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 24766560]
KB	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 25899338]
KB-V1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human KB-V1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human KB-V1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
KB-V1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human vinblastine resistant KB-V1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human vinblastine resistant KB-V1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
KG-1	IC₅₀	1.15 μM Compound: 1, SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 24525003]
KG-1	IC₅₀	1.59 μM Compound: SA, SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 24694055]
KG-1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 25462271]
KG-1	IC₅₀	0.68 μM Compound: 6, SAHA	Cytotoxicity against human KG1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
KG-1	IC₅₀	0.64 μM Compound: SAHA, Zolinza	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26100440]
KG-1	IC₅₀	0.68 μM Compound: 1, SAHA	Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
KG-1	IC₅₀	2.75 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26216016]
KG-1	IC₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26907204]
KG-1	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	[PMID: 29787262]
KG-1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human KG-1 cells incubated for 72 hrs by MTT assay	[PMID: 32961382]
KG-1	IC₅₀	0.59 μM Compound: 1; SAHA	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
KG-1	IC₅₀	0.07 μM Compound: SAHA	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
KG-1	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
KG-1	IC₅₀	0.79 μM Compound: SAHA; 6	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
KG-1	IC₅₀	1.11 μM Compound: SAHA	Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
KM12	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human KM12 cells after 72 hrs by MTS assay Growth inhibition of human KM12 cells after 72 hrs by MTS assay	[PMID: 22435669]
KM12	GI₅₀	1.88 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	[PMID: 24015327]
KM12	GI₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
KM3/BTZ	IC₅₀	78.2 nM Compound: SAHA	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM3/BTZ	IC₅₀	860 nM Compound: SAHA	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM-H2	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay	[PMID: 29150335]
KMS-12-BM	IC₅₀	0.94 μM Compound: 1; SAHA	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay	[PMID: 27541357]
KMS-12-BM	IC₅₀	0.94 μM Compound: 2	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
KMS-12-BM	IC₅₀	0.94 μM Compound: 4	Antiproliferative activity against human KMS-12-BM cells after 72 hrs by MTT assay Antiproliferative activity against human KMS-12-BM cells after 72 hrs by MTT assay	[PMID: 30243158]
KMS-12-BM	EC₅₀	0.94 μM Compound: 3; SAHA	Antiproliferative activity against human KMS-12-BM cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human KMS-12-BM cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
KYSE-30	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human KYSE-30 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human KYSE-30 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
KYSE-450	IC₅₀	6.478 μM Compound: Vorinostat	Antiproliferative activity against human KYSE-450 cells Antiproliferative activity against human KYSE-450 cells	[PMID: 37875056]
KYSE-510	IC₅₀	0.59 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	0.7 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	4.62 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
KYSE-510	IC₅₀	4.66 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
KYSE-520 cell line	IC₅₀	2.81 μM Compound: SAHA	Antiproliferative activity against human KYSE520 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human KYSE520 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
L02	IC₅₀	>50000 nM Compound: SAHA	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
L02	IC₅₀	>10 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
L02	IC₅₀	27.4 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]
L02	IC₅₀	5.45 μM Compound: Vorinostat	cytotoxicity against human HL-7702 cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay cytotoxicity against human HL-7702 cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	[PMID: 33493830]
L02	IC₅₀	>50 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34509167]
L02	IC₅₀	1.35 μM Compound: SAHA	Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
L02	IC₅₀	0.948 μM Compound: SAHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
L02	IC₅₀	>100 μM Compound: SAHA	Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin based microplate reader analysis Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
L02	IC₅₀	7.23 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
L1210	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
L1210	IC₅₀	1.5 μM Compound: SAHA	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
L-363	IC₅₀	0.48 μM Compound: 4; SAHA	Antiproliferative activity against human L-363 cells Antiproliferative activity against human L-363 cells	[PMID: 37652098]
L-428	IC₅₀	0.87 μM Compound: SAHA	Antiproliferative activity against human L428 cells after 72 hrs by MTT assay Antiproliferative activity against human L428 cells after 72 hrs by MTT assay	[PMID: 29150335]
L-428	IC₅₀	2.3 μM Compound: SAHA	Antiproliferative activity against human L-428 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human L-428 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
L6	IC₅₀	266 nM Compound: 1, SAHA	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 25563890]
Lewis lung carcinoma cell line	IC₅₀	9.68 μM Compound: 4; SAHA	Antiproliferative activity against mouse LLC cells after 48 hrs by CCK-8 assay Antiproliferative activity against mouse LLC cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
LNCaP	IC₅₀	1 μM Compound: SAHA	Concentration required to inhibit human LNCaP prostate carcinoma cells Concentration required to inhibit human LNCaP prostate carcinoma cells	[PMID: 16033284]
LNCaP	IC₅₀	1 μM Compound: 5, SAHA	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
LNCaP	IC₅₀	0.58 μM Compound: SAHA	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 20143778]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as growth inhibition by MTS assay Cytotoxicity against human LNCAP cells assessed as growth inhibition by MTS assay	[PMID: 23547652]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Inhibition of HDAC6 in human LNCAP cells assessed as tubulin acetylation by Western blot analysis Inhibition of HDAC6 in human LNCAP cells assessed as tubulin acetylation by Western blot analysis	[PMID: 25240614]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 25240614]
LNCaP	IC₅₀	1.22 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
LNCaP	IC₅₀	0.69 μM Compound: SAHA	Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
LNCaP	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
LNCaP	IC₅₀	1.34 μM Compound: 1; SAHA	Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
LoVo	GI₅₀	1700 nM Compound: SAHA, vorinostat	Antiproliferative activity against human LoVo cells after 72 hrs by WST-1 assay Antiproliferative activity against human LoVo cells after 72 hrs by WST-1 assay	[PMID: 21080647]
LoVo	IC₅₀	6.75 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
LoVo	IC₅₀	3.7 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human LoVo cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
LoVo	IC₅₀	6.75 μM Compound: SAHA	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30108831]
LoVo	IC₅₀	2.15 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
LoVo	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human LoVo cells by MTT assay Antiproliferative activity against human LoVo cells by MTT assay	[PMID: 31546197]
LOX IMVI	EC₅₀	1.3 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells	[PMID: 15715470]
LOX IMVI	GI₅₀	1.39 μM Compound: 2, SAHA	Antiproliferative activity against human LOX-IMVI cells by SRB assay Antiproliferative activity against human LOX-IMVI cells by SRB assay	[PMID: 16723227]
LOX IMVI	GI₅₀	1.39 μM Compound: 1, SAHA	Growth inhibition of LOX-IMVI cells by SRB assay Growth inhibition of LOX-IMVI cells by SRB assay	[PMID: 17477518]
LOX IMVI	GI₅₀	1.6 μM Compound: SAHA	Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay	[PMID: 17662606]
LOX IMVI	EC₅₀	1.3 μM Compound: SAHA	Inhibition of human LOX-IMVI cells Inhibition of human LOX-IMVI cells	[PMID: 18247554]
LOX IMVI	GI₅₀	1.3 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
LOX IMVI	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human LOXIMVI cells after 72 hrs by MTS assay Growth inhibition of human LOXIMVI cells after 72 hrs by MTS assay	[PMID: 22435669]
LOX IMVI	GI₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
LP-1	IC₅₀	1.39 μM Compound: SAHA	Antiproliferative activity against human LP-1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human LP-1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
M14	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human M14 cells after 72 hrs by MTS assay Growth inhibition of human M14 cells after 72 hrs by MTS assay	[PMID: 22435669]
M14	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
Malme-3M	GI₅₀	0.32 μM Compound: SAHA, Zolinza	Growth inhibition of human MALME-3M cells after 72 hrs by MTS assay Growth inhibition of human MALME-3M cells after 72 hrs by MTS assay	[PMID: 22435669]
Malme-3M	GI₅₀	0.37 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay	[PMID: 24015327]
MC-38	GI₅₀	2.4 μM Compound: 7; SAHA	Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay	[PMID: 34783558]
MC-38	GI₅₀	2.74 μM Compound: 3; SAHA	Antiproliferative activity against mouse MC38 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells after 72 hrs by CCK-8 assay	[PMID: 35390714]
MC-38	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against mouse MC38 cells after 48 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
MC-38	IC₅₀	2.22 μM Compound: 1; SAHA	Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MCF-10A	IC₅₀	31 μM Compound: 81, SAHA	Antitumor activity against human MCF10A cells Antitumor activity against human MCF10A cells	[PMID: 19534534]
MCF-10A	GI₅₀	9.6 μM Compound: SAHA, Zolinza	Growth inhibition of human MCF10A cells after 48 hrs by MTT assay Growth inhibition of human MCF10A cells after 48 hrs by MTT assay	[PMID: 22435669]
MCF-10A	IC₅₀	31 μM Compound: 3, SAHA	Cytotoxicity against human MCF10A cells after 96 hrs by MTA reduction assay Cytotoxicity against human MCF10A cells after 96 hrs by MTA reduction assay	[PMID: 23293738]
MCF-10A	IC₅₀	28 μM Compound: SAHA	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MCF-10A	IC₅₀	2.11 μM Compound: SAHA	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF-10A	IC₅₀	0.42 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF-10A	IC₅₀	1.1 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF-10A	IC₅₀	>50 μM Compound: 1; SAHA	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MCF7	IC₅₀	1.5 μM Compound: SAHA	Inhibition of MCF7 cell proliferation (mean of two experiments) Inhibition of MCF7 cell proliferation (mean of two experiments)	[PMID: 17095213]
MCF7	IC₅₀	1.5 μM Compound: SAHA	Inhibition of MCF7 cell proliferation (mean of two experiments) Inhibition of MCF7 cell proliferation (mean of two experiments)	[PMID: 17107790]
MCF7	IC₅₀	6.7 μM Compound: 2	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17691763]
MCF7	IC₅₀	500 nM Compound: SAHA	Growth inhibition of MCF7 cells Growth inhibition of MCF7 cells	[PMID: 17958342]
MCF7	IC₅₀	>100 μM Compound: SAHA	Inhibition of human MCF7 cells Inhibition of human MCF7 cells	[PMID: 18247554]
MCF7	CC₅₀	3000 nM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
MCF7	IC₅₀	8.5 μM Compound: 81, SAHA	Antitumor activity against human MCF7 cells Antitumor activity against human MCF7 cells	[PMID: 19534534]
MCF7	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after hrs by ATP content assay Antiproliferative activity against human MCF7 cells after hrs by ATP content assay	[PMID: 20143778]
MCF7	IC₅₀	2.81 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21714538]
MCF7	IC₅₀	1.15 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21924799]
MCF7	IC₅₀	0.13 μg/mL Compound: SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 22036991]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 22260166]
MCF7	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 22435669]
MCF7	IC₅₀	8.5 μM Compound: 3, SAHA	Cytotoxicity against human MCF7 cells after 96 hrs by MTA reduction assay Cytotoxicity against human MCF7 cells after 96 hrs by MTA reduction assay	[PMID: 23293738]
MCF7	GI₅₀	0.689 μM Compound: SAHA	Cytotoxicity against human MCF7 cells after 48 hrs by Sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by Sulforhodamine B assay	[PMID: 23639537]
MCF7	IC₅₀	4.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MCF7	IC₅₀	2.29 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human MCF7 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
MCF7	GI₅₀	2.19 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24015327]
MCF7	IC₅₀	60.2 μM Compound: SAHA, Vorinostat	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 24095016]
MCF7	GI₅₀	0.45 μM Compound: 1, SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
MCF7	IC₅₀	6.42 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24185378]
MCF7	IC₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24296013]
MCF7	IC₅₀	3.78 μM Compound: SA, SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24694055]
MCF7	IC₅₀	1.1 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 24766560]
MCF7	GI₅₀	8.6 μM Compound: 1, SAHA	Growth inhibition of human MCF7 cells after 72 hrs by XTT assay Growth inhibition of human MCF7 cells after 72 hrs by XTT assay	[PMID: 24900500]
MCF7	GI₅₀	2.2 μM Compound: vorinostat, SAHA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
MCF7	IC₅₀	3.78 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25462271]
MCF7	GI₅₀	0.61 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
MCF7	IC₅₀	0.58 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26100440]
MCF7	IC₅₀	4.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26475519]
MCF7	IC₅₀	0.32 μM Compound: 6; SAHA	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MCF7	IC₅₀	2.5 μM Compound: SAHA; vorinostat	Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 26725029]
MCF7	IC₅₀	4.2 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26741358]
MCF7	GI₅₀	1.34 μM Compound: 1, SAHA	Growth inhibition of human MCF7 cells after 96 hrs by MTT assay Growth inhibition of human MCF7 cells after 96 hrs by MTT assay	[PMID: 26814680]
MCF7	IC₅₀	0.65 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27541357]
MCF7	IC₅₀	6 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells up to 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells up to 72 hrs by MTT assay	[PMID: 27541357]
MCF7	GI₅₀	29.1 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
MCF7	IC₅₀	3.27 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
MCF7	IC₅₀	0.9 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MCF7	IC₅₀	3.47 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF7	GI₅₀	17.9 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28629630]
MCF7	IC₅₀	0.65 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28953386]
MCF7	IC₅₀	4.69 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
MCF7	IC₅₀	4.48 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29288941]
MCF7	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 29317150]
MCF7	IC₅₀	1.6 μM Compound: Vor; SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
MCF7	IC₅₀	2.18 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29396364]
MCF7	IC₅₀	38.2 μM Compound: SAHA	Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 29496367]
MCF7	IC₅₀	0.65 μM Compound: 4	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 29945795]
MCF7	IC₅₀	4.83 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
MCF7	IC₅₀	0.45 μM Compound: 6; SAHA	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF7	IC₅₀	0.95 μM Compound: 6; SAHA	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF7	IC₅₀	0.81 μM Compound: 4	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30243158]
MCF7	IC₅₀	4.22 μM Compound: SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 30245394]
MCF7	IC₅₀	354 nM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30629434]
MCF7	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	[PMID: 30660827]
MCF7	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 30660827]
MCF7	IC₅₀	939.97 nM Compound: SAHA	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30819618]
MCF7	IC₅₀	4.1 μM Compound: 5; SAHA	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 31117517]
MCF7	IC₅₀	637.2 nM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 31177073]
MCF7	IC₅₀	5.43 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MCF7	IC₅₀	3.27 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	EC₅₀	0.65 μM Compound: 3; SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MCF7	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
MCF7	IC₅₀	0.18 μg/mL Compound: Vorinostat	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MCF7	IC₅₀	3.49 μM Compound: SAHA	Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MCF7	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
MCF7	IC₅₀	6.17 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MCF7	IC₅₀	2.7 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of erlotinib by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of erlotinib by MTT assay	[PMID: 32320239]
MCF7	IC₅₀	4.2 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 32320239]
MCF7	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
MCF7	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
MCF7	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MCF7	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	9.798 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MCF7	IC₅₀	1.04 μM Compound: SAHA	Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay	[PMID: 33045329]
MCF7	IC₅₀	4.2 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 33077264]
MCF7	IC₅₀	>50 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
MCF7	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
MCF7	IC₅₀	4.339 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
MCF7	GI₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
MCF7	IC₅₀	>150 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
MCF7	EC₅₀	0.01 μM Compound: 25a	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay	[PMID: 34591488]
MCF7	GI₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 6 days by WST8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 6 days by WST8 assay	[PMID: 34610548]
MCF7	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
MCF7	IC₅₀	1.11 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
MCF7	IC₅₀	2.36 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
MCF7	IC₅₀	0.16 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
MCF7	IC₅₀	5.15 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
MCF7	IC₅₀	6.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
MCF7	IC₅₀	5.15 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells measured after 72 hrs Antiproliferative activity against human MCF7 cells measured after 72 hrs	[PMID: 35697181]
MCF7	IC₅₀	7.11 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
MCF7	IC₅₀	6.23 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MCF7	IC₅₀	1.31 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
MCF7	IC₅₀	4.78 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
MCF7	IC₅₀	3.56 μM Compound: 4; SAHA	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 37652098]
MCF7	IC₅₀	2.98 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
MCF7	GI₅₀	3.02 μM Compound: 1; SAHA	Anticancer activity against human MCF7 cells overexpressing HDAC1 and HDAC2 assessed as inhibition of cell growth incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells overexpressing HDAC1 and HDAC2 assessed as inhibition of cell growth incubated for 48 hrs by sulforhodamine B assay	[PMID: 37847303]
MCF7	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	1.03 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 37875056]
MCF7	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MCF7	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	>50 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
MCF7	IC₅₀	4.17 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
MCF7	IC₅₀	3.57 μM Compound: SAHA	Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
MCF7	IC₅₀	0.91 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MCF7	IC₅₀	0.294 μM Compound: SAHA	Inhibition of cell viability in human MCF7 cells incubated for 12 days with every 3 day treatment by Alamar blue staining based analysis Inhibition of cell viability in human MCF7 cells incubated for 12 days with every 3 day treatment by Alamar blue staining based analysis	[PMID: 38838548]
MCF7	IC₅₀	3.26 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
MCF7	IC₅₀	28.66 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
MCF7	IC₅₀	54.55 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
MCF7	IC₅₀	9.59 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
MDA-MB-231	EC₅₀	1.5 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells	[PMID: 15715470]
MDA-MB-231	GI₅₀	0.66 μM Compound: 2, SAHA	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 16723227]
MDA-MB-231	IC₅₀	12.3 μM Compound: SAHA	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments) Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	[PMID: 17095213]
MDA-MB-231	IC₅₀	12.3 μM Compound: SAHA	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments) Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	[PMID: 17107790]
MDA-MB-231	GI₅₀	0.66 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 17477518]
MDA-MB-231	GI₅₀	0.89 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay	[PMID: 17662606]
MDA-MB-231	IC₅₀	2.2 μM Compound: 2	Cytotoxicity against human MDA-MB-231cells Cytotoxicity against human MDA-MB-231cells	[PMID: 17691763]
MDA-MB-231	GI₅₀	2 μM Compound: 2, SAHA	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 17904843]
MDA-MB-231	EC₅₀	1.5 μM Compound: SAHA	Inhibition of human MDA-MB-231 cells Inhibition of human MDA-MB-231 cells	[PMID: 18247554]
MDA-MB-231	IC₅₀	2.11 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay	[PMID: 20143778]
MDA-MB-231	IC₅₀	2 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 20850971]
MDA-MB-231	IC₅₀	1.31 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21476600]
MDA-MB-231	IC₅₀	1.18 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21733698]
MDA-MB-231	IC₅₀	1.91 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21924799]
MDA-MB-231	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 22435669]
MDA-MB-231	GI₅₀	2.5 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-231	GI₅₀	0.97 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 22439863]
MDA-MB-231	GI₅₀	2 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	1.66 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	2.69 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	5.6 μM Compound: 1, SAHA	Inhibition of human MDA-MB-231 cell proliferation after 48 hrs by MTT assay Inhibition of human MDA-MB-231 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
MDA-MB-231	IC₅₀	3.4 μM Compound: SAHA, vorinostat	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MDA-MB-231	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23906422]
MDA-MB-231	GI₅₀	2.32 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 24015327]
MDA-MB-231	IC₅₀	0.16 μM Compound: SAHA, Vorinostat	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24095016]
MDA-MB-231	IC₅₀	4.61 μM Compound: 1, SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24525003]
MDA-MB-231	IC₅₀	1.72 μM Compound: SA, SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24694055]
MDA-MB-231	IC₅₀	1.29 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24702857]
MDA-MB-231	IC₅₀	2.29 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25311567]
MDA-MB-231	IC₅₀	1.72 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25462271]
MDA-MB-231	GI₅₀	2 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 5 days by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
MDA-MB-231	IC₅₀	7.4 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25815139]
MDA-MB-231	IC₅₀	3.96 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
MDA-MB-231	IC₅₀	13.48 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26100440]
MDA-MB-231	IC₅₀	2.02 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
MDA-MB-231	IC₅₀	4.61 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26216016]
MDA-MB-231	IC₅₀	0.96 μM Compound: 6; SAHA	Antiproliferative activity against human MDA-MB-231 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MDA-MB-231 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MDA-MB-231	GI₅₀	1.81 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells after 96 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 26814680]
MDA-MB-231	IC₅₀	1.73 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26907204]
MDA-MB-231	IC₅₀	1.19 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27541357]
MDA-MB-231	IC₅₀	4.5 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay	[PMID: 27541357]
MDA-MB-231	IC₅₀	6000 nM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27665180]
MDA-MB-231	GI₅₀	2 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human MDA-MB-231 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
MDA-MB-231	GI₅₀	2.67 μM Compound: 1; SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
MDA-MB-231	IC₅₀	0.43 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	3.3 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	4.53 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28757101]
MDA-MB-231	IC₅₀	>100 μM Compound: 1; SAHA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
MDA-MB-231	IC₅₀	1.98 μM Compound: SAHA	Anti-proliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Anti-proliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28947154]
MDA-MB-231	IC₅₀	1.19 μM Compound: 2	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28953386]
MDA-MB-231	IC₅₀	0.201 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
MDA-MB-231	IC₅₀	2.59 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
MDA-MB-231	IC₅₀	3.02 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29787262]
MDA-MB-231	IC₅₀	1.19 μM Compound: 4	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 29945795]
MDA-MB-231	IC₅₀	4.93 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29954683]
MDA-MB-231	IC₅₀	0.61 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MDA-MB-231	IC₅₀	0.97 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MDA-MB-231	IC₅₀	1.49 μM Compound: 4	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30243158]
MDA-MB-231	IC₅₀	2.14 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 30245394]
MDA-MB-231	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
MDA-MB-231	IC₅₀	1710 nM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 31177073]
MDA-MB-231	IC₅₀	3.31 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MDA-MB-231	EC₅₀	1.2 μM Compound: 3; SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MDA-MB-231	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MDA-MB-231	IC₅₀	4.66 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MDA-MB-231	GI₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
MDA-MB-231	IC₅₀	8.14 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 32791401]
MDA-MB-231	IC₅₀	>411 nM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MDA-MB-231	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MDA-MB-231	IC₅₀	4.585 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MDA-MB-231	IC₅₀	1.45 μM Compound: 1; SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 33077264]
MDA-MB-231	IC₅₀	3.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
MDA-MB-231	IC₅₀	1.09 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
MDA-MB-231	IC₅₀	1.77 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
MDA-MB-231	IC₅₀	2.03 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
MDA-MB-231	IC₅₀	6.04 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 2 days by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 2 days by CCK8 assay	[PMID: 34610548]
MDA-MB-231	IC₅₀	8.25 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
MDA-MB-231	IC₅₀	5.8 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MDA-MB-231	IC₅₀	2.36 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
MDA-MB-231	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
MDA-MB-231	IC₅₀	3.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
MDA-MB-231	IC₅₀	5.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
MDA-MB-231	IC₅₀	3 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
MDA-MB-231	IC₅₀	3.52 μM Compound: SAHA	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation	[PMID: 35944852]
MDA-MB-231	IC₅₀	3.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells harboring wild type BRCA1 and wild BRCA2 assessed as reduction in cell viability Cytotoxicity against human MDA-MB-231 cells harboring wild type BRCA1 and wild BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
MDA-MB-231	IC₅₀	3.07 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MDA-MB-231	IC₅₀	2.23 μM Compound: SAHA	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
MDA-MB-231	GI₅₀	2.73 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
MDA-MB-231	IC₅₀	1.6 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
MDA-MB-231	IC₅₀	2.5 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
MDA-MB-231	IC₅₀	1480 nM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MDA-MB-231	IC₅₀	0.46 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay	[PMID: 37796543]
MDA-MB-231	IC₅₀	9.2 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37796543]
MDA-MB-231	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	2.9 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay	[PMID: 38141287]
MDA-MB-231	IC₅₀	1.91 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
MDA-MB-231	IC₅₀	0.9 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-231	IC₅₀	1.98 μM Compound: XII; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MDA-MB-231	IC₅₀	3.26 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
MDA-MB-231	IC₅₀	1.11 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
MDA-MB-231	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	10.1039/C4MD00211C
MDA-MB-238	IC₅₀	4.92 μM Compound: 1; SAHA	Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
MDA-MB-435	IC₅₀	1.9 μM Compound: 3 (SAHA)	Antiproliferative activity against MDA-435 (human breast carcinoma) cell line. Antiproliferative activity against MDA-435 (human breast carcinoma) cell line.	[PMID: 12749893]
MDA-MB-435	IC₅₀	1900 nM Compound: 1 (SAHA)	Inhibitory concentration against MDA-435 cells proliferation Inhibitory concentration against MDA-435 cells proliferation	[PMID: 14613312]
MDA-MB-435	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-435 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-435 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-435	GI₅₀	0.88 μM Compound: 1, SAHA	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
MDA-MB-435	GI₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
MDA-MB-436	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-436 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MDA-MB-436 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MDA-MB-453	IC₅₀	0.37 μM Compound: 5; SAHA	Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay	[PMID: 31117517]
MDA-MB-468	IC₅₀	1.3 μM Compound: 2	Cytotoxicity against human MDA-MB-468 cells Cytotoxicity against human MDA-MB-468 cells	[PMID: 17691763]
MDA-MB-468	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 20143778]
MDA-MB-468	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-468	IC₅₀	2.69 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
MDA-MB-468	IC₅₀	10.03 μM Compound: SAHA	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MDA-MB-468	IC₅₀	0.95 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay	[PMID: 32961382]
MDA-MB-468	IC₅₀	2.75 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
MDA-MB-468	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-468 cells harboring wild type BRCA1 and BRCA2 mutant reduction in assessed as cell viability Cytotoxicity against human MDA-MB-468 cells harboring wild type BRCA1 and BRCA2 mutant reduction in assessed as cell viability	[PMID: 36053318]
MDA-MB-468	IC₅₀	2.85 μM Compound: SAHA	Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
MDA-MB-468	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-468	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-468	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MEF	IC₅₀	4.4 μM Compound: SAHA	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 23570542]
MG-63	GI₅₀	>10 μM Compound: SAHA, vorinostat	Antiproliferative activity against human MG63 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MG63 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MGC-803	IC₅₀	8.75 μM Compound: SAHA	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
MGC-803	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability Cytotoxicity against human MGC803 cells assessed as reduction in cell viability	[PMID: 30660827]
MGC-803	IC₅₀	3.51 μM Compound: SAHA	Antiproliferative activity against human MGC803 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MGC-803	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
MGC-803	IC₅₀	8.67 μM Compound: Vorinostat	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	[PMID: 33831778]
MGC-803	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 33957387]
MGC-803	IC₅₀	2.678 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
MGC-803	IC₅₀	9.74 μM Compound: SAHA	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
MGC-803	IC₅₀	1.58 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MGC-803	IC₅₀	2.82 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MGC-803	IC₅₀	8.06 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
MIA PaCa-2	IC₅₀	1.1 μM Compound: SAHA	Cytotoxicity against human Mia Paca2 cells after 72 hrs by MTT assay Cytotoxicity against human Mia Paca2 cells after 72 hrs by MTT assay	[PMID: 18494463]
MIA PaCa-2	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human MiaPaca2 cells after 72 hrs by MTT assay Antiproliferative activity against human MiaPaca2 cells after 72 hrs by MTT assay	[PMID: 18642892]
MIA PaCa-2	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human MIAPaCa2 cells by MTT assay Antiproliferative activity against human MIAPaCa2 cells by MTT assay	[PMID: 19419863]
MIA PaCa-2	IC₅₀	1.1 μM Compound: 1a, SAHA	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 20055418]
MIA PaCa-2	GI₅₀	3500 nM Compound: SAHA, vorinostat	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MIA PaCa-2	GI₅₀	790 nM Compound: SAHA	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24999749]
MIA PaCa-2	IC₅₀	2.2 μM Compound: SAHA	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MIA PaCa-2	IC₅₀	996 nM Compound: 1; SAHA	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MKN-45	GI₅₀	7.3 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human MKN45 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN45 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
MKN-45	IC₅₀	1.25 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MKN45 cells by MTT assay Cytotoxicity against human MKN45 cells by MTT assay	[PMID: 24766560]
MKN-45	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human MKN-45 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MKN-45 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
MM1.S	IC₅₀	0.82 μM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1S cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
MM1.S	IC₅₀	2844 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay	[PMID: 29795767]
MM1.S	IC₅₀	573 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay	[PMID: 30629434]
MM1.S	IC₅₀	590.3 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay	[PMID: 31177073]
MM1.S	IC₅₀	1.54 μM Compound: SAHA	Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MM1.S	IC₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human MM.1S cells assessed as inhibition of cell growth incubated for 72 hrs by microplate photometer analysis Antiproliferative activity against human MM.1S cells assessed as inhibition of cell growth incubated for 72 hrs by microplate photometer analysis	[PMID: 38116436]
MM473	IC₅₀	8.2 μM Compound: SAHA	Antiproliferative activity against human MM473 cells at 10 uM after 72 hrs by MTT assay relative to control Antiproliferative activity against human MM473 cells at 10 uM after 72 hrs by MTT assay relative to control	[PMID: 29150335]
MM473	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human MM473 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MM473 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MM96L	EC₅₀	0.01 μM Compound: 25a	Antiproliferative activity against human MM96L cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MM96L cells assessed as cell growth inhibition by SRB assay	[PMID: 34591488]
MOLM-13	IC₅₀	984.9 nM Compound: SAHA	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
MOLM-13	EC₅₀	1.2 μM Compound: SAHA	Growth inhibition of human MOLM13 cells after 44 hrs by MTT assay Growth inhibition of human MOLM13 cells after 44 hrs by MTT assay	[PMID: 28337317]
MOLM-13	IC₅₀	0.345 μM Compound: 1; SAHA	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MOLM-14	EC₅₀	0.54 μM Compound: 3; SAHA	Antiproliferative activity against human MOLM14 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MOLM14 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
MOLT-4	GI₅₀	670 nM Compound: SAHA, vorinostat	Antiproliferative activity against human MOLT4 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MOLT-4	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human MOLT4 cells after 72 hrs by MTS assay Growth inhibition of human MOLT4 cells after 72 hrs by MTS assay	[PMID: 22435669]
MOLT-4	GI₅₀	0.68 μM Compound: vorinostat, SAHA	Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
MOLT-4	GI₅₀	542 nM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
MOLT-4	IC₅₀	0.33 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28336407]
MOLT-4	IC₅₀	0.7 μM Compound: SAHA	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MOLT-4	IC₅₀	0.56 μM Compound: Vorinostat	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28371677]
MOLT-4	IC₅₀	0.52 μM Compound: Vor; SAHA	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
MOLT-4	IC₅₀	1.08 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 29500131]
MOLT-4	IC₅₀	0.41 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 29533873]
MOLT-4	IC₅₀	0.36 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 29787262]
MOLT-4	IC₅₀	0.4 μM Compound: 3; SAHA	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
MOLT-4	IC₅₀	0.38 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
MOLT-4	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MOLT-4	IC₅₀	0.41 μM Compound: SAHA	Antiproliferative activity against human MOLT-4 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MOLT-4 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
MOLT-4	IC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MOLT-4	GI₅₀	3.3 μM Compound: 1	Growth inhibition of human MOLT-4 cells measured after 24 hrs by MTT assay Growth inhibition of human MOLT-4 cells measured after 24 hrs by MTT assay	[PMID: 37429084]
MOLT-4	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MOLT-4	IC₅₀	0.33 μM Compound: Vorinostat	Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 38107170]
MOLT-4	IC₅₀	3.09 μM Compound: XII; SAHA	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MRC5	IC₅₀	68.7 μM Compound: SAHA	Anti-proliferative activity against human MRC5 cells after 48 hrs by MTT assay Anti-proliferative activity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 28947154]
MV4-11	GI₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
MV4-11	IC₅₀	0.7 μM Compound: 2; SAHA	Cytotoxicity against human MV411 cells Cytotoxicity against human MV411 cells	[PMID: 26005563]
MV4-11	IC₅₀	85 nM Compound: SAHA	Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 26443078]
MV4-11	IC₅₀	0.72 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27142751]
MV4-11	IC₅₀	230 nM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
MV4-11	IC₅₀	496.1 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
MV4-11	EC₅₀	<30 nM Compound: Vorinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	[PMID: 27754681]
MV4-11	IC₅₀	0.98 μM Compound: 5; SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 28765013]
MV4-11	EC₅₀	0.53 μM Compound: Vor; SAHA	Induction of cell death in human MV4-11 cells measured at 48 hrs by fluorescence based microplate reader analysis Induction of cell death in human MV4-11 cells measured at 48 hrs by fluorescence based microplate reader analysis	[PMID: 29360358]
MV4-11	EC₅₀	0.9 μM Compound: Vor; SAHA	Induction of apoptosis in human MV4-11 cells assessed as increase in caspase 3/7 activity measured at 24 hrs in presence of Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)2-rhodamine110 by fluorescence based microplate reader analysis Induction of apoptosis in human MV4-11 cells assessed as increase in caspase 3/7 activity measured at 24 hrs in presence of Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)2-rhodamine110 by fluorescence based microplate reader analysis	[PMID: 29360358]
MV4-11	IC₅₀	0.43 μM Compound: Vor; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
MV4-11	IC₅₀	0.5 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30034592]
MV4-11	IC₅₀	220 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 30629434]
MV4-11	IC₅₀	0.31 μM Compound: 1; SAHA	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MV4-11	EC₅₀	418.1 nM Compound: SAHA; Vor	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	[PMID: 32321249]
MV4-11	IC₅₀	0.26 μM Compound: 10; SAHA	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 33077265]
MV4-11	IC₅₀	0.38 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay	[PMID: 34101461]
MV4-11	IC₅₀	8.44 μM Compound: 4; SAHA	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as reduction in cell viability Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as reduction in cell viability	[PMID: 34314844]
MV4-11	IC₅₀	0.29 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MV4-11	IC₅₀	471.4 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells Antiproliferative activity against human MV4-11 cells	[PMID: 35580726]
MV4-11	IC₅₀	0.24 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs in presence of SHP099 by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs in presence of SHP099 by CCK-8 assay	[PMID: 36097406]
MV4-11	IC₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
MV4-11	IC₅₀	0.85 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MV4-11	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
MV4-11	IC₅₀	0.37 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MV4-11	IC₅₀	0.47 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
MV4-11	IC₅₀	0.421 μM Compound: Vorinostat	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay	[PMID: 37659198]
MV4-11	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
MV4-11	IC₅₀	0.22 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
MV4-11	IC₅₀	537 nM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells harboring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based fluorescence analysis Antiproliferative activity against human MV4-11 cells harboring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based fluorescence analysis	[PMID: 38224650]
MV4-11	IC₅₀	2.41 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
MV4-11	IC₅₀	0.51 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
MV4-11	IC₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay	[PMID: 38456618]
MV4-11	IC₅₀	483 nM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
MV4-11	IC₅₀	0.88 μM Compound: SAHA; 6	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
MV4-11	IC₅₀	0.4 μM Compound: SAHA	Inhibition of cell viability in human MV4-11 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human MV4-11 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells incubated for 96 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells incubated for 96 hrs by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	0.7 μM Compound: SAHA	Inhibition of cell viability in human MV4-11 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human MV4-11 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	439 nM Compound: SAHA	Growth inhibition of human MV4-11 cells assessed as ATP level after 72 hrs by CellTiterGlo assay Growth inhibition of human MV4-11 cells assessed as ATP level after 72 hrs by CellTiterGlo assay	10.1039/C3MD00285C
N2a	IC₅₀	1.45 μM Compound: SAHA	Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo 2.0 Luminescent cell assay Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo 2.0 Luminescent cell assay	[PMID: 33845233]
NALM-6	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
NAMALVA	IC₅₀	0.11 μM Compound: 1; SAHA	Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
NAMALVA	IC₅₀	0.11 μM Compound: Vorinostat	Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
NB1	IC₅₀	2.71 μM Compound: Vorinostat	Antiproliferative activity against human NB-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human NB-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
NB-4	IC₅₀	0.7 μM Compound: SAHA, vorinostat	Growth inhibition of human NB4 cells by SRB assay Growth inhibition of human NB4 cells by SRB assay	[PMID: 17892933]
NB-4	IC₅₀	0.6 μM Compound: SAHA, vorinostat	Antiproliferative activity against human NB4 cells after 48 hrs Antiproliferative activity against human NB4 cells after 48 hrs	[PMID: 18723349]
NB-4	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human NB4 cells after 72 hrs Antiproliferative activity against human NB4 cells after 72 hrs	[PMID: 19084294]
NB-4	IC₅₀	1.52 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human NB4 cells after 48 hrs by MTT assay Cytotoxicity against human NB4 cells after 48 hrs by MTT assay	[PMID: 21476600]
NB-4	IC₅₀	0.98 μM Compound: SAHA, Vorinostat	Induction of apoptosis in human NB4 cells after 48 hrs by Annexin V test Induction of apoptosis in human NB4 cells after 48 hrs by Annexin V test	[PMID: 23792316]
NB-4	IC₅₀	0.7 μM Compound: SAHA	Growth inhibition of human NB4 cells after 72 hrs Growth inhibition of human NB4 cells after 72 hrs	[PMID: 26376355]
NB-4	IC₅₀	3.3 μM Compound: SAHA	Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay	[PMID: 29150335]
NB-4	IC₅₀	880 nM Compound: Vorinostat	Cytotoxicity against human NB-4 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NB-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NB-4	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human NB-4 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human NB-4 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
NB-4	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
NB-4	IC₅₀	0.71 μM Compound: SAHA	Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
NCI/ADR-RES	GI₅₀	0.16 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-ADR-RES cells after 72 hrs by MTS assay Growth inhibition of human NCI-ADR-RES cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI/ADR-RES	IC₅₀	1413.4 nM Compound: SAHA	Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay	[PMID: 30819618]
NCI-H1299	IC₅₀	7240 nM Compound: SAHA (1)	Inhibitory activity against H1299 human lung carcinoma cell growth Inhibitory activity against H1299 human lung carcinoma cell growth	[PMID: 14521422]
NCI-H1299	IC₅₀	7.24 μM Compound: 3, SAHA	Antiproliferative activity against H1299 cells Antiproliferative activity against H1299 cells	[PMID: 16904890]
NCI-H1299	IC₅₀	0.55 μM Compound: SAHA	Cytotoxicity against human NCI-H1299 by SRB assay Cytotoxicity against human NCI-H1299 by SRB assay	[PMID: 20855208]
NCI-H1299	IC₅₀	8200 nM Compound: 1, SAHA	Antiproliferative activity against human H1299 cells Antiproliferative activity against human H1299 cells	[PMID: 21650221]
NCI-H1299	IC₅₀	3.46 μM Compound: Vorinostat	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
NCI-H1299	IC₅₀	4.92 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
NCI-H1299	IC₅₀	7.02 μM Compound: SAHA	Antiproliferative activity against human H1299 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human H1299 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
NCI-H1299	IC₅₀	5.1 μM Compound: 5; SAHA	Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-H1299	IC₅₀	5.53 μM Compound: Vorinostat	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H1373	IC₅₀	0.13 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
NCI-H1373	IC₅₀	1.46 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days by celltiter-glo luminescent assay Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days by celltiter-glo luminescent assay	[PMID: 38456618]
NCI-H157	IC₅₀	1.33 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H157 cells Antiproliferative activity against human NCI-H157 cells	[PMID: 37875056]
NCI-H1581	IC₅₀	2.501 μM Compound: SAHA	Cytotoxicity against human NCI-1581 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-1581 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
NCI-H1650	IC₅₀	5.5 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H1975	IC₅₀	1.9 μM Compound: 8	Antiproliferative activity against human NCI-H1975 expressing EGFR T790M/L858R mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 expressing EGFR T790M/L858R mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
NCI-H1975	GI₅₀	1.41 μM Compound: SAHA; 1	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
NCI-H1975	GI₅₀	2.61 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
NCI-H1975	GI₅₀	0.98 μM Compound: 1; SAHA	Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay	[PMID: 32058238]
NCI-H1975	IC₅₀	2.04 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
NCI-H1975	IC₅₀	1.7 μM Compound: SAHA	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay	[PMID: 38141287]
NCI-H1975	IC₅₀	2.08 μM Compound: SAHA	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
NCI-H2122	IC₅₀	7.5 μM Compound: SAHA	Antiproliferative activity against human NCI-H2122 cells Antiproliferative activity against human NCI-H2122 cells	[PMID: 20143778]
NCI-H2126	IC₅₀	1.319 μM Compound: SAHA	Cytotoxicity against human NCI-H2126 by SRB assay Cytotoxicity against human NCI-H2126 by SRB assay	[PMID: 20855208]
NCI-H226	EC₅₀	2.6 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human NCI-H226 cells Effective Concentration of compound to inhibit the growth of human NCI-H226 cells	[PMID: 15715470]
NCI-H226	EC₅₀	2.6 μM Compound: SAHA	Inhibition of human NCI-H226 cells Inhibition of human NCI-H226 cells	[PMID: 18247554]
NCI-H226	IC₅₀	3.48 μM Compound: SAHA	Cytotoxicity against human NCI-H226 by SRB assay Cytotoxicity against human NCI-H226 by SRB assay	[PMID: 20855208]
NCI-H226	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H226 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H226 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H226	IC₅₀	8.33 μM Compound: SAHA	Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
NCI-H23	GI₅₀	0.92 μM Compound: 2, SAHA	Antiproliferative activity against human NCI-H23 cells by SRB assay Antiproliferative activity against human NCI-H23 cells by SRB assay	[PMID: 16723227]
NCI-H23	GI₅₀	0.92 μM Compound: 1, SAHA	Growth inhibition of NCI-H23 cells by SRB assay Growth inhibition of NCI-H23 cells by SRB assay	[PMID: 17477518]
NCI-H23	GI₅₀	1.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay	[PMID: 17662606]
NCI-H23	GI₅₀	2.34 μM Compound: 1, SAHA	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 20850971]
NCI-H23	IC₅₀	0.383 μM Compound: SAHA	Cytotoxicity against human NCI-H23 by SRB assay Cytotoxicity against human NCI-H23 by SRB assay	[PMID: 20855208]
NCI-H23	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H23 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H23 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H23	GI₅₀	2.34 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition by SRB assay Cytotoxicity against human NCI-H23 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
NCI-H23	GI₅₀	2.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells after 5 days by sulforhodamine B assay Growth inhibition of human NCI-H23 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
NCI-H23	GI₅₀	2.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human NCI-H23 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
NCI-H23	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
NCI-H23	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H23	IC₅₀	1.44 μM Compound: SAHA	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCI-H23	GI₅₀	2 μM Compound: SAHA; NSC759852	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition at 10 uM incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition at 10 uM incubated for 24 hrs by MTT assay	[PMID: 36306372]
NCI-H23	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H23 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human NCI-H23 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
NCI-H23	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H23 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human NCI-H23 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
NCI-H292	IC₅₀	1.11 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	2.01 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells in LDL depleted FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells in LDL depleted FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	4.61 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells in FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells in FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	5.15 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells after 72 hrs in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells after 72 hrs in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H322M	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H322M cells after 72 hrs by MTS assay Growth inhibition of human NCI-H322M cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H358	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H441	IC₅₀	0.686 μM Compound: SAHA	Cytotoxicity against human H441 by SRB assay Cytotoxicity against human H441 by SRB assay	[PMID: 20855208]
NCI-H446	IC₅₀	0.34 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H460	IC₅₀	1.2 μM Compound: 2	Cytotoxicity against human NCI H460 cells Cytotoxicity against human NCI H460 cells	[PMID: 17691763]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA, vorinostat	Growth inhibition of human H460 cells by SRB assay Growth inhibition of human H460 cells by SRB assay	[PMID: 17892933]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells after 72 hrs Antiproliferative activity against human H460 cells after 72 hrs	[PMID: 19084294]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Cytotoxicity against human H460 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human H460 cells after 24 hrs by sulforhodamine B assay	[PMID: 19359173]
NCI-H460	IC₅₀	1.7 μM Compound: SAHA	Antiproliferative activity against human H460 cells after hrs by ATP content assay Antiproliferative activity against human H460 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H460	GI₅₀	8 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 20605448]
NCI-H460	IC₅₀	3.448 μM Compound: SAHA	Cytotoxicity against human NCI-H460 by SRB assay Cytotoxicity against human NCI-H460 by SRB assay	[PMID: 20855208]
NCI-H460	IC₅₀	3.4 μM Compound: 2, SAHA	Growth inhibition of human H460 cells after 48 hrs by SRB assay Growth inhibition of human H460 cells after 48 hrs by SRB assay	[PMID: 21073160]
NCI-H460	IC₅₀	0.68 μg/mL Compound: SAHA	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 22036991]
NCI-H460	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H460 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H460	GI₅₀	1 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 23538115]
NCI-H460	GI₅₀	0.85 μM Compound: 1, SAHA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
NCI-H460	IC₅₀	2.77 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24185378]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA, Vorinostat	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 24345446]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human H460 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
NCI-H460	IC₅₀	0.82 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human H460 cells by MTT assay Cytotoxicity against human H460 cells by MTT assay	[PMID: 24766560]
NCI-H460	IC₅₀	3400 nM Compound: 1, SAHA	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 25563890]
NCI-H460	GI₅₀	0.85 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Growth inhibition of human H460 cells after 72 hrs Growth inhibition of human H460 cells after 72 hrs	[PMID: 26376355]
NCI-H460	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 26443078]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human H460 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
NCI-H460	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 29150335]
NCI-H460	IC₅₀	0.425 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H460 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
NCI-H460	IC₅₀	6.29 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
NCI-H460	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
NCI-H460	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability	[PMID: 30660827]
NCI-H460	IC₅₀	100 μM Compound: 5; SAHA	Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-H460	IC₅₀	3.04 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
NCI-H460	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
NCI-H460	IC₅₀	11.92 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
NCI-H460	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H460	IC₅₀	4.136 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
NCI-H460	IC₅₀	4.2 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
NCI-H460	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
NCI-H522	IC₅₀	0.832 μM Compound: SAHA	Cytotoxicity against human NCI-H522 by SRB assay Cytotoxicity against human NCI-H522 by SRB assay	[PMID: 20855208]
NCI-H522	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H522 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H522 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H522	IC₅₀	1.72 μM Compound: SAHA	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
NCI-H522	IC₅₀	2.38 μM Compound: SAHA	Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
NCI-H526	GI₅₀	0.481 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H526 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Antiproliferative activity against human NCI-H526 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
NCI-H661	IC₅₀	>5 μM Compound: 3, SAHA	Antiproliferative activity against H661 cells Antiproliferative activity against H661 cells	[PMID: 16904890]
NCI-H661	IC₅₀	1 μM Compound: 1	Antiproliferative activity against human H661 cells after 48 hrs Antiproliferative activity against human H661 cells after 48 hrs	[PMID: 17157009]
NCI-H661	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against H661 cells after 48 hrs Antiproliferative activity against H661 cells after 48 hrs	[PMID: 17897824]
NCI-H661	IC₅₀	0.13 μM Compound: SAHA, Zolinza	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
NCI-H661	IC₅₀	0.13 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
NCI-H69	EC₅₀	2.06 μM Compound: SAHA	Cytotoxicity against human NCI-H69 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human NCI-H69 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
NCI-H69	IC₅₀	0.6 μM Compound: SAHA	Cytotoxicity against human H69 cells Cytotoxicity against human H69 cells	[PMID: 23906422]
NCI-H727	IC₅₀	1.37 μM Compound: SAHA	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
NCI-H838	IC₅₀	5.18 μM Compound: Vorinostat	Antiproliferation activity against human NCI-H838 cells incubated for 72 hrs by MTT assay Antiproliferation activity against human NCI-H838 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
NCI-H929	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25238284]
NCI-H929	IC₅₀	2.83 μM Compound: SAHA	Antiproliferative activity against human NCI-H929 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human NCI-H929 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
NCI-H929	EC₅₀	1.4 μM Compound: 3; SAHA	Antiproliferative activity against human NCI-H929 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human NCI-H929 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
NCI-N87	IC₅₀	1027 nM Compound: 1; SAHA	Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
NFF	IC₅₀	5170 nM Compound: SAHA	Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay	[PMID: 30245402]
NFF	IC₅₀	5.5 μM Compound: SAHA	Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay	[PMID: 39208744]
NIH3T3	EC₅₀	4.8 μM Compound: SAHA	Cytotoxicity against mouse NIH/3T3 cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
NIH3T3	IC₅₀	16.6 μM Compound: SAHA	Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay	[PMID: 37463500]
Non-small cell lung cancer cell line	IC₅₀	>1 μM Compound: 1; SAHA	Antiproliferative activity against non-small cell lung cancer cell line (unknown origin) Antiproliferative activity against non-small cell lung cancer cell line (unknown origin)	[PMID: 33077264]
NSC	IC₅₀	4 μM Compound: Chemical Probe: Vorinostat	Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay	[PMID: 30559935]
NUGC-3	GI₅₀	2.79 μM Compound: 2, SAHA	Growth inhibition of human NUGC3 cells by SRB assay Growth inhibition of human NUGC3 cells by SRB assay	[PMID: 17904843]
NUGC-3	GI₅₀	2.94 μM Compound: 1, SAHA	Growth inhibition of human NUGC3 cells Growth inhibition of human NUGC3 cells	[PMID: 20850971]
NUGC-3	GI₅₀	2.94 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human NUGC3 cells assessed as growth inhibition by SRB assay Cytotoxicity against human NUGC3 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
NUGC-3	GI₅₀	2.94 μM Compound: SAHA	Growth inhibition of human NUGC3 cells after 5 days by sulforhodamine B assay Growth inhibition of human NUGC3 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
NUGC-3	GI₅₀	2.94 μM Compound: SAHA	Growth inhibition of human NUGC3 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human NUGC3 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
OCI-AML2	IC₅₀	0.78 μM Compound: 5; SAHA	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay	[PMID: 28765013]
OCI-AML2	IC₅₀	390 nM Compound: SAHA	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay	[PMID: 30629434]
OCI-AML-3	IC₅₀	1365 nM Compound: SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
OCI-AML-3	IC₅₀	0.85 μM Compound: 5; SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 28765013]
OCI-AML-3	IC₅₀	300 nM Compound: SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 30629434]
OCI-Ly3	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay	[PMID: 29150335]
OE19	GI₅₀	1.42 μM Compound: Vorinostat	Antiproliferative activity against human OE19 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay Antiproliferative activity against human OE19 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	[PMID: 31420257]
OE33	GI₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human OE33 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay Antiproliferative activity against human OE33 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	[PMID: 31420257]
ONS-76	IC₅₀	2.04 μM Compound: Vorinostat	Antiproliferative activity against human ONS76 cells after 72 hrs by Celltiter-Glo assay Antiproliferative activity against human ONS76 cells after 72 hrs by Celltiter-Glo assay	[PMID: 28581289]
OPM-2	IC₅₀	2.91 μM Compound: 1; SAHA	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27541357]
OPM-2	IC₅₀	2.91 μM Compound: 2	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
OPM-2	EC₅₀	2.9 μM Compound: 3; SAHA	Antiproliferative activity against human OPM2 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human OPM2 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
Osteoclast-like	EC₅₀	150 μM Compound: SAHA	Compound was tested for anti-proliferative activity in human bone marrow cells Compound was tested for anti-proliferative activity in human bone marrow cells	[PMID: 14698179]
OVCAR-3	GI₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
OVCAR-4	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR4 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR4 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-5	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR5 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR5 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-5	GI₅₀	1.78 μM Compound: 1, SAHA	Antiproliferative activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
OVCAR-5	GI₅₀	1.78 μM Compound: SAHA	Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
OVCAR-8	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR8 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR8 cells after 72 hrs by MTS assay	[PMID: 22435669]
PANC-1	IC₅₀	450 nM Compound: 5, Zolinza	Antiproliferative activity against human PANC1 cells Antiproliferative activity against human PANC1 cells	[PMID: 17588744]
PANC-1	GI₅₀	678 nM Compound: SAHA	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 24999749]
PANC-1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
PANC-1	IC₅₀	>10 μM Compound: SAHA	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PANC-1	IC₅₀	3.14 μM Compound: SAHA	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
PANC-1	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
PANC-1	IC₅₀	2.43 μM Compound: SAHA	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
PANC-1	IC₅₀	2.52 μM Compound: SAHA	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
PBL	IC₅₀	3.4 μM Compound: Vorinostat	Cytotoxicity against human PBL cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human PBL cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 30004697]
PBMC	IC₅₀	<3.5 μM Compound: Vorinostat	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
PBMC	IC₅₀	229 nM Compound: SAHA	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated TNF-alpha production incubated for 30 mins prior to LPS-challenge measured after overnight incubation Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated TNF-alpha production incubated for 30 mins prior to LPS-challenge measured after overnight incubation	10.1039/C3MD00285C
PBMC	IC₅₀	955 nM Compound: SAHA	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated IL-6 production incubated for 30 mins prior to LPS-challenge measured after overnight incubation Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated IL-6 production incubated for 30 mins prior to LPS-challenge measured after overnight incubation	10.1039/C3MD00285C
PC-3	IC₅₀	6.5 μM Compound: SAHA	Concentration required to inhibit human PC-3 prostate carcinoma cells Concentration required to inhibit human PC-3 prostate carcinoma cells	[PMID: 16033284]
PC-3	GI₅₀	0.89 μM Compound: 2, SAHA	Antiproliferative activity against human PC3 cells by SRB assay Antiproliferative activity against human PC3 cells by SRB assay	[PMID: 16723227]
PC-3	IC₅₀	3.11 μM Compound: SAHA	Inhibition of PC3 cell proliferation (mean of two experiments) Inhibition of PC3 cell proliferation (mean of two experiments)	[PMID: 17095213]
PC-3	GI₅₀	0.89 μM Compound: 1, SAHA	Growth inhibition of PC3 cells by SRB assay Growth inhibition of PC3 cells by SRB assay	[PMID: 17477518]
PC-3	GI₅₀	0.71 μM Compound: SAHA	Growth inhibition of human PC3 cells after 21 hrs by MTT assay Growth inhibition of human PC3 cells after 21 hrs by MTT assay	[PMID: 17662606]
PC-3	IC₅₀	1.9 μM Compound: 2	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17691763]
PC-3	GI₅₀	2.69 μM Compound: 2, SAHA	Growth inhibition of human PC3 cells by SRB assay Growth inhibition of human PC3 cells by SRB assay	[PMID: 17904843]
PC-3	GI₅₀	4.6 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
PC-3	GI₅₀	8.17 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 19822426]
PC-3	IC₅₀	6.5 μM Compound: vorinostat	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 20403695]
PC-3	IC₅₀	1.21 μM Compound: SAHA	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 20451378]
PC-3	IC₅₀	2.69 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	[PMID: 20850971]
PC-3	GI₅₀	2000 nM Compound: SAHA, vorinostat	Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
PC-3	IC₅₀	1.21 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
PC-3	GI₅₀	1.02 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 21712146]
PC-3	IC₅₀	1.33 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21714538]
PC-3	IC₅₀	1.98 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21924799]
PC-3	IC₅₀	0.94 μg/mL Compound: SAHA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 22036991]
PC-3	GI₅₀	1.21 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 22439863]
PC-3	GI₅₀	2.69 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human PC3 cells assessed as growth inhibition by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
PC-3	IC₅₀	9.9 μM Compound: 1, SAHA	Inhibition of human PC3 cell proliferation after 48 hrs by MTT assay Inhibition of human PC3 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
PC-3	EC₅₀	>166.67 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23820574]
PC-3	IC₅₀	4.31 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 24185378]
PC-3	IC₅₀	9.79 μM Compound: 1, SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24525003]
PC-3	IC₅₀	3.57 μM Compound: SA, SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24694055]
PC-3	IC₅₀	1.74 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 24766560]
PC-3	GI₅₀	0.96 μM Compound: Vorinostat	Growth inhibition of human PC3 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human PC3 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
PC-3	IC₅₀	5.79 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25311567]
PC-3	IC₅₀	3.57 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25462271]
PC-3	GI₅₀	2.69 μM Compound: SAHA	Growth inhibition of human PC3 cells after 5 days by sulforhodamine B assay Growth inhibition of human PC3 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
PC-3	IC₅₀	1.92 μM Compound: SAHA, Zolinza	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26100440]
PC-3	IC₅₀	2.78 μM Compound: 1, SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
PC-3	IC₅₀	7.3 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
PC-3	IC₅₀	10.4 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26216016]
PC-3	IC₅₀	3052.4 nM Compound: SAHA	Inhibition of Class 2a histone deacetylase in human PC3 cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay Inhibition of Class 2a histone deacetylase in human PC3 cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	[PMID: 26349626]
PC-3	IC₅₀	447.6 nM Compound: SAHA	Inhibition of Class 1 histone deacetylase in human PC3 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay Inhibition of Class 1 histone deacetylase in human PC3 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	[PMID: 26349626]
PC-3	IC₅₀	5.36 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
PC-3	GI₅₀	1.77 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells after 96 hrs by MTT assay Growth inhibition of human PC3 cells after 96 hrs by MTT assay	[PMID: 26814680]
PC-3	IC₅₀	7.26 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26907204]
PC-3	GI₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 27344487]
PC-3	IC₅₀	0.85 μM Compound: 1; SAHA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27541357]
PC-3	IC₅₀	873.26 nM Compound: 1; SAHA	Antiproliferative activity against human PC3 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human PC3 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
PC-3	GI₅₀	2.69 μM Compound: SAHA	Growth inhibition of human PC3 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human PC3 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
PC-3	IC₅₀	16.28 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28336407]
PC-3	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
PC-3	IC₅₀	13.91 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28371677]
PC-3	GI₅₀	0.6 μM Compound: 1; SAHA	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
PC-3	GI₅₀	18.83 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28629630]
PC-3	IC₅₀	2.92 μM Compound: SAHA	Anti-proliferative activity against human PC3 cells after 48 hrs by MTT assay Anti-proliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28947154]
PC-3	IC₅₀	0.85 μM Compound: 2	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28953386]
PC-3	IC₅₀	3.46 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
PC-3	IC₅₀	1.5 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 29223096]
PC-3	IC₅₀	3.07 μM Compound: Vor; SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
PC-3	IC₅₀	6.7 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29533873]
PC-3	IC₅₀	>5 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29787262]
PC-3	IC₅₀	0.85 μM Compound: 4	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 29945795]
PC-3	IC₅₀	1 μM Compound: 4	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30243158]
PC-3	IC₅₀	2.58 μM Compound: SAHA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 30245394]
PC-3	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human PC3 cells assessed as reduction in cell viability Cytotoxicity against human PC3 cells assessed as reduction in cell viability	[PMID: 30660827]
PC-3	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells by CCK8 assay Antiproliferative activity against human PC3 cells by CCK8 assay	[PMID: 30660827]
PC-3	GI₅₀	5 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
PC-3	IC₅₀	1.86 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30879863]
PC-3	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
PC-3	IC₅₀	1.81 μM Compound: SAHA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 31883490]
PC-3	IC₅₀	60.8 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human PC3 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
PC-3	IC₅₀	2.03 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
PC-3	GI₅₀	>410 nM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PC-3	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PC-3	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
PC-3	IC₅₀	2.459 μM Compound: SAHA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PC-3	IC₅₀	1.82 μM Compound: SAHA	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	IC₅₀	1.56 μM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method	[PMID: 33077264]
PC-3	IC₅₀	3.31 μM Compound: 1; SAHA	Cytotoxicity against human PC-3 cells Cytotoxicity against human PC-3 cells	[PMID: 33077264]
PC-3	IC₅₀	3 μM Compound: 2; SAHA	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
PC-3	IC₅₀	1.14 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
PC-3	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
PC-3	IC₅₀	3.6 μM Compound: 1; SAHA	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
PC-3	IC₅₀	1791 nM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	1.41 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
PC-3	IC₅₀	3.22 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
PC-3	GI₅₀	1.7 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 37875056]
PC-3	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
PC-3	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human PC-3 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
PC-3	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human PC-3 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
PC-3	IC₅₀	403 nM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 37875056]
PC-3	IC₅₀	16.28 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 38107170]
PC-3	IC₅₀	2.38 μM Compound: SAHA	Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
PC-3	IC₅₀	1.34 μM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
PC-3	IC₅₀	3.02 μM Compound: XII; SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
PC-3	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
PC-3	IC₅₀	1.42 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
PC-9	IC₅₀	1181 nM Compound: 1; SAHA	Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-9	IC₅₀	1.15 μM Compound: SAHA	Antiproliferative activity against human PC-9 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
PC-9	IC₅₀	1.1 μM Compound: SAHA; 6	Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
PLC	IC₅₀	1.534 μM Compound: SAHA	Cytotoxicity against human PLC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PLC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PLC-PRF-5	IC₅₀	1.87 μM Compound: Vor; SAHA	Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
PLC-PRF-5	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PLC-PRF-5	IC₅₀	2.22 μM Compound: SAHA	Antiproliferative activity against human PLC-PRF-5 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human PLC-PRF-5 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
PT-45	IC₅₀	4000 nM Compound: 5, Zolinza	Antiproliferative activity against human drug-resistant PT45 cells Antiproliferative activity against human drug-resistant PT45 cells	[PMID: 17588744]
Raji	IC₅₀	0.97 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 28325601]
Raji	IC₅₀	9.44 μM Compound: SAHA	Antiproliferative activity against human Raji cells after 3 days by MTT assay Antiproliferative activity against human Raji cells after 3 days by MTT assay	[PMID: 28601509]
Raji	IC₅₀	1.11 μM Compound: Vor; SAHA	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Raji	IC₅₀	0.97 μM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 29534936]
Raji	IC₅₀	196 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 30629434]
Raji	IC₅₀	867.4 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 31177073]
Raji	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Raji	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
Raji	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Ramos	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay Cytotoxicity against human Ramos cells after 72 hrs by MTT assay	[PMID: 26443078]
Ramos	IC₅₀	0.52 nM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 28325601]
Ramos	IC₅₀	0.62 μM Compound: Vor; SAHA	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Ramos	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 29534936]
Ramos	IC₅₀	514.6 nM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 31177073]
Ramos	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Ramos	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human Ramos cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human Ramos cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
Ramos	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human Ramos cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Ramos cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Ramos	IC₅₀	5.3 μM Compound: SAHA	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
RAW264.7	IC₅₀	0.76 μM Compound: 1, SAHA	Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA	[PMID: 17477518]
RAW264.7	IC₅₀	1.88 μM Compound: 1, SAHA	Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA	[PMID: 17477518]
RAW264.7	IC₅₀	110 nM Compound: SAHA, WR-308364	Antimalarial activity against Plasmodium falciparum infected in mouse RAW264.7 cells Antimalarial activity against Plasmodium falciparum infected in mouse RAW264.7 cells	[PMID: 18644969]
Rec1	IC₅₀	0.35 μM Compound: SAHA; 6	Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
RPMI-8226	IC₅₀	2.39 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by WST8 assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by WST8 assay	[PMID: 25261927]
RPMI-8226	IC₅₀	2.4 μM Compound: SAHA	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 25490132]
RPMI-8226	IC₅₀	2.39 μM Compound: SAHA	Cytotoxicity against human RPMI8226 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human RPMI8226 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
RPMI-8226	IC₅₀	423 nM Compound: SAHA	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 26443078]
RPMI-8226	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
RPMI-8226	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	[PMID: 28213282]
RPMI-8226	IC₅₀	0.66 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 29534936]
RPMI-8226	IC₅₀	10.6 μM Compound: SAHA	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30594434]
RPMI-8226	IC₅₀	585.8 nM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 31177073]
RPMI-8226	IC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
RPMI-8226	IC₅₀	0.684 μM Compound: SAHA	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
RPMI-8226	IC₅₀	870 nM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
RPMI-8226	GI₅₀	1.5 μM Compound: SAHA; NSC759852	Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 36306372]
RPMI-8226	IC₅₀	0.43 μM Compound: SAHA	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay	[PMID: 37660484]
RS4-11	IC₅₀	3.98 μM Compound: SAHA	Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
RWPE-1	IC₅₀	3.64 μM Compound: SAHA	Cytotoxicity against human RWPE1 cells Cytotoxicity against human RWPE1 cells	[PMID: 30245394]
RWPE-1	IC₅₀	0.48 μM Compound: 1; SAHA	Cytotoxicity against human RWPE-1 cells Cytotoxicity against human RWPE-1 cells	[PMID: 33077264]
RWPE-1	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
RXF 393	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human RXF393 cells after 72 hrs by MTS assay Growth inhibition of human RXF393 cells after 72 hrs by MTS assay	[PMID: 22435669]
RXF 393	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
RXF 631	GI₅₀	2 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human RXF631L cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RXF631L cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
S2	IC₅₀	59 nM Compound: 4, SAHA	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
S9	IC₅₀	>100 nM Compound: 6, SAHA	Inhibition of human recombinant HDAC4 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of human recombinant HDAC4 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	120.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	21.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	34.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect S9 cells after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect S9 cells after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	5.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC8 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC8 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	58.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC3 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC3 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
SAOS-2	IC₅₀	2.3 μM Compound: 2	Cytotoxicity against human Saos2 cells Cytotoxicity against human Saos2 cells	[PMID: 17691763]
SCC-15	IC₅₀	2.49 μM Compound: SAHA	Antiproliferative activity against human SCC15 cells Antiproliferative activity against human SCC15 cells	[PMID: 20143778]
SCC-25	IC₅₀	1.93 μM Compound: SAHA	Antiproliferative activity against human SCC25 cells Antiproliferative activity against human SCC25 cells	[PMID: 20143778]
Sf21	IC₅₀	0.037 μM Compound: 2a	Inhibition of Flag tagged human recombinant HDAC3 expressed in Sf21 cells coexpressing SMRT DAD domain Inhibition of Flag tagged human recombinant HDAC3 expressed in Sf21 cells coexpressing SMRT DAD domain	[PMID: 21080629]
Sf21	IC₅₀	1.2 μM Compound: 2a	Inhibition of Flag tagged human recombinant HDAC8 expressed in Sf21 cells Inhibition of Flag tagged human recombinant HDAC8 expressed in Sf21 cells	[PMID: 21080629]
Sf21	IC₅₀	0.26 μM Compound: SAHA	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	[PMID: 26890116]
Sf21	IC₅₀	0.306 μM Compound: 1; SAHA	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	[PMID: 27541357]
Sf21	IC₅₀	1.6 μM Compound: SAHA	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf21 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf21 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
SF-268	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human SF268 cells after 72 hrs by MTS assay Growth inhibition of human SF268 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-295	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human SF295 cells after 72 hrs by MTS assay Growth inhibition of human SF295 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-539	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human SF539 cells after 72 hrs by MTS assay Growth inhibition of human SF539 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-539	GI₅₀	2 μM Compound: SAHA; NSC759852	Cytotoxicity against human SF-539 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human SF-539 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 36306372]
Sf9	IC₅₀	174 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC2 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC2 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	23 nM Compound: SAHA	Inhibition of recombinant full length human HDAC1 (1 to 482) expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant full length human HDAC1 (1 to 482) expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	23 nM Compound: SAHA	Inhibition of recombinant N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	56 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC3/NcoR2 complex expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC3/NcoR2 complex expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	8.8 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC8 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC class 2a substrate after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC8 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC class 2a substrate after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	0.029 μM Compound: SAHA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 26890116]
Sf9	IC₅₀	0.081 μM Compound: SAHA	Inhibition of C-terminal GST-tagged human recombinant HDAC2 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis Inhibition of C-terminal GST-tagged human recombinant HDAC2 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	[PMID: 26907204]
Sf9	IC₅₀	3.7 μM Compound: SAHA	Inhibition of C-terminal His-tagged human recombinant HDAC8 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis Inhibition of C-terminal His-tagged human recombinant HDAC8 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	[PMID: 26907204]
Sf9	IC₅₀	370 nM Compound: SAHA	Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate by fluorometric assay Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate by fluorometric assay	[PMID: 27055940]
Sf9	IC₅₀	11 nM Compound: SAHA	Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured a Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured a	[PMID: 27186676]
Sf9	IC₅₀	0.02 μM Compound: 1; SAHA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	[PMID: 27541357]
Sf9	IC₅₀	0.78 μM Compound: SAHA	Inhibition of recombinant full-length human C-terminal HDAC8 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant full-length human C-terminal HDAC8 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	0.8 μM Compound: SAHA	Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	8.7 μM Compound: SAHA	Inhibition of recombinant full-length human HDAC11 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant full-length human HDAC11 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	13 nM Compound: SAHA	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	35 nM Compound: SAHA	Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	>1000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	[PMID: 30629434]
Sf9	IC₅₀	170 nM Compound: SAHA	Inhibition of recombinant full length N-terminal FLAG-tagged human HDAC10 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay Inhibition of recombinant full length N-terminal FLAG-tagged human HDAC10 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	[PMID: 30629434]
Sf9	IC₅₀	32 nM Compound: 5; SAHA	Inhibition of recombinant C-terminal His/FLAG-tagged HDAC1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr Inhibition of recombinant C-terminal His/FLAG-tagged HDAC1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr	[PMID: 31117517]
Sf9	IC₅₀	>10000 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	>10000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	>10000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC4 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC4 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	>10000 nM Compound: SAHA	Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	>10000 nM Compound: SAHA	Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	208 nM Compound: SAHA	Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	29 nM Compound: SAHA	Inhibition of recombinant full length human HDAC2 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC2 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	33 nM Compound: SAHA	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	682 nM Compound: SAHA	Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	101 nM Compound: Vorinostat	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a	[PMID: 31391882]
Sf9	IC₅₀	34.3 nM Compound: Vorinostat	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay	[PMID: 31391882]
Sf9	IC₅₀	0.038 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.089 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal Flag/His-tagged HDAC1 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal Flag/His-tagged HDAC1 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.105 μM Compound: Vorinostat	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric m Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric m	[PMID: 31420257]
Sf9	IC₅₀	0.183 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal Flag-tagged HDAC2 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal Flag-tagged HDAC2 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	19 nM Compound: SAHA	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence b Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence b	[PMID: 31505452]
Sf9	IC₅₀	328 nM Compound: SAHA	Inhibition of full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 240 mins by fluorescence based assay Inhibition of full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 240 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	49 nM Compound: SAHA	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed b Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed b	[PMID: 31505452]
Sf9	IC₅₀	51 nM Compound: SAHA	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	102 nM Compound: Zolinza	Inhibition of full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay Inhibition of full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	[PMID: 31531206]
Sf9	IC₅₀	47 nM Compound: Zolinza	Inhibition of full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay Inhibition of full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	[PMID: 31531206]
Sf9	IC₅₀	0.0097 μM Compound: Vorinostat	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9 Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9	[PMID: 31762274]
Sf9	IC₅₀	0.102 μM Compound: Vorinostat	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.111 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.146 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	>1 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.0058 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.00657 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.497 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	144.7 nM Compound: SAHA; Vor	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo	[PMID: 32321249]
Sf9	IC₅₀	0.032 μM Compound: SAHA	Inhibition of recombinant full length human HDAC6 expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay Inhibition of recombinant full length human HDAC6 expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay	10.1039/C4MD00203B
Sf9	IC₅₀	0.051 μM Compound: SAHA	Inhibition of recombinant full length human HDAC1 (1 to 482 amino acids) expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay Inhibition of recombinant full length human HDAC1 (1 to 482 amino acids) expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay	10.1039/C4MD00203B
Sf9	IC₅₀	0.23 μM Compound: SAHA	Inhibition of recombinant full length human HDAC8 expressed in Baculovirus infected insect Sf9 cells preincubated for 30 mins followed by substrate addition measured after 15 to 45 mins by luminescence assay Inhibition of recombinant full length human HDAC8 expressed in Baculovirus infected insect Sf9 cells preincubated for 30 mins followed by substrate addition measured after 15 to 45 mins by luminescence assay	10.1039/C4MD00203B
SGC-7901	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human SGC7901 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
SGC-7901	IC₅₀	135.71 μM Compound: SAHA	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
SGC-7901	IC₅₀	0.64 μM Compound: 1; SAHA	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
SGC-7901	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
SGC-7901	IC₅₀	3.3 μM Compound: Vorinostat	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
SGC-7901	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human SGC-7901 cells Antiproliferative activity against human SGC-7901 cells	[PMID: 37875056]
SGC-7901	IC₅₀	2.89 μM Compound: SAHA	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
SGC-7901	IC₅₀	9.73 μM Compound: SAHA	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
SH-SY5Y	IC₅₀	0.5 μM Compound: SAHA	Inhibition of HDAC in human SHSY5Y cells by fluorimetric cellular activity assay Inhibition of HDAC in human SHSY5Y cells by fluorimetric cellular activity assay	[PMID: 19344175]
SH-SY5Y	IC₅₀	2 μM Compound: SAHA	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 19344175]
SH-SY5Y	EC₅₀	>50 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 24 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 24 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	EC₅₀	17.4 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	EC₅₀	25.6 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 48 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	IC₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
SH-SY5Y	IC₅₀	7.87 μM Compound: SAHA	Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay	[PMID: 36645952]
SH-SY5Y	IC₅₀	3.59 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SH-SY5Y	IC₅₀	32.2 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SH-SY5Y	IC₅₀	5.43 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SiHa	IC₅₀	4.34 μM Compound: XII; SAHA	Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
SK-BR-3	IC₅₀	2.6 μM Compound: 2	Cytotoxicity against human SKBR3 cells Cytotoxicity against human SKBR3 cells	[PMID: 17691763]
SK-BR-3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 18247554]
SK-BR-3	IC₅₀	1.19 μM Compound: SAHA	Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay	[PMID: 20143778]
SK-BR-3	EC₅₀	2.1 μM Compound: 1a, SAHA	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human SK-BR-3 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
SK-BR-3	IC₅₀	2.6 μM Compound: 2a	Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay	[PMID: 21080629]
SK-BR-3	GI₅₀	1.2 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human SK-BR-3 cells after 72 hrs by WST1 assay Cytotoxicity against human SK-BR-3 cells after 72 hrs by WST1 assay	[PMID: 24015327]
SK-BR-3	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SK-BR-3	IC₅₀	2.58 μM Compound: 8	Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
SK-BR-3	IC₅₀	2.13 μM Compound: Vorinostat	Antiproliferation activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay Antiproliferation activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
SK-HEP1	IC₅₀	3.46 μM Compound: SAHA	Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay	[PMID: 20143778]
SK-HEP1	IC₅₀	1.85 μM Compound: Vor; SAHA	Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SK-HEP1	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SK-HEP1	IC₅₀	36.93 μM Compound: SAHA	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
SK-HEP1	IC₅₀	3.3 μM Compound: 2; SAHA	Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
SK-MEL-2	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-2 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-2 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MEL-28	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MEL-28	IC₅₀	0.482 μM Compound: 1; SAHA	Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
SK-MEL-5	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-5 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-5 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MES-1	EC₅₀	2.42 μM Compound: SAHA	Cytotoxicity against human SKMES1 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human SKMES1 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
SK-MES-1	IC₅₀	2.42 μM Compound: SAHA	Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay	[PMID: 22260166]
SK-N-AS	IC₅₀	0.7 μM Compound: Vorinostat	Antiproliferative activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
SK-N-BE(2)	IC₅₀	4.58 μM Compound: SAHA	Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
SK-N-BE(2)	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
SK-OV-3	EC₅₀	2.5 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells	[PMID: 15715470]
SK-OV-3	IC₅₀	2.2 μM Compound: 2	Cytotoxicity against human SK-OV-3 cells Cytotoxicity against human SK-OV-3 cells	[PMID: 17691763]
SK-OV-3	EC₅₀	2.5 μM Compound: SAHA	Inhibition of human SKOV3 cells Inhibition of human SKOV3 cells	[PMID: 18247554]
SK-OV-3	GI₅₀	2.5 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
SK-OV-3	IC₅₀	1.66 mM Compound: vorinostat, SAHA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 20171895]
SK-OV-3	IC₅₀	2.2 μM Compound: 2a	Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay	[PMID: 21080629]
SK-OV-3	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human SKOV3 cells after 72 hrs by MTS assay Growth inhibition of human SKOV3 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-OV-3	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 23906422]
SK-OV-3	IC₅₀	>1000 nM Compound: SAHA	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SK-OV-3	IC₅₀	1130 nM Compound: SAHA	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 31177073]
SK-OV-3	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
SMMC-7721	IC₅₀	5.61 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29288941]
SMMC-7721	IC₅₀	5.61 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30108831]
SMMC-7721	IC₅₀	5.23 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
SMMC-7721	IC₅₀	5.2 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31120744]
SMMC-7721	IC₅₀	5.274 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
SMMC-7721	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
SMMC-7721	IC₅₀	1.99 μM Compound: SAHA	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
SMMC-7721	IC₅₀	5.46 μM Compound: 1; SAHA	Cytotoxicity against human SMMC-7721 cells Cytotoxicity against human SMMC-7721 cells	[PMID: 33077264]
SMMC-7721	IC₅₀	5.46 μM Compound: 1; CTCL	Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 33143937]
SMMC-7721	IC₅₀	>10 μM Compound: SAHA	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
SN12C	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human SN12C cells after 72 hrs by MTS assay Growth inhibition of human SN12C cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-19	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SNB19 cells after 72 hrs by MTS assay Growth inhibition of human SNB19 cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-75	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human SNB75 cells after 72 hrs by MTS assay Growth inhibition of human SNB75 cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-75	GI₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
SNB-78	EC₅₀	16 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human SNB-78 cells Effective Concentration of compound to inhibit the growth of human SNB-78 cells	[PMID: 15715470]
SNB-78	EC₅₀	16 μM Compound: SAHA	Inhibition of human SNB78 cells Inhibition of human SNB78 cells	[PMID: 18247554]
SNB-78	GI₅₀	16 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human SNB78 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB78 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
SNU-16	IC₅₀	0.29 μM Compound: 3; SAHA	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
SNU-387	IC₅₀	2.45 μM Compound: Vor; SAHA	Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-387	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SNU-398	IC₅₀	1.39 μM Compound: Vor; SAHA	Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-398	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SNU-423	IC₅₀	0.079 μM Compound: SAHA	Antiproliferative activity against human SNU-423 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human SNU-423 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
SQ20B	IC₅₀	3 μM Compound: SAHA	Inhibition of human SQ20B cells Inhibition of human SQ20B cells	[PMID: 18247554]
SR	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human SR cells after 72 hrs by MTS assay Growth inhibition of human SR cells after 72 hrs by MTS assay	[PMID: 22435669]
SR	GI₅₀	0.4 μM Compound: SAHA	Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
St-4	EC₅₀	5.2 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human St-4 cells Effective Concentration of compound to inhibit the growth of human St-4 cells	[PMID: 15715470]
St-4	EC₅₀	5.2 μM Compound: SAHA	Inhibition of human St4 cells Inhibition of human St4 cells	[PMID: 18247554]
SU.86.86	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against human SU 86.86 cells after 72 hrs by MTT assay Cytotoxicity against human SU 86.86 cells after 72 hrs by MTT assay	[PMID: 18494463]
SU.86.86	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human SU.86.86 cells after 72 hrs by MTT assay Antiproliferative activity against human SU.86.86 cells after 72 hrs by MTT assay	[PMID: 18642892]
SU.86.86	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human SU-8686 cells by MTT assay Antiproliferative activity against human SU-8686 cells by MTT assay	[PMID: 19419863]
SU.86.86	IC₅₀	1.3 μM Compound: 1a, SAHA	Growth inhibition of human SU-8686 cells after 72 hrs by MTS assay Growth inhibition of human SU-8686 cells after 72 hrs by MTS assay	[PMID: 20055418]
SU-DHL10	IC₅₀	0.47 μM Compound: 1; SAHA	Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
SU-DHL-6	IC₅₀	0.58 μM Compound: Vor; SAHA	Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SU-DHL-6	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SUM-159-PT	IC₅₀	1.381 μM Compound: SAHA	Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
SUM-159-PT	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human SUM159PT cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability Cytotoxicity against human SUM159PT cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
SW1990	IC₅₀	3.8 μM Compound: 5; SAHA	Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay	[PMID: 31117517]
SW1990	IC₅₀	5.72 μM Compound: SAHA	Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
SW480	IC₅₀	3.97 μM Compound: SAHA	Antiproliferative activity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
SW480	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human SW480 cells measured after 72 hrs Antiproliferative activity against human SW480 cells measured after 72 hrs	[PMID: 35697181]
SW480	IC₅₀	1.89 μM Compound: SAHA	Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
SW-620	IC₅₀	0.6 μM Compound: SAHA	Inhibition of human SW620 cells Inhibition of human SW620 cells	[PMID: 18247554]
SW-620	IC₅₀	0.5 μg/mL Compound: SAHA	Cytotoxicity against human SW620 cells Cytotoxicity against human SW620 cells	[PMID: 22036991]
SW-620	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SW620 cells after 72 hrs by MTS assay Growth inhibition of human SW620 cells after 72 hrs by MTS assay	[PMID: 22435669]
SW-620	GI₅₀	0.54 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human SW620 cells after 48 hrs by SRB assay Cytotoxicity against human SW620 cells after 48 hrs by SRB assay	[PMID: 24015327]
SW-620	IC₅₀	3.7 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	[PMID: 24185378]
SW-620	IC₅₀	4.32 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
SW-620	IC₅₀	3.87 μM Compound: SAHA	Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
SW-620	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as reduction in cell viability Cytotoxicity against human SW620 cells assessed as reduction in cell viability	[PMID: 30660827]
SW-620	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
SW-620	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
SW-620	IC₅₀	6.94 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
SW-620	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
SW-620	IC₅₀	4.31 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SW-620	IC₅₀	1.12 μM Compound: SAHA	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
SW-620	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human SW620 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human SW620 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
SW-620	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human SW620 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human SW620 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
SW-620	IC₅₀	403 nM Compound: Vorinostat	Antiproliferative activity against human SW620 cells Antiproliferative activity against human SW620 cells	[PMID: 37875056]
T-24	EC₅₀	0.12 μM Compound: SAHA, Zolinza	Induction of histone H3 acetylation in human T24 cells after 3 hrs by ELISA Induction of histone H3 acetylation in human T24 cells after 3 hrs by ELISA	[PMID: 19084395]
T-24	EC₅₀	0.25 μM Compound: SAHA, Zolinza	Induction of alpha tubulin acetylation in human T24 cells after 3 hrs by ELISA Induction of alpha tubulin acetylation in human T24 cells after 3 hrs by ELISA	[PMID: 19084395]
T-24	IC₅₀	2.4 μM Compound: SAHA	Antiproliferative activity against human T24 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human T24 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
T47D	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human T47D cells after 72 hrs by MTS assay Growth inhibition of human T47D cells after 72 hrs by MTS assay	[PMID: 22435669]
T47D	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 28601509]
T47D	IC₅₀	3.01 μM Compound: Vorinostat	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
T47D	GI₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
T47D	IC₅₀	2.243 μM Compound: SAHA	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
T47D	IC₅₀	1.5 μM Compound: 4; SAHA	Antiproliferative activity against human T47D cells Antiproliferative activity against human T47D cells	[PMID: 37652098]
T47D	IC₅₀	3.21 μM Compound: SAHA	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
TAMH	IC₅₀	7.86 μM Compound: 1; SAHA	Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay	[PMID: 27541357]
TAMH	IC₅₀	7.86 μM Compound: 2	Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 28953386]
T-cell	EC₅₀	0.6 μM Compound: SAHA, Vorinostat	Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis	[PMID: 24495105]
TE-1	IC₅₀	2.25 μM Compound: SAHA	Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
THP-1	IC₅₀	>10 μg/mL Compound: SAHA	Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	IC₅₀	0.5 μg/mL Compound: SAHA	Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	IC₅₀	18 μM Compound: SAHA, Vorinostat	Cytotoxicity against human THP1 cells assessed as reduction in cell viability Cytotoxicity against human THP1 cells assessed as reduction in cell viability	[PMID: 26264503]
THP-1	IC₅₀	1.1 μM Compound: SAHA	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
THP-1	IC₅₀	9.5 μM Compound: 5; SAHA	Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay	[PMID: 31117517]
THP-1	GI₅₀	15.5 μM Compound: SAHA	Growth inhibition of human THP-1 cells Growth inhibition of human THP-1 cells	[PMID: 32320239]
THP-1	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human THP-1 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
THP-1	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
THP-1	GI₅₀	15.4 μM Compound: 1	Growth inhibition of human THP-1 cells Growth inhibition of human THP-1 cells	[PMID: 37429084]
THP-1	IC₅₀	0.18 μM Compound: Vorinostat	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
THP-1	IC₅₀	0.62 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
THP-1	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human THP-1 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
TK-10	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human TK10 cells after 72 hrs by MTS assay Growth inhibition of human TK10 cells after 72 hrs by MTS assay	[PMID: 22435669]
TPC1	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human TPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human TPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
TSGH	IC₅₀	2.09 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human TSGH cells by MTT assay Cytotoxicity against human TSGH cells by MTT assay	[PMID: 24766560]
U-251	GI₅₀	6.5 μM Compound: SAHA	Cytotoxicity against human U251 cells after 48 hrs by MTT assay Cytotoxicity against human U251 cells after 48 hrs by MTT assay	[PMID: 20605448]
U-251	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human U251 cells after 72 hrs by MTS assay Growth inhibition of human U251 cells after 72 hrs by MTS assay	[PMID: 22435669]
U-251	GI₅₀	2 μM Compound: SAHA	Cytotoxicity against human U251 cells by MTT assay Cytotoxicity against human U251 cells by MTT assay	[PMID: 23538115]
U-251	GI₅₀	1.53 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human U251 cells after 48 hrs by SRB assay Cytotoxicity against human U251 cells after 48 hrs by SRB assay	[PMID: 24015327]
U-251	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
U-251	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
U-251	IC₅₀	17.87 μM Compound: 1; SAHA	Cytotoxicity against human TMZ-sensitive U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human TMZ-sensitive U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35005974]
U-251	IC₅₀	8.94 μM Compound: SAHA	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37399711]
U-251	IC₅₀	2.58 μM Compound: SAHA	Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
U-266	IC₅₀	1.09 μM Compound: SAHA	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 25462271]
U-266	IC₅₀	1.35 μM Compound: SAHA	Cytotoxicity against human U266 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U266 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
U-266	IC₅₀	581 nM Compound: SAHA	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 26443078]
U-266	IC₅₀	0.88 μM Compound: SAHA	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 28757101]
U-266	IC₅₀	42.6 μM Compound: SAHA	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 30594434]
U-266	IC₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
U-266	IC₅₀	3070 nM Compound: SAHA	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
U-266	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-266	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
U-266	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-266 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U2932	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay	[PMID: 29150335]
U2932	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human U2932 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human U2932 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
U2OS	IC₅₀	5.7 μM Compound: Vorinostat	Cytotoxicity against human U2OS cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 32791404]
U2OS	IC₅₀	2.23 μM Compound: SAHA	Anticancer activity against human U2OS cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human U2OS cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
U-87MG ATCC	IC₅₀	11 μM Compound: 2	Cytotoxicity against human U87MG cells Cytotoxicity against human U87MG cells	[PMID: 17691763]
U-87MG ATCC	IC₅₀	10 μM Compound: 5; SAHA	Antiproliferative activity against human U87 cells after 96 hrs by MTT assay Antiproliferative activity against human U87 cells after 96 hrs by MTT assay	[PMID: 31117517]
U-87MG ATCC	IC₅₀	15.71 μM Compound: 1; SAHA	Antiproliferation activity against human U-87 MG cells assessed as growth inhibition measured after 1 hr by MTT assay Antiproliferation activity against human U-87 MG cells assessed as growth inhibition measured after 1 hr by MTT assay	[PMID: 33744690]
U-87MG ATCC	IC₅₀	52 μM Compound: SAHA	Antiproliferative activity against human U-87 MG cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human U-87 MG cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
U-87MG ATCC	IC₅₀	15.71 μM Compound: I; SAHA	Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay	[PMID: 36630883]
U-87MG ATCC	IC₅₀	1.949 μM Compound: SAHA	Antiproliferative activity against human U-87 MG cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U-87 MG cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
U-87MG ATCC	IC₅₀	4.19 μM Compound: Vorinostat	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37875056]
U-937	EC₅₀	33 μM Compound: SAHA	Compound was tested for anti-proliferative activity in U-937 human leukemia cell line Compound was tested for anti-proliferative activity in U-937 human leukemia cell line	[PMID: 14698179]
U-937	CC₅₀	1050 nM Compound: 1	Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
U-937	EC₅₀	0.82 μM Compound: 1a, SAHA	Antiproliferative activity against human U937 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human U937 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
U-937	GI₅₀	390 nM Compound: SAHA	Growth inhibition of human U937 cells after 72 hrs by SRB assay Growth inhibition of human U937 cells after 72 hrs by SRB assay	[PMID: 20884208]
U-937	GI₅₀	450 nM Compound: SAHA, vorinostat	Antiproliferative activity against human U937 cells after 72 hrs by WST-1 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
U-937	IC₅₀	2.3 μM Compound: 1, SAHA	Inhibition of human U937 cell proliferation after 48 hrs by MTT assay Inhibition of human U937 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
U-937	IC₅₀	1.45 μM Compound: SA, SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 24694055]
U-937	GI₅₀	1.42 μM Compound: vorinostat, SAHA	Antiproliferative activity against human U937 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human U937 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
U-937	IC₅₀	0.97 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 25462271]
U-937	IC₅₀	2.83 μM Compound: SAHA, Zolinza	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
U-937	IC₅₀	5.49 μM Compound: 6, SAHA	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
U-937	IC₅₀	2.83 μM Compound: Vorinostat	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
U-937	IC₅₀	0.37 μM Compound: SAHA, Zolinza	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 26100440]
U-937	IC₅₀	4.82 μM Compound: 1, SAHA	Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
U-937	IC₅₀	100 μM Compound: SAHA, Vorinostat	Cytotoxicity against human U937 cells assessed as reduction in cell viability Cytotoxicity against human U937 cells assessed as reduction in cell viability	[PMID: 26264503]
U-937	GI₅₀	1460 nM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
U-937	IC₅₀	3.35 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
U-937	IC₅₀	907.5 nM Compound: SAHA	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
U-937	EC₅₀	0.88 μM Compound: SAHA	Growth inhibition of human U937 cells after 44 hrs by MTT assay Growth inhibition of human U937 cells after 44 hrs by MTT assay	[PMID: 28337317]
U-937	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28419930]
U-937	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28601509]
U-937	IC₅₀	1.64 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28757101]
U-937	EC₅₀	0.88 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay	[PMID: 29150330]
U-937	IC₅₀	1.53 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29500131]
U-937	CC₅₀	0.78 μM Compound: Vorinostat	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 29541372]
U-937	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29954683]
U-937	IC₅₀	1.53 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 30879863]
U-937	IC₅₀	1.235 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as cell growth inhibition after 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells assessed as cell growth inhibition after 72 hrs by CCK8 assay	[PMID: 34454126]
U-937	IC₅₀	1.58 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
U-937	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
U-937	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-937	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
U-937	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
U-937	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-937	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells by MTT assay Antiproliferative activity against human U-937 cells by MTT assay	[PMID: 37875056]
U-937	IC₅₀	0.52 μM Compound: 1; SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay	[PMID: 38456618]
U-937	IC₅₀	0.73 μM Compound: 1; SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
U-937	IC₅₀	4.33 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
UACC-257	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human UACC257 cells after 72 hrs by MTS assay Growth inhibition of human UACC257 cells after 72 hrs by MTS assay	[PMID: 22435669]
UACC-62	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human UACC62 cells after 72 hrs by MTS assay Growth inhibition of human UACC62 cells after 72 hrs by MTS assay	[PMID: 22435669]
UO-31	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human UO31 cells after 72 hrs by MTS assay Growth inhibition of human UO31 cells after 72 hrs by MTS assay	[PMID: 22435669]
Vero	IC₅₀	1200 ng/mL Compound: SAHA	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	[PMID: 19914074]
Vero	IC₅₀	261.6 ng/mL Compound: SAHA	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	478.9 ng/mL Compound: SAHA	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	1.375 μg/mL Compound: SAHA	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	[PMID: 20669972]
Vero	IC₅₀	0.9 μM Compound: SAHA, vorinostat	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Vero	EC₅₀	5.2 μM Compound: SAHA	Cytotoxicity against african green monkey Vero cells cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against african green monkey Vero cells cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
Vero	IC₅₀	4.1 μM Compound: SAHA	Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
Vero	IC₅₀	1.03 μM Compound: SAHA	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
Vero	IC₅₀	1.45 μM Compound: SAHA	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 30245394]
Vero	IC₅₀	4.465 μM Compound: SAHA	Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
Vero	IC₅₀	1.45 μM Compound: 1; SAHA	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 33077264]
Vero	IC₅₀	4.1 μM Compound: SAHA	Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
Vero	IC₅₀	2.85 μM Compound: SAHA	Antiproliferative activity against green monkey Vero cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay Antiproliferative activity against green monkey Vero cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay	[PMID: 38367494]
WI-38	GI₅₀	6080 nM Compound: SAHA	Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
WI-38	IC₅₀	49.87 μM Compound: SAHA	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
WI-38	IC₅₀	10.07 μM Compound: 1; SAHA	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
WI-38	IC₅₀	>30 μM Compound: SAHA; NSC759852	Cytotoxicity against human WI-38 cells assessed as reduction in cell survival incubated for 30 mins by methylene blue staining based analysis Cytotoxicity against human WI-38 cells assessed as reduction in cell survival incubated for 30 mins by methylene blue staining based analysis	[PMID: 36306372]
YAC-1	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse YAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse YAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Z-138	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human Z138 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human Z138 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
ZR-75-1	IC₅₀	1629 nM Compound: 1; SAHA	Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
ZR-75-1	IC₅₀	6.86 μM Compound: SAHA; 6	Antiproliferative activity against human ZR-75-1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human ZR-75-1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]

In Vitro

Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21^WAF1 expression and apoptosis in MES-SA cells^[1].
Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC₂₅ values of 1 μM and 0.5 μM, respectively^[2].
Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers apoptosis in HPV-infected, differentiated cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×10⁶ MES-SA cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 149647-78-9
Appearance Solid
Molecular Weight 264.32
Formel C₁₄H₂₀N₂O₃
Color White to light yellow
SMILES

O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
Synonyms

SAHA; Suberoylanilide hydroxamic acid
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (166)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer. [Abstract]

2025 Oct 14;10(1):341. PMID: 41083431
Science

Multistep genomics on single cells and live cultures in subnanoliter capsules. [Abstract]

2026 Mar 12;391(6790):1130-1137. PMID: 41411409
Cancer Discov

Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and Intrinsic Drug Resistance in T Cell Cancer. [Abstract]

2025 Jun 16. PMID: 40516109
Mil Med Res

Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. [Abstract]

2022 Sep 27;9(1):54. PMID: 36163081
Cancer Res

Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells. [Abstract]

2025 Jul 25. PMID: 40712058
Cancer Res

Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma. [Abstract]

2025 Jun 2;85(11):2100-2116. PMID: 40053472
Nat Commun

Vitamin D supplementation ameliorates ductular reaction, liver inflammation and fibrosis in mice by upregulating TXNIP in ductular cells. [Abstract]

2025 May 13;16(1):4420. PMID: 40360509
Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
Nat Commun

Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. [Abstract]

2021 Mar 3;12(1):1407. PMID: 33658498
Nat Commun

Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. [Abstract]

2017 Dec 20;8(1):2207. PMID: 29263324

Vorinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Dec 20;8(1):2207. [Abstract]

HCT116 cells are treated with Vorinostat for 24 h, followed by by western blot analysis for the indicated proteins.
Acta Pharm Sin B

Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy. [Abstract]

2022 Feb;12(2):838-852. PMID: 35256949
Adv Sci (Weinh)

The Nuclear Localization of ACLY Guards Early Embryo Development Through Recruiting P300 and HAT1 to Promote Histone Acetylation and Transcription. [Abstract]

2025 Jun 5:e14367. PMID: 40470746
Adv Sci (Weinh)

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. [Abstract]

2025 Jan 30:e2413445. PMID: 39887933
Adv Sci (Weinh)

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. [Abstract]

2025 Jan 31:e2408845. PMID: 39888307
Adv Sci (Weinh)

Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]

2024 Aug 23:e2400156. PMID: 39178136
Adv Sci (Weinh)

SNORA28 Promotes Proliferation and Radioresistance in Colorectal Cancer Cells through the STAT3 Pathway by Increasing H3K9 Acetylation in the LIFR Promoter. [Abstract]

2024 Jun 26:e2405332. PMID: 38924373
Adv Sci (Weinh)

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer. [Abstract]

2023 Nov;10(31):e2304638. PMID: 37702443
Nat Chem Biol

Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1. [Abstract]

2025 Feb;21(2):227-237. PMID: 38965385
J Clin Invest

Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer. [Abstract]

2026 Jun 9:e203835. PMID: 42262878
Theranostics

A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy. [Abstract]

2024 Jun 3;14(9):3565-3582. PMID: 38948069
J Adv Res

HDAC2 enhances the antimicrobial activity of neutrophils by promoting the formation of neutrophil extracellular traps (NETs) in sepsis. [Abstract]

2025 Aug 22:S2090-1232(25)00655-1. PMID: 40850685
J Exp Clin Cancer Res

CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages. [Abstract]

2025 Feb 24;44(1):67. PMID: 39994810
Protein Cell

Senktide blocks aberrant RTN3 interactome to retard memory decline and tau pathology in social isolated Alzheimer's disease mice. [Abstract]

2024 Apr 1;15(4):261-284. PMID: 38011644
Carbohydr Polym

2026 Jun 25.
J Biomed Sci

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. [Abstract]

2025 Mar 17;32(1):36. PMID: 40091020
Cell Rep Med

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer. [Abstract]

2025 Jul 15;6(7):102215. PMID: 40609538
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Exp Med

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. [Abstract]

2022 Jan 3;219(1):e20210789. PMID: 34825915
Cancer Lett

HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers. [Abstract]

2026 Mar 28:218465. PMID: 41912135
Cancer Lett

Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance. [Abstract]

2024 Jul 31:217147. PMID: 39094826
Mol Psychiatry

Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. [Abstract]

2017 May;22(5):711-723. PMID: 27620840

Vorinostat purchased from MedChemExpress. Usage Cited in: Mol Psychiatry. 2017 May;22(5):711-723. [Abstract]

Oral SAHA administration increases brain plasma membrane calcium ATPase (PMCA) levels, reduces oxidative stress, improves behavioral deficits and prevents neurodegeneration in ASM knockout (ASMko) mice. (a,b) Western blot of hippocampal membrane extracts from wt (a) and ASMko (b) mice orally administered SAHA complexed to HOP-β-CDX (SAHA) or HOP-β-CDX (control), and probed for PMCA and ATP6V1A.
Cell Death Dis

Identification and targeting oxidative phosphorylation/glycolysis to overcome anti-CSF-1R therapy resistance in glioblastoma. [Abstract]

2025 Dec 10. PMID: 41365876
Adv Healthc Mater

Optimizing Adoptive Cell Therapy for Solid Tumors via Epigenetic Regulation of T-cell Destiny. [Abstract]

2024 Dec;13(32):e2402209. PMID: 39301920
Cell Death Dis

Pyruvate dehydrogenase kinase 1 protects against neuronal injury and memory loss in mouse models of diabetes. [Abstract]

2023 Nov 7;14(11):722. PMID: 37935660
Cell Death Dis

HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells. [Abstract]

2023 Jan 18;14(1):38. PMID: 36653340
Cell Death Dis

Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-β2 signaling axis. [Abstract]

2023 Jan 25;14(1):59. PMID: 36697384
Cell Death Dis

Global crotonylome reveals hypoxia-mediated lamin A crotonylation regulated by HDAC6 in liver cancer. [Abstract]

2022 Aug 17;13(8):717. PMID: 35977926
Cell Death Dis

Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function. [Abstract]

2021 Jun 7;12(6):582. PMID: 34099635
Cell Death Dis

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer. [Abstract]

2020 Sep 15;11(9):753. PMID: 32934224
Cell Death Dis

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. [Abstract]

2020 Sep 18;11(9):778. PMID: 32948748
Sci China Life Sci

Low-dose exposure to microplastics retards meiotic maturation via HDAC3 insufficiency. [Abstract]

2025 May;68(5):1410-1422. PMID: 39976862
Cell Commun Signal

Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss. [Abstract]

2024 Mar 4;22(1):160. PMID: 38439009
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
Acta Pharmacol Sin

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]

2021 May;42(5):814-823. PMID: 32855532
Acta Pharmacol Sin

The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation. [Abstract]

2019 Jan;40(1):98-110. PMID: 29789664
Phytomedicine

Wikstrol B reactivates latent human immunodeficiency virus (HIV-1) via the nuclear factor-κB (NF-κB) pathway. [Abstract]

2025 Jun:141:156667. PMID: 40233507
Apoptosis

HSPA8 lactylation attenuates neuronal pyroptosis via E3 ligase-mediated NLRP3 degradation after ischemic stroke. [Abstract]

2026 Jan 10;31(1):37. PMID: 41518395
Neoplasia

Metabolic regulation of histone acetylation by ACLY supports MDR1 expression in colorectal cancer and highlights a targetable vulnerability. [Abstract]

2026 Jul:77:101314. PMID: 42066427
Neoplasia

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. [Abstract]

2025 Jan 25:60:101121. PMID: 39864337
Br J Pharmacol

Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1-mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation. [Abstract]

2021 Sep;178(17):3428-3447. PMID: 33864382
Cell Syst

A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. [Abstract]

2019 Jul 24;9(1):35-48.e5. PMID: 31302153
NPJ Breast Cancer

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]

2023 Aug 11;9(1):66. PMID: 37567892
J Transl Med

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia. [Abstract]

2024 Sep 27;22(1):867. PMID: 39334157
Oncogene

BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. [Abstract]

2021 Apr;40(15):2711-2724. PMID: 33712705
Cell Death Discov

Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells. [Abstract]

2025 Apr 10;11(1):162. PMID: 40210861
Neurotherapeutics

Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [Abstract]

2025 Apr;22(3):e00575. PMID: 40118716
Cell Rep

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. [Abstract]

2023 Jan 31;42(1):112027. PMID: 36848231
J Med Chem

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. [Abstract]

2025 Feb 20. PMID: 39979078
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
Anal Chem

HDAC6-Activatable Multifunctional Near-Infrared Probe for Glioma Cell Detection and Elimination. [Abstract]

2024 Feb 13;96(6):2406-2414. PMID: 38308568
Int J Nanomedicine

LincRNA-p21: A Double-Edged Sword in Ethanol-Induced Liver Damage and Its Nanoparticle Solution. [Abstract]

2026 Feb 14:21:577455. PMID: 41717312
J Anim Sci Biotechnol

Glutamine relieves feed restriction-induced ruminal epithelial function damage through histone lysine lactylation in yaks. [Abstract]

2025 Dec 18;16(1):174. PMID: 41408320
JCI Insight

Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. [Abstract]

2022 Jan 11;7(1):e153948. PMID: 34874914
J Bone Miner Res

Hdac3-deficiency increases senescence-associated distention of satellite DNA and telomere-associated foci in osteoprogenitor cells. [Abstract]

2024 Jun 6:zjae085. PMID: 38843356
Biochem Pharmacol

HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer. [Abstract]

2024 Jul:225:116257. PMID: 38705532
Biochem Pharmacol

A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo. [Abstract]

2022 Jul:201:115070. PMID: 35526597
Biochem Pharmacol

A synthetic resveratrol analog termed Q205 reactivates latent HIV-1 through activation of P-TEFb. [Abstract]

2022 Mar:197:114901. PMID: 34971588
Biochem Pharmacol

A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b. [Abstract]

2019 Jun:164:237-251. PMID: 30991051
Biochem Pharmacol

PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1. [Abstract]

2018 Oct:156:511-523. PMID: 30170098
Virulence

Thymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency in vitro. [Abstract]

2026 Dec;17(1):2645858. PMID: 41824632
Commun Biol

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. [Abstract]

2021 Oct 29;4(1):1235. PMID: 34716410

Vorinostat purchased from MedChemExpress. Usage Cited in: Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]

TNBC model cells (MDA-MB-231 and BT-549) were treated with indicated HDACi (Vorinostat: 10 µM; Panobinostat: 1 µM; Romidepsin: 1 µM; Givinostat: 1 µM) for 24 h and expression of LIFR, p-STAT3(Y705), and STAT3 were determined using Western blotting.
Life Sci

A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway. [Abstract]

2021 Feb 15;267:118427. PMID: 32941894
J Clin Endocrinol Metab

Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. [Abstract]

2021 Jan 1;106(1):e232-e246. PMID: 33000123
Drug Des Devel Ther

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]

2018 Apr 30:12:1009-1017. PMID: 29750014
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
Immunology

Histone hyperacetylation mediates enhanced IL-1β production in LPS/IFN-γ-stimulated macrophages. [Abstract]

2020 Jun;160(2):183-197. PMID: 32061096
Int J Mol Sci

Characterization of the Activities of Vorinostat Against Toxoplasma gondii. [Abstract]

2025 Jan 18;26(2):795. PMID: 39859508
Int J Mol Sci

SAHA/5-AZA Enhances Acetylation and Degradation of mutp53, Upregulates p21 and Downregulates c-Myc and BRCA-1 in Pancreatic Cancer Cells. [Abstract]

2024 Jun 27;25(13):7020. PMID: 39000128
Int J Mol Sci

Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis. [Abstract]

2023 Aug 4;24(15):12448. PMID: 37569823
Int J Oncol

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition. [Abstract]

2020 Jun;56(6):1429-1441. PMID: 32236593
Biomolecules

Inherited Retinal Degeneration: Towards the Development of a Combination Therapy Targeting Histone Deacetylase, Poly (ADP-Ribose) Polymerase, and Calpain. [Abstract]

2023 Mar 23;13(4):581. PMID: 37189329
Pharmaceuticals (Basel)

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment. [Abstract]

2022 Mar 10;15(3):338. PMID: 35337136
Front Cell Infect Microbiol

CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins. [Abstract]

2021 Jul 19:11:686035. PMID: 34350133
Pharm Biol

Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. [Abstract]

2021 Dec;59(1):21-30. PMID: 33417512
Int J Cancer

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition. [Abstract]

2026 Feb 24. PMID: 41735198
Eur J Pharmacol

VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]

2025 Sep 15:1003:177942. PMID: 40651787
Eur J Pharmacol

Low-dose treatment with Epirubicin, a novel histone deacetylase 1 inhibitor, exerts anti-leukemic effects by inducing ferroptosis. [Abstract]

2024 Dec 15:985:177058. PMID: 39413949
Eur J Pharmacol

Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors. [Abstract]

2023 Dec 5:960:176114. PMID: 37863412
Eur J Pharmacol

Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. [Abstract]

2021 Oct 5:908:174399. PMID: 34331954
RSC Adv

Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1. [Abstract]

2018 May 11;8(31):17279-17292. PMID: 35539279

Vorinostat purchased from MedChemExpress. Usage Cited in: RSC Adv. 2018 May 11;8(31):17279-17292. [Abstract]

The NH2 cells expressing Tat. All tested cells are treated with SAHA for 24 h. The expression of GFP for tested J-Lat A2 and 2D10 cells is measured by FACS. Whole cell extracts for tested NH1 and NH2 cells are prepared and examined for the luciferase activities.
Molecules

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]

2018 Mar 23;23(4). pii: E736. PMID: 29570606
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Antimicrob Agents Chemother

A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription. [Abstract]

2021 Nov 17;65(12):e0047021. PMID: 34491808
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Biomed J

Sleep deprivation affects pain sensitivity by increasing oxidative stress and apoptosis in the medial prefrontal cortex of rats via the HDAC2-NRF2 pathway. [Abstract]

2025 Jan 2:100826. PMID: 39755172
ACS Omega

XQ2, a Novel Derivative of Resveratrol, Reactivates Latent HIV‑1 via the Activation of Positive Transcription Elongation Factor B. [Abstract]

2026 Feb 11;11(7):11739-11752. PMID: 41768657
Nanomaterials

Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. [Abstract]

2020 Jan 16;10(1):158. PMID: 31963267
Mediators Inflamm

The Histone Deacetylase Activator ITSA-1 Improves the Prognosis of Cardiac Arrest Rats by Alleviating Systemic Inflammatory Responses Following Cardiopulmonary Resuscitation. [Abstract]

2025 Mar 20:2025:8156593. PMID: 40151316
Biochim Biophys Acta Mol Basis Dis

A Trichostatin A (TSA)/Sp1-mediated mechanism for the regulation of SALL2 tumor suppressor in Jurkat T cells. [Abstract]

2018 May 18;S1874-9399(18)30028-2. PMID: 29778644

Vorinostat purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2018 May 18;S1874-9399(18)30028-2. [Abstract]

Jurkat T cells are treated for various times with Vorinostat 1 μM and Chidamide at 0.6 μM. Levels of SALL2 and cleaved PARP are evaluated by Western blot analysis. β-actin is used as a loading control.
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
J Neurochem

Effects of Lysine Deacetylation Inhibition Alone or in Combination With Arimoclomol on TDP-43 Proteinopathy. [Abstract]

2026 Jun;170(6):e70493. PMID: 42283221
Hum Gene Ther

Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells. [Abstract]

2019 Apr;30(4):497-510. PMID: 30381966
Sci Rep

Disruption of zinc homeostasis reduces histone acetylation levels in normal and tumor cells. [Abstract]

2026 Jan 10;16(1):4983. PMID: 41519875
Sci Rep

Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. [Abstract]

2022 Jun 15;12(1):9951. PMID: 35705678
Aging

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. [Abstract]

2021 May 28;13(11):15336-15352. PMID: 34047714
J Virol

Development of a Novel In Vitro Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription. [Abstract]

2021 Sep 9;95(19):e0022721. PMID: 34287050
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
PLoS Genet

ciRS-7 expression is epigenetically regulated in cancer cells across human adenocarcinomas. [Abstract]

2025 Jun 2;21(6):e1011726. PMID: 40455824
ACS Pharmacol Transl Sci

Epigenetic Targeting of Heparan Sulfate 3- O- and 6- O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities. [Abstract]

2024 Jul 30;7(8):2484-2495. PMID: 39144559
J Proteome Res

Chemoproteomics Reveals FAM114A2 as a Functional Target of Wikstroelide E for Reversal of HIV-1 Latency. [Abstract]

2025 Oct 23. PMID: 41131870
Neurocrit Care

miR-452-3p Targets HDAC3 to Inhibit p65 Deacetylation and Activate the NF-κB Signaling Pathway in Early Brain Injury after Subarachnoid Hemorrhage. [Abstract]

2022 Oct;37(2):558-571. PMID: 35641805
J Proteome Res

An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies. [Abstract]

2022 Apr 1;21(4):953-964. PMID: 35172096
Viruses

Autophagy Deregulation in HIV-1-Infected Cells Increases Extracellular Vesicle Release and Contributes to TLR3 Activation. [Abstract]

2024 Apr 20;16(4):643. PMID: 38675983
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Toxicol Appl Pharmacol

A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition. [Abstract]

2024 May 10:487:116957. PMID: 38735590
BMC Cancer

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways. [Abstract]

2023 Jan 25;23(1):87. PMID: 36698167
Front Oncol

Adipocytes Provide Fatty Acids to Acute Lymphoblastic Leukemia Cells. [Abstract]

2021 Apr 22:11:665763. PMID: 33968771
Front Oncol

Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer. [Abstract]

2021 Mar 8:11:620154. PMID: 33763356
IUBMB Life

HIF Signalling Modulates p53/miR-145-5p Axis in Hypoxia-Driven Tumorigenesis of HepG2 Tumourspheres. [Abstract]

2026 Apr;78(4):e70103. PMID: 42015891
Hum Cell

HDAC inhibitors promote pancreatic stellate cell apoptosis and relieve pancreatic fibrosis by upregulating miR-15/16 in chronic pancreatitis. [Abstract]

2020 Oct;33(4):1006-1016. PMID: 32524326
Am J Cancer Res

Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. [Abstract]

2022 Feb 15;12(2):713-728. PMID: 35261797
J Sep Sci

Box-Behnken assisted development and validation of HPLC method for simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. [Abstract]

2023 Feb;46(3):e2200731. PMID: 36427291
Onco Targets Ther

Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females. [Abstract]

2018 Apr 17:11:2177-2184. PMID: 29713186
SLAS Discov

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3. [Abstract]

2024 Feb 12;29(2):100147. PMID: 38355016
Vet Microbiol

U18666A inhibits classical swine fever virus replication through interference with intracellular cholesterol trafficking. [Abstract]

2019 Nov;238:108436. PMID: 31648726
PLoS One

Polypyrimidine tract binding proteins PTBP1 and PTBP2 associate with distinct proteins and have distinct post-translational modifications in neuronal nuclear extract. [Abstract]

2025 Jun 4;20(6):e0325143. PMID: 40465779
Virology

H1N1 swine influenza viruses upregulate NEU1 expression through histone H3 acetylation regulated by HDAC2. [Abstract]

2024 Nov 15:601:110305. PMID: 39566266
Virology

Fentanyl enhances HIV infection in vitro. [Abstract]

2022 Dec:577:43-50. PMID: 36279602
Biochem Biophys Res Commun

In Silico modeling for assessment of the most effective ratio and interaction of anticancer drugs. [Abstract]

2025 Sep 8:778:152341. PMID: 40674821
Oncol Lett

Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy. [Abstract]

2024 Jul 19;28(3):444. PMID: 39091583
Histol Histopathol

Elp3 activates the JNK/MAPK pathway through histone acetylation to promote gastric cancer proliferation, migration, and invasion. [Abstract]

2025 Oct 6:25001. PMID: 41048082
J Taibah Univ Med Sci

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus. [Abstract]

2022 Jul 21;18(1):9-18. PMID: 36398015
Biol Pharm Bull

Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor. [Abstract]

2017;40(10):1747-1753. PMID: 28966246

Vorinostat purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2017;40(10):1747-1753. [Abstract]

Synergistic Decrease Bcl-2 Expression by the Combination of Vorinostat with BMS-354825 in MCF-7 Cells.
bioRxiv

Gut Microbiota-derived Acetate Safeguards the Colonic Epithelial Acetyl-CoA Reserve to Avert Colonic Senescence. [Abstract]

2026 May 19:2026.05.15.725523. PMID: 42239342
bioRxiv

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]

2026 May 26:2026.05.22.726988. PMID: 42244620
bioRxiv

2026 Mar 14.
SSRN

2026 Mar 20.
bioRxiv

2025 Oct 8.
bioRxiv

2025 Oct 13.
Patent

US20250288582A1.
University of Alabama

2025.
bioRxiv

2025 Sep 21.
bioRxiv

FSP1 and histone deacetylases suppress cancer persister cell ferroptosis. [Abstract]

2025 Aug 25:2025.08.21.671520. PMID: 40909720
bioRxiv

2025 Jul 31.
Patent

US20250152731A1.
Authorea

2025 Apr 18.
bioRxiv

Multi-step genomics on single cells and live cultures in sub-nanoliter capsules. [Abstract]

2025 Mar 17:2025.03.14.642839. PMID: 40166192
bioRxiv

2025 March 12.
bioRxiv

2025 January 15.
bioRxiv

PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]

2024 Nov 6:2024.11.04.621884. PMID: 39574568
Research Square Preprint

2024 Jan 2.
bioRxiv

Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic Reprogramming. [Abstract]

2023 Aug 8:2023.08.07.552383. PMID: 37609341
bioRxiv

2023 Jun 5.
medRxiv

Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients. [Abstract]

2023 Feb 24:2023.02.24.23286403. PMID: 36865297
Research Square Print

September 20th, 2022.
Research Square Preprint

2022 Feb.
Research Square Preprint

2021 May.
Università degli Studi di CAGLIARI

2021 May.
bioRxiv

2021 Jan 5.
Eur Rev Med Pharmacol Sci

Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis. [Abstract]

2020 May;24(10):5726-5733. PMID: 32495908
Albert-ludwigs-university Of Freiburg

2019 Dec.
Florida Southern College

2019 May.
Patent

US20180263995A1.
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827
Oncotarget

Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma. [Abstract]

2017 May 23;8(21):34362-34373. PMID: 28416766

Vorinostat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 23;8(21):34362-34373. [Abstract]

Notch3 protein levels after treatment with SAHA at different concentrations or DMSO (vehicle control), determined by western blot.
Universidad Autónoma de Madrid

2015 Jun 15.

Vorinostat purchased from MedChemExpress. Usage Cited in: Universidad Autónoma de Madrid. 2015 Jun 15.

SAHA, a histone deacetylase inhibitor that is shown to increase PMCA levels and to enhance calcium clearance in a breast cancer cell model.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (378.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7833 mL

18.9165 mL

37.8329 mL

5 mM

0.7567 mL

3.7833 mL

7.5666 mL

10 mM

0.3783 mL

1.8916 mL

3.7833 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% HP-β-CD in Saline

Solubility: 3.33 mg/mL (12.60 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Cell lysates are prepared by using RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), and the protein concentration is determined by Bio-Rad DC Protein Assay. Protein lysates are separated by SDS-PAGE and transferred to nitrocellulose membrane. Following antibodies and dilutions are used: rabbit anti HDAC1 (1 μg/mL); rabbit anti HDAC2 (1 μg/mL); rabbit anti HDAC3 (9 μg/mL); rabbit anti HDAC7 (3 μg/mL); mouse anti p21WAF1 (0.5 μg/mL). As secondary antibodies, the rabbit anti-mouse and swine anti-rabbit HRP-coupled antibodies at a final concentration of 1 μg/mL. An overnight incubation at 4°C is used for all primary antibodies, followed by washing and 2-hours incubation at RT with secondary antibodies. Specific protein bands are visualized by enhanced chemiluminescence assay. To demonstrate equal loading of protein samples all western blots are probed for β-tubulin.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Twelve weeks old male mice (n=14) are anesthetized with Isofluran and 5×10⁶ MES-SA cells are injected subcutaneously into the right flank of the animal. Mice from a control group receives placebo containing 300 μL of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice receives vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat are administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w² × l × 0.52; measured by caliper) are estimated twice a week. All mice are treated for 21 days and afterwards sacrificed by cervical dislocation. Each tumor is isolated as a whole and different tumor parameters are determined. Finally, tumor slices are cryo preserved and formalin fixed (4%) for further analyses.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49. [Content Brief]

[2]. Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. PLoS One. 2012;7(7):e40816. [Content Brief]

[3]. Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7. [Content Brief]

[4]. Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [Content Brief]

[5]. Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry. 2017 May;22(5):711-723. [Content Brief]

[6]. Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun. 2017 Dec 20;8(1):2207. [Content Brief]

[7]. Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7833 mL	18.9165 mL	37.8329 mL	94.5823 mL
	5 mM	0.7567 mL	3.7833 mL	7.5666 mL	18.9165 mL
	10 mM	0.3783 mL	1.8916 mL	3.7833 mL	9.4582 mL
	15 mM	0.2522 mL	1.2611 mL	2.5222 mL	6.3055 mL
	20 mM	0.1892 mL	0.9458 mL	1.8916 mL	4.7291 mL
	25 mM	0.1513 mL	0.7567 mL	1.5133 mL	3.7833 mL
	30 mM	0.1261 mL	0.6305 mL	1.2611 mL	3.1527 mL
	40 mM	0.0946 mL	0.4729 mL	0.9458 mL	2.3646 mL
	50 mM	0.0757 mL	0.3783 mL	0.7567 mL	1.8916 mL
	60 mM	0.0631 mL	0.3153 mL	0.6305 mL	1.5764 mL
	80 mM	0.0473 mL	0.2365 mL	0.4729 mL	1.1823 mL
	100 mM	0.0378 mL	0.1892 mL	0.3783 mL	0.9458 mL

Keywords

Vorinostat

166 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Vorinostat

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Mitochondria-Targeted Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radiosensitizer Library

Mitophagy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Vorinostat

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle Filovirus Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (166)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Vorinostat Related Classifications

Art. -Nr.: HY-10221